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By Mulinde Ronnie Goodman Ruyonga 
 




Amino-cyclohexanol derivatives have been successful models for pH-triggered 
conformational switches.  By changing the groups on the amine nitrogen, these models provide a 
wide pH-range in which a switch can occur.  The pH-induced switch of conformation can be 
monitored by 1H NMR. 
In this work, structurally similar trans-2-(azaarylsulfanyl)-cyclohexanol derivatives and 
trans-2-triazolylcyclohexanol derivatives have been explored for the first time as compounds 
with a potential for the analogous pH-induced conformational switch.  The azaarylsulfanyl 
groups showed selective conformational flexibility while the triazolyl group showed a strong 
preference for the equatorial position.  Further, conformational studies were done on a series of 
trans-2-triazolylcyclohexanols and triazolycyclohexanes to determine the previously unknown 
conformational energy of the triazolyl group.In addition, a series of carbasugar analogues based 
on trans-2-(1,2,3-triazolyl)-cyclohexanol moiety was synthesized and tested for activity 
(inhibition or activation) towards fungal glycosidases from Aspergillus and Penicillium sp due to 




TABLE OF CONTENTS 
 
List of Tables .................................................................................................................................11 
List of Figures ................................................................................................................................12 
List of Schemes ..............................................................................................................................14 
List of Abbreviations .....................................................................................................................18 
Chapter 1: Introduction ..................................................................................................................20 
1.1 Molecular Switches ..................................................................................................... 20 
1.1.1 Cyclohexane-Based Conformational Switches ............................................ 21 
1.1.2 Structural Effects on Conformation Switches.............................................. 23 
1.1.3 Cyclohexane Complexation-Induced Conformational Switch .................... 27 
1.1.4 pH-Induced Conformational Switch ............................................................ 30 
1.1.5 Double Conformational Switch ................................................................... 35 
1.1.6 Non-Cyclic Complexation-Induced Conformational Switch....................... 37 
1.2 Glycosidase Activity ................................................................................................... 40 
1.2.1 Glycosidases ................................................................................................ 40 
1.2.2 Mechanism for Enzyme-Catalyzed Hydrolysis by Glycosidases ................ 41 
1.2.3 Glycosidase Inhibitors ................................................................................. 44 
Chapter 2: Research Goals .............................................................................................................46 
2.1 Molecular Switches ..................................................................................................... 46 
2.2 Glycosidase Inhibitors and Activators ............................................................................... 46 
Chapter 3: Results and Discussions ...............................................................................................48 
3.1 Molecular Switches ..................................................................................................... 48 
3.1.1 Library of trans-2Aazaarylsulfanylcyclohexanol Derivatives ..................... 50 
8 
3.1.2 Synthesis of trans-2-(Azaarylsulfanyl)-Cyclohexanol Derivatives ............. 53 
3.1.3 Conformational Study of trans-2-Azaarylsulfanylcyclohexanol      
Derivatives ............................................................................................................ 56 
 
3.1.4 Factors Affecting Conformational Equlibrium of                                     
trans-2-(azaarylsulfanyl)-Cyclohexanol Derivatives ............................................ 66 
 
3.1.4.1 Effect of Azaarylsulfanyl Groups as a Polar-Head ....................... 66 
3.1.4.2 Effect of the Position of Nitrogen on Azaarylsulfanyl Group ...... 80 
3.1.4.3 Effect of R-Groups on Azaarysulfanyl Groups ............................ 81 
3.1.4.4 Effect of t-Butyl Counterbalance .................................................. 82 
3.1.4.5 Effect of OR .................................................................................. 87 
3.1.4.6 Effect of Solvent ........................................................................... 89 
3.1.5 Library of trans-2-Triazolylcyclohexanol/Cyclohexylacetate      
Dicarboxylate Derivatives .................................................................................... 94 
 
3.1.6 Synthesis of trans-2-Triazolylcyclohexanol Dicarboxylate             
Derivatives ............................................................................................................ 97 
 
3.1.7 Conformational Study of trans-2-Triazolylcyclohexanol           
Dicarboxylate Derivatives .................................................................................. 100 
 
3.1.8 Factors Affecting Conformational Equlibrium of                                    
trans-2-Triazolylcyclohexanol Dicarboxylate Derivatives ................................. 105 
 
3.1.8.1 Effect of Ethoxycarbonyl Counterbalances ................................ 105 
3.1.8.2 Effect of R-Groups on Triazole Ring.......................................... 105 
3.1.8.3 Effect of Change in pH ............................................................... 106 
3.1.9 Library of trans-2-Triazolyl-Cyclohexanol/-Cyclohexyl Acetate    
Derivatives .......................................................................................................... 107 
 
3.1.10 Synthesis of trans-2-Triazolylcyclohexanol Derivatives ......................... 108 
3.1.11 Conformational Study of trans-2-Triazolylcyclohexanol Derivatives     
with Counterbalances .......................................................................................... 111 
 
9 
3.1.12 Factors Affecting Conformational Study of                                           
trans-2-Triazolylcyclohexanol Derivatives with Counterbalances .................... 117 
 
3.1.12.1 Effect of Counterbalances ......................................................... 117 
3.1.13 Library of cis/transtriazolylcyclohexanes................................................ 119 
3.1.14 Synthesis of Triazolylcyclohexanes ......................................................... 121 
3.1.15 Conformational Study of cis/trans-Triazolylcyclohexanes ..................... 124 
3.1.16 Factors Affecting Conformational Equlibrium of trans-2-
Triazolylcyclohexanes ........................................................................................ 129 
 
3.1.16.1 Effect of Counterbalances ......................................................... 129 
3.1.17 Calculations for the Conformational Energy of the Triazolyl Group ...... 132 
3.2 Glycosidase Inhibitors and Activators ............................................................................. 136 
3.2.1 Library of 2-Triazolylcyclohexanol Dicarboxylic Acids ........................... 138 
3.2.2 Synthesis of trans/cis-2-Triazolylcyclohexanol Dicarboxylic Acid .......... 141 
3.2.3 NMR Analysis of trans-5-Triazolyl-4-Cyohexanol-trans-1-2-     
Dicarboxylic Acids and trans-5-Triazolyl-4-Cyohexanol-cis-1-2-       
Dicarboxylic Acids ............................................................................................. 142 
 
3.2.4 Library of trans-2-Triazolylcyclohexanol and Hexahydrobenzo-       
Triazolo-Oxazinone Derivatives for Glycosidase Assays .................................. 143 
 
3.2.5 Synthesis Of trans-2-Triazolylcyclohexanol and Hexahydrobenzo-   
Triazolo-Oxazinone Derivatives ......................................................................... 145 
 
3.2.6 NMR Analysis of trans-2-Triazolylcyclohexanols .................................... 147 
3.2.7 NMR Confirmation of Hexahydrobenzo-Triazolo-Oxazinone       
Derivatives .......................................................................................................... 149 
 
3.2.8 Inhibition Assay for trans/cis-2-Triazolylcyclohexanol Dicarboxylic      
Acid, trans-2-Triazolylcyclohexanol and                                      
Hexahydrobenzo-Triazolo-Oxazinone Derivatives ............................................ 150 
 
Chapter 4: Conclusion..................................................................................................................157 
Chapter 5: Experimental ..............................................................................................................159 
10 
5.1 Synthesis ................................................................................................................... 159 
5.2 NMR Analysis of pH-Dependent Conformational Equilibrium ............................... 256 
5.3 Calculations for Conformational Preference of Triazolylcyclohexanes ................... 256 
5.4 Procedure for Glycosidase Inhibition ....................................................................... 257 
References ....................................................................................................................................259 
Appendices 
A. Selected 1H NMH Titration Data ............................................................................... 266 
B. Selected 1H NMR Spectra .......................................................................................... 271 
C. Selected 13C NMR Spectra ......................................................................................... 282 




LIST OF TABLES 
 
Table 
1.  Some Glycosidases and the Disaccharides They Break Down. ................................... 41 
2.  Titration 1H NMR Data and Conformational Parameters for 3g.a). ............................. 61 
3.  1H NMR Data and Conformational Parameters for 5a-m.a). ........................................ 67 
4.  1H NMR Data and Conformational Parameters for 3a-m a). ........................................ 72 
5.  1H NMR Titration-Estimated Basicity a) (pKa) of Dicarboxylate Derivatives              
3c, 3d, 3f, 3g and 3k. ......................................................................................................... 79 
 
6.  1H NMR Data and Conformational Parameters for 8a-m.a). ........................................ 83 
7.  1H NMR Data and Conformational Parameters for 9a-m.a). ........................................ 84 
8.  1H NMR Data and Conformational Parameters for 3k and 3x.a). ................................ 89 
9.  1H NMR data and Conformational Parameters for 3h in Different Deuterated 
Solvents.a). ......................................................................................................................... 90 
 
10.  1H NMR Data and Conformational Parameters for 11-14 And 16.a). ...................... 102 
11.  1H NMR Data and Conformational Parameters for trans-2-Triazolyl-5-
Methyl/Phenyl/t-Butyl-Cyclohexanols. .......................................................................... 112 
 
12.  1H NMR Data and Conformational Parameters for trans-2-Triazolyl-4-
Methyl/Phenyl/t-Butyl-Cyclohexanols ........................................................................... 115 
 
13.  1H NMR Data and Conformational Parameters for trans-Triazolyl-4-
Methyl/Phenyl/t-Butyl-Cyclohexanes............................................................................. 126 
 
14.  1H NMR Data and Conformational Parameters for cis-Triazolyl-4-
Methylcyclohexanols 43a and 43b a). .............................................................................. 130 
 
15.  1H NMR Data and Conformational Parameters for cis-Triazolyl-4-
Phenylcyclohexanols 44a and 44b a). .............................................................................. 131 
 
16.  Calculated Conformational Enthalpy (∆Ho), Free Energy (∆Go) and Free          
Energy Of Solvation in Methanol (∆Gsol
o) for Substituted Cyclohexanes at 298K. ....... 135 
 
12 
LIST OF FIGURES 
 
Figure 
1.1.  Allosteric effect. ........................................................................................................ 21 
3.1.  Acid-induced conformational switch for derivative 3c in CD3OD (0.02M). ........... 59 
3.2.  Titration curves for 3g monitored by 1H NMR in CD3OD with (A) as signal      
width (W) and (B) as chemical shift (δ). .......................................................................... 63 
 
3.3.  Titration curve of 3g in CD3OD monitoring the signal width of H
4       
Corresponding conformer population (nB)........................................................................ 65 
 
3.4.  Titration curves of 3c, 3d, 3f, 3g and 3k in CD3OD monitoring the signal           
width of H4 with its corresponding conformer populations (nB). ...................................... 77 
 
3.5.  Sample estimation of pKa based on 
1H NMR titration curves.74 .............................. 78 
3.6.  Titration curves 3f and 3g in CD3OD monitoring the signal width of H
4                
with their corresponding conformer populations (nB) and show the pKa for their 
conformational switch. ...................................................................................................... 82 
 
3.7.  1H NMR of signal H4 of alcohol 3k and acetate 3x in CDCl3 solvent. ..................... 86 
3.8.  1H NMR of signal H4 of alcohol 3k and acetate 3x in CD3OD solvent. ................... 88 
3.9.  1H NMR spectra of azaarylcyclohexanol dicarboxylate 3h in solvents. ................... 91 
3.10.  X-ray crystal structure of 18b. .............................................................................. 118 
3.11.  1H NMR confirming separation of configuration isomers of 43b. ....................... 124 
3.12.  1H NMR signal (H1) for 44b. ................................................................................ 129 
3.13.  Optimized structures of substituted model cyclohexanes, .................................... 133 
3.14.  Optimized structures of triazolylcyclohexanes. .................................................... 134 
3.15.  1H NMR signals of trans-5-triazolyl-4-cyclohexanol-trans-1-2-             
dicarboxylic acid 47a (in (CD3)2CO). ............................................................................. 142 
 
3.16.  1H NMR signals of trans-5-triazolyl-4-cyclohexanol-trans-1-2-             
dicarboxylic acid 55a (in CDCl3). ................................................................................... 143 
13 
 
3.17.  NOE experiment for 58b in CDCl3. ...................................................................... 147 
3.18.  NOE experiment for 59c in CDCl3. ...................................................................... 148 
3.19.  NOE experiment for 57f in CDCl3........................................................................ 149 
3.20.  X-ray crystal structure for 57e. ............................................................................. 150 
3.21.  Effect of trans-5-triazolylcyclohexanol-1-2-dicarboxylic acids 47a,b,               
55a,b and 56a,b (1mM) on the activity of glycosidases from Aspergillus                   
Oryzae (A) and Penicillium Canenscens (B). ................................................................. 152 
 
3.22.  Effect of hexahydrobenzo-triazolo-oxazinones 57a-f (1mM) on the               
activity of glycosidases from Aspergillus Oryzae (A) and Penicillium               
Canenscens (B). .............................................................................................................. 154 
 
3.23.  Effect of trans-2-triazolylcyclohexanols 58a-d and 59a-c (1mM) on the        
activity Of glycosidases from Aspergillus Oryzae (A) and Penicillium              








1.1.   Conformational Chair Switch in trans and cis-1,4-Cyclohexane Derivatives. ........ 23 
1.2.   Conformational Chair Switch in trans and cis-1,2-Cyclohexane Derivatives. ........ 23 
1.3.   Cyclohexane-Based Crown Ethers with Counterbalances R.9 ................................. 24 
1.4.   Sulfur-Containing Cyclohexane-Based Crown Ethers.9 .......................................... 25 
1.5.   Cyclohexane-Based Podands with Counterbalances.9 ............................................. 25 
1.6.   Sulfur-Containing Cyclohexane Macrocycles. ........................................................ 26 
1.7.   Cyclohexane Podands with Chemically Adjustable Levers.14,15 ............................. 26 
1.8.   Conformational-Locked Cyclohexane Podands.16 ................................................... 27 
1.9.   Complexation of Cyclohexane-Based System with Sodium.21................................ 28 
1.10. Complexation of Cyclohexane-Based System with Potassium.9 ............................. 28 
1.11. Complexation of Cyclohexane-Based Systems with Copper.9 ................................ 29 
1.12. Complexation of Pyranose-Based Systems with Zinc.22,23 ...................................... 29 
1.13. Conformational pH-Induced Switch of trans-1,2-Diacidic Systems.19 ................... 30 
1.14. Conformational Chair-Chair Switches Due to Solvent Effect.31 ............................. 31 
1.15. pH-Induced Conformational Switches of trans-Aminocyclohexanols       
(TACHs).25  ....................................................................................................................... 32 
 
1.16. pH-Controlled Allosteric TACHs System for Cation Complexation.30................... 33 
1.17. Allosteric Enhancement of Ion-Transport Through an Organic Membrane.33 ........ 34 
1.18. Double Conformational Switch of cis-1,3-Diamine Derivatives of            
Fluorescent Moieties.35 ..................................................................................................... 35 
 
1.19. Double Conformational Flip of trans-3-Hydroxy-4morpholinopiperidine.37 .......... 36 
1.20. Complexation of Calcium with Diphenoxyethane.23,39 ............................................ 37 
15 
1.21. Conformational Complexations in Jurczak’s Macrocyclic Polyamides.41 .............. 38 
1.22. Urea-Based Anion Complexation Binding for Diphenylacetylene Scaffold.44 ....... 39 
 
1.23. Conformational Change of pH Responsive Di(methoxyphenyl)pyridine    
Scaffold.46 ......................................................................................................................... 40 
 
1.24. Specification of Functionality of α/β-D-Glucosidases. ........................................... 41 
1.25. Mechanism for Glycosidic Cleavage with Retention of Configuration.50 ............... 42 
1.26. Mechanism for Glyosidic Cleavage With Inversion of Configuration.52 ................ 43 
1.27. Nojirimycin and Deoxynojirimycin as α- and β- Glycosidase inhibitors.60 ............ 44 
1.28. New Nitrogen Based Glycosidase Inhibitors. .......................................................... 45 
3.1.   pH-Induced Conformational Switch of TACHs ...................................................... 49 
3.2.   pH-Induced Conformational Switch of trans-2-Azaarylsulfanylcylohexanols ....... 49 
3.3.   Library of trans-2-Azaarylcylohexanol/trans-2-Azaarylcyclohexanyl Acetate 
Dicarboxylates. ................................................................................................................. 50 
 
3.4.   Library of trans-2-(Azaarylsulfanyl)-Cylohexanols. ............................................... 51 
3.5.   Library of 4/5-tert-Butyl-trans-2-(Azaarylsulfanyl)-Cylohexanols. ....................... 52 
3.6.   Synthesis of trans-2-(Azaarylsulfanyl)-Cylohexanol Dicarboxylates 3a-m. ........... 53 
3.7.   Synthesis of trans-2-(Azaarylsulfanyl)-Cylohexanols 5a-m. .................................. 55 
3.8.   Synthesis of 4/5-tert-Butyl-trans-(Azaarylsulfanyl)- Cyclohexanols 8a-c and         
9a-c. ................................................................................................................................... 55 
 
3.9.   Limiting Parameters WA and WB for H
4 in Individual Conformers of trans-2-
Azaarylsulfanyl Cyclohexanols. ....................................................................................... 56 
 
3.10. Synthesis of Diethyl 4-((1H-benzoimidazol-2-yl)thio)-5-          
Acetoxycyclohexane-1,2-Dicarboxylate 3x by Acetylation. ............................................ 85 
 
3.11. Intermolecular Hydrogen Bonding of 3h in (CD3)2SO. ........................................... 92 
3.12. Intermolecular Hydrogen Bonding of 3h in CD3OD. .............................................. 93 
16 
3.13. Intramolecular Deuterium Based-Hydrogen Bonding of 3h due to DCl in        
CDCl3 and the Partial Stabilization of Conformer B. ....................................................... 93 
 
3.14. Acid-Induced Shift of the Conformational Equilibrium of trans-2-
Triazolylcyclohexanol Derivatives. .................................................................................. 94 
 
3.15. Library of Hexahydrobenzo-Triazolo-Oxazinone Dicarboxylate Derivatives ........ 95 
 
3.16. Library of Bis-Ethoxycarbonyl-trans-2-Triazolylcyclohexanol Derivatives. ......... 96 
3.17. Synthesis of trans-2-(1,4)Triazolylcyclohexanol/Cyclohexylacetate     
Dicarboxylate Derivatives ................................................................................................ 97 
 
3.18. Synthesis of trans-2-(1,4 and 1,5)Triazolylcyclohexanol Dicarboxylate  
Derivatives. ....................................................................................................................... 98 
 
3.19. Synthesis of trans-2-(1,4 and 1,5)Triazolylcyclohexylacetate Dicarboxylate 
Derivatives. ....................................................................................................................... 98 
 
3.20. Synthesis of trans-2-(4,5-diphenyl)Triazolylcyclohexanol/Cyclohexylacetate 
Dicarboxylate Derivatives. ............................................................................................... 99 
 
3.21. Synthesis of trans-2-(4,5)Triazolylcyclohexanol and                       
Hexahydrobenzo-Triazolo-Oxazinone Dicarboxylate Derivatives. .................................. 99 
 
3.22. Limiting Parameters WA and WB For H
4 in Individual Conformers of               
trans-2-Triazolylcyclohexanols Dicarboxylates and the Observed Averaged Signal  
Width W.   ....................................................................................................................... 101 
 
3.23. Library of trans-2-Triazolylcyclohexanol/Cyclohexyl Acetate Derivatives          
with and without Counterbalances. ................................................................................. 107 
 
3.24. Synthesis of trans-2-Triazolylcyclohexanols/Cyclohexyl Acetates. ..................... 109 
3.25. Synthesis of trans-2-(4,5-diphenyl)Triazolylcyclohexanol 18c. ........................... 109 
3.26. Synthesis of trans-2-Triazolyl-4/5-Methyl/Phenyl/t-Butyl-Cyclohexanols. ......... 110 
3.27. Synthesis of trans-2-Triazolyl-4/5-Methyl/Phenyl/t-Butyl-Cyclohexyl         
Acetates.  ......................................................................................................................... 111 
 
3.28. Library of cis/trans-Triazolylcylcohexanes. .......................................................... 121 
3.29. Synthesis of Triazolylcyclohexanes. ...................................................................... 121 
3.30. Synthesis of cis/trans-Triazolyl-4Methyl/Phenyl/t-Butyl-Cyclohexanes. ............. 123 
17 
3.31. Conformational Equilibrium in trans-Triazolylcyclohexanes. .............................. 124 
3.32. Conformational Equilibrium in cis-Triazolylcyclohexanes. .................................. 125 
3.33 4-Hydroxy-5alkoxy-1,2-Cylohexanedicarboxylic Acids-Glycosidase    
Inhibitors.85,86 .................................................................................................................. 137 
 
3.34. Library of trans-5-Triazolyl-4-Cylohexanol-trans/cis1-2-Dicarboxylic             
Acids. .............................................................................................................................. 138 
 
3.35. Synthesis of trans-5-Triazolyl-1-2-Cylohexanol Dicarboxylic Acids. .................. 139 
3.36. Synthesis of cis-2-Triazolylcylohexanol Dicarboxylic Acids. .............................. 141 
3.37. Library of trans-2-Triazolylcylohexanols And Hexahydrobenzo-Triazolo-
Oxazinones.   ................................................................................................................... 144 
 
3.38. Synthesis of trans-2-Triazolylcylohexanols and Hexahydrobenzo-Triazolo-
Oxazinone Derivatives. ................................................................................................... 145 
 
3.39. Synthesis of Hexahrdrobenzo-Triazolo-Oxazinone-4-Carboxylate           
Derivatives. ..................................................................................................................... 146 
 
3.40. Synthesis of trans-2-Triazolylcyclohexanol Derivatives....................................... 146 






LIST OF ABBREVIATIONS 
 
A   axial position of a substituent 
AA   diaxial position of substituents 
Borax   Sodium tetraborate 
COSY   Correlated Spectroscopy 
CuAAC  Copper (I) catalyzed alkyne-azide cycloaddition  
Dart   Direct Annalysis in Real Time 
DCM   Dichloromethane / Methylene chloride 
DMF   Dimethylformamide 
DMSO   Dimethyl sulfoxide 
E   equatorial position of a substituent 
EtOAc   Ethyl Acetate 
Hex   Hexanes 
HRMS   High Resolution Mass Spectrometry  
HMQC  Heteronuclear Multiple-Quantum Correlation 
IMHB   Intramolecular hydrogen bonding 
EE   diequatorial position of substituents 
NMR   Nuclear Magnetic Reasonance 
NOESY  Nuclear Overhauser Effect Spectroscopy 
mCPBA  meta-Chloroperoxybenzoic acid 
Ph   Phenyl group 
ROESY  Rotating-frame Overhauser Effect Spectroscopy 
THF   Tetrahydrofurane 
TACH   trans-amino cylohexanol 
19 
TLC   Thin layer chromatography 
























CHAPTER 1: INTRODUCTION 
 
Molecular Switches 
Molecular switches are molecules whose properties, shape or conformation, can be 
altered reversibly.  The requirements for a molecule to be classified as a molecular switch 
include: two or more stable or meta-stable states, reversibility of switching within the given 
states and activation of switching by external stimuli1.  These switches are triggered by metal 
complexation, electric fields, light at specific wavelength, pH changes etc.  On exposure to these 
external stimuli, some molecules exhibit a conformational change, hence the term mechanical or 
conformational switch.  Molecular switches are useful in designing controllable compounds with 
variety of functionality, which may include drug release, information storage and information 
transmission.1–6  
Allosteric systems are among the most studied conformationally switchable systems.  The 
presence of two or more binding sites on the allosteric system (e.g.  enzyme molecules) enables 
the switching capability of the molecule to be monitored.  The binding of an allosteric activator, 
in a form of another molecule or ion, results in the mechanical transmission of a signal thought 
the allosteric system leading to a conformational change at the active site (Figure 1.1).  This 
same approach can be used for allosteric inhibition.  The principle of allosteric activity is well 
studied and the effects of small molecules as inhibitors or activators is also well known.7,8 
21 
 
Figure 1.1.  Allosteric effect. (a) Binding of the allosteric inhibitor to one end of the system 
changes the conformation enabling inhibition at the active site and blocking the binding of the 
substrate.  (b) Binding of the allosteric activator to one end of the system changes the conformation 




Cyclohexane-Based Conformational Switches 
The cyclohexane-based molecular systems provide an efficient model for conformational 
switches in relation to allosteric systems.  The conformational switches in cyclohexanes are 
elucidated by monitoring the chair-chair conformational transition in relation to the positioning 
of the protons9.  A negative cooperativity within the cyclohexane switches can be observed by 
the position of the protons on the molecule when a switch occurs upon interaction with external 
stimuli.  The effect of interacting with external stimuli on one end of the cyclohexane is 
transferred through the ring.  While switching, the position of all protons and substituents will 
change from axial to equatorial and vice versa depending on their initial positioning10.   
Trans and cis-cyclohexane derivatives (Scheme 1.1 and 1.2)  have been well studied due 
to the simplicity of their structures.9,11,12 Trans-1,4- and cis-1,4-cyclohexane derivatives help to 
22 
explore the interaction of the substituents with the ring and the ability for one of the substituents 
to act as a “counterbalance.” The diequatorial conformer B for trans-1,4-cyclohexane derivative 
(Scheme 1.1) is more stable than the diaxial conformer A due to the steric repulsion between the 
substituents and the ring.  Trans and cis-1,2-cyclohexane derivatives (Scheme 1.2) help to 
compare the gauche repulsion for the substituents in conformer B and the steric repulsion of the 
axial substituents in conformer A.  The latter repulsion usually causes more strain on the ring 
leading to a preference for conformer B.  However, interactions like hydrogen bonding and ionic 
attraction may also lead to the stabilization of conformer B.  Other factors that may affect this 
equilibrium include; shape, size, polarity, intra- and intermolecular interactions, temperature, 
solvent interactions etc.  Several illustrated examples of the cyclohexane-based conformation-














Scheme 1.1.  Conformational Chair-Chair Switch in trans and cis-1,4-Cyclohexane Derivatives. 
 
 
Scheme 1.2.  Conformational Chair-Chair Switch in trans and cis-1,2-Cyclohexane Derivatives.   
 
Structural Effects on Conformation Switches 
Given the unfavorable conditions with substituents in the axial position experiencing 
steric repulsion in structures 1-4, the same trend is expected in the conformational behavior of 
trans-cyclohexano-15-crown-5 and trans-cyclohexano-18-crown-6 structures (Scheme 1.3).9 
Therefore with no counterbalance (R = H) there is a conformational preference for structures 5E, 
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as compared to 5A.  The conformational preference can be determined by the free energy 




Scheme 1.3.  Cyclohexane-Based Crown Ethers with Counterbalances R.  9 
 
Introduction of bulky substituents or attractive/repulsive interactions on a cyclohexane 
ring can affect the conformational equilibrium and the preference for conformer A or E.   These 
bulky substituents can act as counterbalances and transmit conformational change through the 
cyclohexane ring.  The presence of small counterbalances, like R = CH3, on trans-cyclohexano-
15-crown-5 and trans-cyclohexano-18-crown-6 structures (Scheme 1.3) shows a considerable 
shift in equilibrium towards conformation A.  The axial methyl group in conformer 5E 
destabilizes the structure by at least 8 kJ/mol.  A similar effect is seen with the presence of axial 
cyano group (R = CN).  Therefore, the presence of counterbalances in these crown ethers shifts 






Scheme 1.4.  Sulfur-Containing Cyclohexane-Based Crown Ethers.9  
 
The preference for the equatorial position on a cyclohexane is dependent on the size and 
rigidity of the substituents.  For example, the sulfur-containing cyclohexane-based crown ethers 
6 and 7 (Scheme 1.4), that are more flexible, have a substantially less predominance for the 
equatorial conformation E as compared to analogous cyclohexane-based crown ethers.9 
 
 
Scheme 1.5.  Cyclohexane-Based Podands with Counterbalances.9 
 
Podands (Scheme 1.5), noncyclic structural analogs of crown ethers (Scheme 1.3), have 
less rigidity due to their noncyclic ether chains that allow for movement and structural flexibility.  
In the absence of a counterbalance (R = H) podand 8 has a higher population of conformer A 
compared to the analogous crown ether 5.  In the presence of counterbalances, R = CH3, 
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CH(OCH2CH2O) or COCH3, podand 8 shows even greater increase in population of conformer 
A as compared to analogous crown ethers.9,17,18  
 
 
Scheme 1.6.  Sulfur-Containing Cyclohexane Macrocycles  
 
In the presence of more than one substituent attached to the cyclohexane ring, the 
equilibrium can be shifted based on the interaction of the substituents with each other and with 
the cyclohexane ring.  For example, two axial ethoxycarbonyl groups of the sulfur-containing 




Scheme 1.7.  Cyclohexane Podands with Chemically Adjustable Levers.14,15 
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If a bulky group can be chemically modified into a smaller group, then the relative 
stability of the conformers can be varied.   For example, the presence of an acetal group, a bulky 
substituent, on podand 11 gives complete preference for conformer 11A (Scheme 1.7).  Upon the 
hydrolysis of the acetal group to a smaller acetyl group in podand 12, there is now a complete 
change in conformational orientation to favor 12E.  This interaction is used to control the 
complexation of podands with alkali metals which is possible for only 12E.16 
 
 
Scheme 1.8.  Conformational-Locked Cyclohexane Podands.  16 
 
An alternative approach can be locking the sterically unfavorable conformer A by 
chemically inserting a five-member cyclic acetal on the cyclohexane ring 13A.  The bridge 
forces the polyether groups to stay in axial positions.  However, the conformer E favorable for 
complexation can be achieved by hydrolysis of the acetal group to diols (Scheme 1.8).  16 The 
resulting structure has the polyether groups in energetically preferred equatorial positions (14 E) 
Cyclohexane Complexation-Induced Conformational Switch 
Complexation is an avenue for altering the conformational preference.  Given that the 
interaction during complexation is powerful in terms of energy and can be transmitted through 
the molecule by the mechanics of the cyclohexane ring, the bulky substituents can move from the 
equatorial to axial position.  The only constraint for these systems is that their conformational 
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energy cannot exceed the energy needed to screw the ring into a twist form (23–26 kJ/mol).9,10 
Consequently, complexation can be used as a conformational trigger based on the interactions at 
the complexation site.18 This complexation usually involves the interactions of the compounds 
with cations from sodium, potassium, copper, zinc, and others metals.  For instance, the shift of 
dipodand 15E from diequatorial orientation to diaxial orientation, 16A, occurs due to 
complexation with sodium (Scheme 1.9).21 
 
 
Scheme 1.9.  Complexation of Cyclohexane-Based System with Sodium.  21 
 
 
Scheme 1.10.  Complexation of Cyclohexane-Based System with Potassium.  9 
 
Compounds with the structure 17, podands with R = CH2CH3 and R1 = CH2CH3, and 
crown ethers with R = CH3 or CN and R1 = CH2CH2, have an initial preference for 
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conformation A (Scheme 1.10).  These compounds adopt conformation E upon the complexation 
with KSCN.   Crown ethers and podands of this nature are potential sensor materials in PVC-
matrix membranes of ion-selective electrodes.9 
The same interaction is seen between copper cations and cis-1,3diaminocyclohexane 18.  
Before complexation, 18E is the predominant conformer.  Upon interaction with a copper ligand, 
its conformation changes from diequatorial, 18E, to diaxial 18A, due to the attraction of both 
amino groups to the copper ion (Scheme 1.11)9.   
 
 
Scheme 1.11.  Complexation of Cyclohexane-Based Systems with Copper.  9 
 
 
Scheme 1.12.  Complexation of Pyranose-Based Systems with Zinc.22,23 
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Similar to cyclohexane-based systems, pyranose- based systems, saccharides made of six-
membered ring consisting of five carbon atoms and one oxygen atom, are known to complex 
with metals.  This particular system was designed to be part of the bilayers of liposomes, 
spherical vesicles comprising of a lipid bilayer that can be disrupted by stimuli to release its 
load.24 This liposome, containing 2,4-diaminoxylopyranoside, is able to release its cargo upon 
interaction with zinc.  The Zinc cation binds to the amino groups and holds them in diaxial 
positions resulting into the hydrophobic alkoxy groups switching to diaxial positions; thus the 
conformational preference form 19E to 19A (Scheme 1.12).22,23 
pH-Induced Conformational Switch 
Cyclohexanes are also good potential models for pH-controlled molecular switches.  The 
two adjacent carboxylic groups in compounds 20 and 21 energetically favor conformer E due to 
the intra-molecular hydrogen bonding between these two groups.  Upon addition of base, these 
two carboxylic groups are converted to carboxylate ions that experience strong electrostatic 
gauche repulsion.   This shifts the conformational preference from E to A.  However, the 
preference for E can be restored by addition of acid.  The energy of this conformational switch 




Scheme 1.13.  Conformational pH-Induced Switch of trans-1,2-Diacidic Systems.19 
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The interactions due to intramolecular and intermolecular forces can also function as 
counterbalances in the conformational preferences of trans-2-aminocyclohexanols.  This 
functionality can be monitored by analyzing the conformational behavior in different solvents9.  
In CDCl3, conformer 22A is more stabilized due to the formation of intramolecular hydrogen 
bonding of the type OH...N between vicinal substituents.   In CD3OD or CD3CN, the 
conformational equilibrium shifted towards conformer 22E.  This is because the intramolecular 
hydrogen bonding is disrupted and replaced by an intermolecular hydrogen bonding with solvent 
(Scheme 1.14).   Other trans-2-amino-cyclohexanol showed the same characteristics.9,25–31 
 
                    
Scheme 1.14.  Conformational Chair-Chair Switches Due to Solvent Effect.  31 
 
An adaptable way of altering the conformational equilibrium of trans-
aminocyclohexanols  is the use of acid to protonate the amino group and create a strong 
intramolecular hydrogen bond between the proton on the protonated amine and the hydroxyl 
group’s lone pair electrons (O...H-N+ type) as seen in 23AH+ (Scheme 1.15).9,19,29–32 
Upon protonation, the trans-aminocyclohexanol’s hydroxyl and protonated amino groups 
adopt a strong attraction due to the hydrogen bond.  This attraction, whose energy may exceed 20 
kJ/mol, is transmitted mechanically thought the cyclohexane ring and is able to alter the position 
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of the substituents on the other end of the ring.  This translation alters the interactions of 
substituents across the ring.  Hence, the vicinal OH/NR2 groups are a plausible target due to their 
specificity in binding to protons in allosteric systems with high negative cooperativity, bringing 
trans-2-aminocyclohexanols potential applications in aspects of pH-sensitive membrane 
transport and targeted drug delivery to importance.9,31,32 
 
 




Scheme 1.16.  pH-Controlled Allosteric TACHs System for Cation Complexation.30 
 
The effect of protonation and complexation can be merged in controlling the 
conformational equilibrium of trans-aminocyclohexanols.  By adding acid, that can protonate the 
amine group and avail the hydrogen for intramolecular bonding, the crown ether’s and podand’s 
affinity for metal ions can be regulated. 
For instance, crown compounds 24 and 25 (Scheme 1.16) have two different sites that 
alter the conformation of the cyclohexane; HO….HN+R2 groups’ interactions and complexation 
of potassium ions with ether tails of podands or crown ethers respectively.  Diequatorial 
arrangement of the ether tails in conformer E is necessary to aid in cation complexation, as 
discussed in Scheme 1.10, and further strengthens the equatorial positioning in conformer 
EK+.9,18,30   
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Scheme 1.17.  Allosteric Enhancement of Ion-Transport Through an Organic Membrane.33 
 
The effect of complexation and protonation can also be used in ion transport with trans-
2-cylohexanols as the carrier.34 For instance, compound 26 transports potassium cations in 
membranes between phases of different pH (Scheme 1.17).  In a low pH environment, the crown 
ether undergoes a conformational change from 26E.3K+, which is able to complex with 
potassium cations, to 26AK+, which is not able to undergo complexation.  During this process, 
potassium ion can be transferred more effectively from the source phase (higher pH) to the 







Double Conformational Switch 
 
 





Amino compounds 27 undergo a more complex protonation-induced conformational 
switching.  The neutral, monocationic and dicationic states of the molecule all play roles in the 
conformational preference.  These three amine protonation states are formed with the stepwise 
addition if acid.  The amino groups 27E (Scheme 1.18) were initially in diequatorial orientation 
to ease repulsion.  Upon protonation by a low concentration of acid, one of the amino groups is 
protonated and interacts with the other to form a bridge hydrogen bond which fixes the ring in a 
tetra-axial conformation 27AD+.  Consequent to the addition of more acid, the second amino 
group is protonated.  This results in the breakage of the hydrogen bond and recreates repulsion 
due to the positive charges on the amino groups.  This results into the stabilization of the tetra-
equatorial conformation 27E2D+.  Fluorescent substituents were used to follow the stepwise and 
reversible conformational behavior under the influence of pH.   At 395 nm, monomer emissions 
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of neutral 27E and dication 27E2D+ were present.  This is because the tetra-equatorial 
conformation restricts any close proximity of the fluorescent substituents.   However, the 
initiation of 27AD+ resulted in a shift in fluorescence emission at 460 nm due tetra-axial locked 
cyclohexane ring conformation.  9,22,35,36  
 
 
Scheme 1.19.  Double Conformational Flip of trans-3-Hydroxy-4Morpholinopiperidine.  37 
 
Trans-3-hydroxy-4-morpholinopiperdines undergo a more complex conformational 
system of two consecutive conformational flips or double flips.   This flipping is dependent on 
the initial protonation of the secondary amine in the piperdinyl cycle and a further final 
protonation of tertiary amine in the morpholinyl cycle.  Compound 28 (Scheme 1.19), in 
hydrochloride form, was used to characterize the pH-induced conformational equilibrium in 
CD3OD.  It was noticed that both 28E, achieved by adding excess base (DBU), and the double 
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protonated form 28E2H+, achieved by addition of excess acid (d-TFA), prefer the diequatorial 
conformations and are more stable than the diaxial conformations by 1.6 kcal/mol.  This double 
flip was confirmed by monitoring signal width using 1H NMR.37,38 
Non-Cyclic Complexation-Induced Conformational Switch 
Complexation of molecules can also happen around non-cyclic bonds.  The flexibility of 
these bonds and the interaction of particular functional groups with ions help to change the 
molecular structures from one orientation to the other.  The ion interactions usually replace or 
support other intramolecular interactions like hydrogen bonding and weaker ion interactions. 
 
 
Scheme 1.20.  Complexation of Calcium with Diphenoxyethane.23,39  
 
A new application for complexation is the development of designer liposomes that 
release their contents due to interaction with metal ions that force conformational changes within 
the lipid layers of the liposome.  This phenomenon is plausible as a drug delivery tool in the 
treatment of malaria due to the increase in concentration of calcium when infected by plasmodia, 
bacteria that cause malaria.40 With molecules of structure 29A (Scheme 1.20) fused in the lipid 
bilayer, the liposome is loaded with a drug that treats malaria.  The drug is released in areas of 
38 
high concentration of calcium ion by perturbation of the lipid bilayer through the complexation 
with calcium to form structure 29B.  23,39 
 
 
Scheme 1.21.  Conformational Complexations in Jurczak’s Macrocyclic Polyamides.  41  
 
Recently, macrocyclic polyamides, that are primarily folded and unfold in the presence of 
anions, were tested for conformational change.41–43 The pyridine-2,6-dicarboxylate derivative 30 
has the most selective binding to chloride and underwent the most noticeable conformational 
switch 30B (Scheme 1.21).   The non-pyridine derivative 31 was less selective, binding to 
chloride, acetate, benzoate and dihydrogen phosphate, but gave crystal structures that were able 
to confirm both conformers 31A and 31B.   This also confirmed that the intramolecular hydrogen 
bonding between the amides was not stronger than the ionic interactions for the macrocylic 
polyamides.   
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Scheme 1.22.  Urea-based Anion Complexation Binding by a Diphenylacetylene Scaffold.  44 
 
Diphenylacetylene fragment is commonly used in ion complexation systems because of 
its rigid structure, low barrier of rotation and electronic ability to interact with cations due to 
centralization of charge.42,44,45 In the interactions of diphenylacetylene derivative 32, absence of 
external stimulus leads to hydrogen bonding between the lactone and the bidentate urea in 32A 
(Scheme 1.22).  In the presence of chloride ions, complexation stabilizes conformer 32B by ionic 
interactions with the bidentate urea.   
Besides complexation, other non-bonding interactions may include hydrogen bonding 
and electrostatic interactions.  One of the advantages of these non-bonding interactions is they 
can be manipulated by external influences like solvent and acids/bases.  This manipulation can 
cause a reversible change in the stability of the conformers.  For instance, some new pH-
responsive lipids, based on a di(methoxyphenyl)pyridine scaffold, exist initially as conformer A 
(Scheme 1.23).  Upon protonation of the pyridine, intramolecular hydrogen bonding between the 
methoxy and pyridinium groups help stabilize conformer B.  The compound 33, 34 and 35 all 










Glycosidases (also known as glycoside- or glycosyl-hydrolases) are enzymes that are 
responsible for the breakdown of sugars through the hydrolytic cleavage of the glycosidic bond.  
These enzymes are found in microorganisms, plants and animals.47 These enzymes play an 
important role in the digestion of oligosaccharides, glycoproteins, glycolipids and carbohydrates.  
On a cellular level, glycosidases are involved in the building of cell walls and other components 
of a cell.  They are also involved in a diverse amount of metabolic disorders and diseases, such 
as diabetes, viral and bacterial infections, HIV and cancer48.  With the growing resistance to 
glycosidase inhibitors by different viruses and bacteria has increased the demand for research 
into efficient inhibitors, and a better understanding of their structure and activity49. 
The stereochemistry of the linkage at the anomeric carbon, α/β linkage, specifies the 
functionality of these enzymes, α/β glucosidases (Scheme 1.24).  Upon recognition, the 
glycosidic bond is hydrolyzed and the polymer, like a disaccharide, is broken down into 
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monomers (Table 1).  This ability for these enzymes to recognize and target a specific glycosidic 
bond has made them a viable target to control specific pathways and treat diseases. 
 
            
Scheme 1.24.  Specification of Functionality of α/β-D-Glucosidases. 
 
Table 1 
Some Glycosidases and the Disaccharides They Break Down 
 
Enzyme Disaccharide Glyco-monomers Glycosidic bond 
β-D-Glucosidase Cellobiose Glucose, Glucose β (1 – 4) 
α-D-Glucosidase Sucrose Glucose, Fructose α (1 – 2) 
β-D-Galactosidase Lactose Galactose, Glucose β (1 – 4) 




Mechanism for Enzyme-Catalyzed Hydrolysis by Glycosidases 
Glycosidase classification is based on the mechanism by which they break the glycosidic 
bond of the substrates that they act upon.  The two classifications are: the glycosidases that retain 
the configuration of the glycosidic bond upon hydrolysis and the glycosidases that invert the 




supported experimentally by generation of different substrates designed to study the kinetics of 
the breaking and reformation of the glycosidic bond.47,50,51 
 
 
Scheme 1.25.  Mechanism for Glycosidic Cleavage with Retention of Configuration.50 
 
Glycosidases that retain configuration exchange the sugar moiety for water or an alcohol 
resulting in the conservation of anomeric configuration.  The mechanism of these glycosidases 
involves a double displacement with two consecutive inversions involving the formation and 
hydrolysis of a covalent glycosyl-enzyme intermediate, both steps proceeding through 
oxocarbenium ion-based transition state (Scheme 1.25).   The carboxylic groups at the active 
sites act in two different steps.   In the first step, as one carboxylic acid protonates the glycosidic 
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oxygen, the bond cleavage occurs.  The second carboxylate performs a nucleophilic attack on the 
substrate forming a covalently bonded glycosyl-enzyme intermediate.  In the second step, as one 
carboxylate deprotonates the water, the second carboxylate forms a covalent bond to the 
substrate.   The deprotonated water attacks the substrate and replaces the sugar.   Both steps 





Scheme 1.26.  Mechanism for Glyosidic Cleavage with Inversion of Configuration.52 
 
Glycosidases that invert configuration are shown in Scheme 1.26.  The process of this 
inversion of configuration proceeds through an SN2 like mechanism.  The carbonyl groups are 
important for protonation of the substrate and deprotonation of water, allowing the substrate and 
water to binding between them.   The inversion of configuration occurs through an 
oxocarbenium ion-like transition state.52,53 
Thus, the functionality of these enzymes depends on the ability of the enzyme to 
recognize the orientation at the anomeric carbon: either retain or alter the conformation of the 
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substrate depending on the substrate’s interaction with the carboxylic acids residues found in the 
enzyme’s active site.54,55 
Glycosidase Inhibitors 
The target for inhibition of glycosidases is usually the substrate or transition state.56–58 
The design of these inhibitors was first envisioned  by Baker.59 The idea of mimicking substrate 
with high affinity and specificity for the active sight would be important in the discovery of 
glycosidase inhibitors.  The substrate is usually a glycoside of a monomer sugar or a 
carbohydrate.  Many glycoside-based inhibitors, both natural and synthetic, have been 
discovered as glycosidase inhibitors.  By conserving the glycone, sugar residue, and altering the 
aglycone, non-sugar residue, many inhibitors have been discovered and are now active drugs.  
The glycone is usually hydrophilic and is recognizable by the enzyme.  The aglycone is usually 
hydrophobic and is designed to interact with the hydrophobic enzyme pocket.51,55 Modification 
to the glycone have been explored to produce notable inhibitors in form of iminosugars49,60 like 
nojirimycin and deoxynojirimycin (Scheme 1.27).  Elongation of R group in deoxynojirimycin 









Scheme 1.28.  New Nitrogen Based Glycosidase Inhibitors. 
 
The growing resistance to glycosidase inhibitors by different viruses and bacteria has 
increased the demand for research into efficient inhibitors, and a better understanding of their 
activity.49 The structural similarity between the inhibitor and substrate, a transition state or a 
product of enzyme catalysis, is important for the stereospecific interaction between the inhibitors 
and the enzyme’s active site.  Analogous to iminosugar-based glycosidase inhibitors, new 
pyrrole, imidazole, and tetrazole-based glycosidase inhibitors51 are emerging drugs (Scheme 
1.28) and this has created some interest in other nitrogen-based cyclic substituents, triazoles.62 
Use of the triazolyl substituent would be advantageous due the synthetic ease for both 1,4 and 
1,5 triazoles.63  
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CHAPTER 2: RESEARCH GOALS 
 
Molecular Switches 
The goal of this project was to synthesize trans-2-(azaarylsulfanyl)-cyclohexanol and 
triazolyl-cyclohexanol derivatives and assess their ability to undergo molecular switching due to 
change in pH.  The aim of the research was as follows: 
• Design and synthesis of a series of novel trans-2-(azaarylsulfanyl)-cyclohexanol and 
triazolyl-cyclohexanol derivatives with differences in structure of the nitrogen-based 
heterocycles. 
 
• Access the influence that counterbalances, ethoxylcarbonyl tails, have on the conformation 
of the hydrophilic nitrogen-based heterocycle heads for trans-2-(azaarylsulfanyl)-
cyclohexanol and triazolyl-cyclohexanol derivatives. 
 
• Access the sensitivity of trans-2-(azaarylsulfanyl)-cyclohexanol and triazolyl-cyclohexanol 
derivatives to change in pH. 
 
• Access the change in conformational equilbrium of trans-2-(azaarylsulfanyl)-cyclohexanol 
and triazolyl-cyclohexanol derivatives in response to change in pH. 
 
• Determine the conformational preference, A-value, of the triazolyl group on a cyclohexane. 
 
Glycosidase Inhibitors and Activators 
The goal of this project was to synthesize trans/cis-2-triazolylcyclohexanol dicarboxylic 
acids, trans-2-triazolylcyclohexanols and hexahydrobenzo-triazolo-oxazinone derivatives, and 
test their glycosidase activity on α/β-D-glucosidases and α/β-D-galactosidases isolated from 
fungi Aspergillus and β-D-glucosidases and α/β-D-galactosidases isolated from Penicillium sp.  
The aim of the research was as follows: 
• Design and synthesize a series of trans/cis-2-triazolylcyclohexanol esters and dicarboxylic 
acids, trans-2-triazolylcyclohexanols and hexahydrobenzo-triazolo-oxazinone derivatives. 
 
• Test the effect of glycosidase activity by trans/cis-2-triazolylcyclohexanol dicarboxylic 
acids, trans-2-triazolylcyclohexanols and hexahydrobenzo-triazolo-oxazinone derivatives on 
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α/β-D-glucosidases and α/β-D-galactosidases isolated from fungi Aspergillus and β-D-












































CHAPTER 3: RESULTS AND DISCUSIONS 
 
Molecular Switches 
Previously, TACHs (Schemes 1.19 and 3.1) were found to undergo a pH-induced 
conformational switch.  Addition of acid to these compounds resulted in protonation of the 
amino group consequentially forming a strong intramolecular hydrogen bond of the type 
HO...H-N+ that altered the conformational preference from diaxial to diequatorial for the amino 
and hydroxyl substituents.  A counterbalance of two ethoxylcarbonyl groups was used to confirm 
the chair-chair flip.  These adjacent ethoxylcarbonyl groups, in trans-configuration to each other, 
exhibited the direct opposite orientation to the amino and hydroxyl groups, i.e., when the amino 
and hydroxyl groups were axil, the adjacent ethyl ester groups were quatorial and vice versa.  
Alterations of the substituents on the amine nitrogen of trans-2-aminocyclohexanols varied the 
basicity of the amino group, resulting in a wide pH range within which molecular switches were 
possible (Scheme 3.1).25,26,31,38,64 
 
 




Scheme 3.2.  pH-Induced Conformational Switch of trans-2-Azaarylsulfanylcylohexanols. 
 
To expand the existing assortment of potential pH-triggers, we designed analogous trans-
2-(azaarylsulfanyl)-cyclohexanols (Scheme 3.2).  The cyclohexanol and two adjacent 
ethoxylcarbonyls were conserved as in TACHs.   The design places sulfur in between the 
cyclohexane ring and a nitrogen-heterocyclic ring.  The advantage of these models could be an 
additional shift of conformational equilibrium towards conformer A due to the gauche repulsion 
between the lone pair electrons of oxygen and sulfur.  The strong initial bias for A would provide 












Library of trans-2-Azaarylsulfanylcyclohexanol Derivatives 
 
 
Scheme 3.3.  Library of trans-2-Azaarylcylohexanol/trans-2-Azaarylcyclohexanyl Acetate 
Dicarboxylates. 
 
With the design of trans-2-azaarylsulfanylcyclohexanols in Scheme 3.2, a library of 
trans-2-azaarylsulfanylcyclohexanols dicarboxylates 3a-m was proposed for synthesis and 
studied as potential conformational switches (Scheme 3.3).  Compounds 3a and 3b were 
designed as the reference models for the structures 3a-m that can undergo intramolecular 
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hydrogen bonding and the stabilization of conformer BH+ in acid conditions.  They contain 
azaaryl groups varying in size, number of nitrogen atom and other heteroatoms, and sometimes 
equipped with additional substituents.  Compound 3x, an acetoxy derivative of 3k, was 
synthesized to compare the interaction of the hydroxyl and acetate substituent with the 
azaarylsulfanyl group’s nitrogen atoms and hence access the conformational preference due to 
each substituent.  This variety of azaarylsulfanyl groups, with their nitrogens in different 
positions, would help explore the strength of pH-induced intramolecular hydrogen bonding. 
 
 
Scheme 3.4.  Library of trans-2-(azaarylsulfanyl)-Cylohexanols. 
 
Compounds 5a-m (Scheme 3.4) were synthesized to mirror compounds 3a-m (Scheme 
3.3), but with no ethoxylcarbonyl groups as counterbalances.  Absence of these ethoxylcarbonyl 
counterbalances isolates the effect of the gauche interactions between the hydroxyl and thiol or 
azaarylsulfanyl groups.   
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Compounds 5a-m were expected to have a very biased conformational equilibrium and 
thus provide the conformational models with hydroxyl and azaarylsulfanyl groups in the 
diequatorial positions.  Contrasting, compounds 8a-c and 9a-c (Scheme 3.5) were designed with 
a strong counterbalance of tert-butyl directly across the hydroxyl and the azaarylsulfanyl groups.  
This would hold the hydroxyl and azaaryl groups in diaxial positions, hence elucidating the 
conformational limits of these groups in that orientation. 
 
 









Synthesis of trans-2-(azaarylsulfanyl)-Cyclohexanol Derivatives 
 
 
Scheme 3.6.  Synthesis of trans-2-(azaarylsulfanyl)-Cylohexanol Dicarboxylates 3a-m. 
 
Trans-2-(azaarylsulfanyl)-cyclohexanol dicarboxylates 3a-m (Scheme 3.6) were 
synthesized beginning with diethyl 4-cyclohexene-trans-1,2-dicarboxylate 1, which was 
previously synthesized19,29,30 through a Diels-Alder reaction between butadiene-sulfone and 
diethyl fumarate.  The synthetic advantage of Diels-Alder reaction is the conservation of 
stereochemical information of the diene and dienophile.   This resulted in the trans orientation of 
the ethoxylcarbonyl groups.  Epoxidation of alkene 1 was done with m-chloroperoxy benzoic 
acid (m-CBPA) in dichloromethane (DCM).  The epoxide, diethyl 7-oxabicyclo[4.1.0]heptane-
3,4-dicarboxylate 2, was isolated by column chromatography.  The final step of the synthesis 
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was the cleavage of the epoxide with azaarylsulfanyl groups.   This was done with various 
solvent ratios of H2O and tetrahydrofuran (THF) depending on the solubility of the 
azaarylsulfanyl compounds.67–70 The synthesis was done under argon (Ar) to avoid oxidation of 
the sulfanyl groups, forming disulfide bridges, in the presence of oxygen.  The products were 
isolated by column chromatography and yields of the pure compounds were satisfactory. 
Similar to compounds 3a-m (Scheme 3.6), trans-2-(azaarylsulfanyl)-cyclohexanols 5a-m 
(Scheme 3.7) were synthesized beginning with commercially available cyclohexene oxide 4.  
Cyclohexene oxide was cleaved with the same conditions for compounds 3a-m and sufficient 
yields of pure compounds were obtained. 
Conformationally biased 4/5-tert-buytl-azaarylsulfanylcyclohexanols 8a-c and 9a-c 
(Scheme 3.8) were synthesized to analyze the NMR data for diaxial orientation of the two 
substituents.  Commercially available 4-(tert-butyl)cyclohexene 6 underwent epoxidation with 
m-CPBA and DCM to produce 3-(tert-butyl)-7-oxabicyclo[4.1.0]heptane 7.  Epoxide 7 was 




Scheme 3.7.  Synthesis of trans-2-(azaarylsulfanyl)-Cylohexanols 5a-m. 
 
 








Scheme 3.9.  Limiting Parameters WA and WB for H
4 in Individual Conformers of trans-2-
Azaarylsulfanyl Cyclohexanols. 
 
The fast equilibrium [A + AH+]  [B + BH+] (Scheme 3.9) was examined by 1H NMR 
spectroscopy (600 MHz).  The vicinal coupling constants 3JHH between several protons attached 
to the cyclohexane moiety are strongly conformationally-dependent, which allows an assignment 
of a predominant conformation and an evaluation of the position of conformational equilibrium: 
100% A
21.5 Hz 27.0 Hz
3.74 3.72 3.70 3.68 PPM
observed
3.74 3.72 3.70 3.68 3.66 PPM
100% B




large vicinal couplings, 9-12 Hz, are observed between the diaxial protons (as H1 and H2 in A, 
Scheme 3.9), and small values, 2-5 Hz, are measured for the axial-equatorial and equatorial-
equatorial vicinal couplings protons (as H4 and H5 in A, Scheme 3.9).71 The observation of a 
single set of well-resolved multiplets with the averaged NMR parameters attests to high rates of 
both conformational and acid-base equilibria on the NMR time scale. 
The conformer populations (nA, nB) in dilute solutions were estimated as described 
previously25–27,30,32,64,65,72 using Eliel’s equation10,13 applied to the averaged signal width W = 
JHH (a sum of spin-spin couplings) of the protons geminal to the substituents: (Wobserved = WA·nA 
+ WB·nB.).  The parameter W was measured as a distance between terminal peaks of a multiplet.  
These signals were usually well resolved and had chemical shifts in a region apart from the 
signals of other protons (Scheme 3.9).   
The limiting parameters WA and WB for individual conformers were obtained from the 
measurements for compounds 3c (Scheme 3.6), 5c and 5k (Scheme 3.7) and 9b (Scheme 3.8).  
WB was assumed to equal 25.1 Hz for H(O) geminal to OH from 5k (Table 3), 26.7 Hz for H(S) 
geminal to RS  from 5c and 5k (Table 3 ), and ~10 Hz for H(COOEt) geminal to 
ethoxylcarbonyl groups  from previous similar structures.25 The limiting parameters due to 
conformational bias towards conformation A were obtained from compound 8 and 9 with a tert-
butyl conformational anchor which held the hydroxyl and azaarylsulfanyl groups in axial 
positions.  WA was set to 8.1 Hz for H(O) from 9b (Table 7), 9.3 Hz for H(S) from 9b (Table 7), 
and 27.7 Hz for H(COOEt), H1 and H2, from 3c (Table 3).  Analogous data for other protons was 
used, when possible, to confirm the conformational assignment. 
Prior to protonation, the evaluated share of conformer A (nA) and conformer B (nB) 
includes both the non-protonated form A and the non-protonated form B.  Upon protonation, the 
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evaluated share of conformer A (nA) includes both the non-protonated form A and the protonated 
form AH+, and the evaluated share of conformer B (nB) includes the non-protonated form B and 
the protonated form BH+.  The concentration of acid correlates with the population of conformer 
BH+ (nB+) in derivatives that are sensitive to acid and undergo conformational changes due to the 
stabilization by intramolecular hydrogen bonding.  In some derivatives of compounds 3, the 
azaaylsulfanyl and hydroxyl groups’ interactions do not facilitate intramolecular hydrogen 
bonding, thus stabilizing conformer AH+ in an acid environment. 
The conformational populations were calculated using the limiting parameters and the 
signal width from the signals of each proton of interest.  Depending on the resolution and clarity 
of the signals, priority in determining the conformer population was given to protons whose 
signals showed more attainable and accurate widths.  Only these signals contributed to the 
conformer population through averaging their individual calculated populations to give a 
percentage of the conformer populations for each compound. 
This can be seen in Figure 3.1 where diethyl 4-hydroxy-5-(pyridin-2-ylthio)cyclohexane-
1,2-dicarboxylate 3c was monitored for conformational switch through the addition of 
concentrated deuterated trifluoroacetic acid (d-TFA).  With the limiting parameters for H4(O) 
geminal to OH as 8.1 – 25.1 Hz, H5(S) geminal to RS as 9.3 – 26.7 Hz  and, H1 and H2 (COOEt) 
geminal to ethoxylcarbonyl groups as ~10 – 27.7 Hz, the conformer population in terms of 
percentages of conformer A and B was obtained.   
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Figure 3.1.  Acid-induced conformational switch for derivative 3c in CD3OD (0.02M): 
(I) no acid present (~100% A); (II) 1 equivalent of d-TFA (~70% A+AD+ and ~30% B+BD+); 
and (III) 2 equivalents (excess) of d-TFA (~50% A+AD+ and ~50% B+BD+). 
H5 H4 H2 H1
W= 10.7 Hz W= 10.0 Hz W= 27.0 Hz W= 27.0 Hz
H5 H4 H2 H1
W= 15.6 Hz W= 15.0 Hz W= 21.7 Hz W= 21.4 Hz
H4 & H5 H2 H1





In the absence of d-TFA, 3c had preference for conformer A.  As the amount of d-TFA 
was increased, the population of conformer BD+ increased until the conformational equilibrium 
showed equal presence of conformer AD+ (nA=50%) and conformer BD+ (nB=50%) in excess d-
TFA.  The final conformer population was determined by only H1 and H2.  This is because the 
overlap of H4 and H5 made it difficult to measure their signal widths. 
The chemical shifts for 3c and all other azaarylsulfanyl cyclohexanols were recorded but 
not used in the conformational equilibrium estimations.  This is because these chemical shifts 
have a wide range of variation, are generally sensitivity to temperature and are solvent 
dependent.  Considering them would introduce multiple inaccuracies. 
In order to monitor the conformational flip due to a change in pD, analogous with pH in 
deuterated environments, 1H NMR titration experiments were done by adding small portions of 
1M d-TFA solution in CD3OD to a 0.03 M solution of azaarylsulfanyl compounds in CD3OD 
solution.  The advantage of using d-TFA is the absence of NMR signals from the acid which 
excludes interference of the titrant’s signals with the signals of the compound of interest.  A 


















Titration 1H NMR Data and Conformational Parameters for 3g.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD 






pD H4 (O) 
           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB 
(nBD+), 
       % 
GB-A, 
kJ/mol 
7.10b) 3.88 10.92 3.45 11.52 2.99 25.07 3.05 25.31 15 4.3 
6.99 b) 3.88 10.88 3.45 11.51 2.99 25.06 3.05 25.30 15 4.3 
5.88 b) 3.88 11.09 3.45 11.59 2.99 24.90 3.05 25.18 15 4.2 
5.39 b) 3.88 11.19 3.45 11.67 2.99 24.69 3.05 25.07 16 4.0 
5.38 b) 3.88 11.28 3.45 11.78 2.99 24.62 3.06 25.08 17 4.0 
5.19 b) 3.87 11.42 3.46 11.91 2.99 24.60 3.06 24.81 17 3.8 
5.16 b) 3.87 11.40 3.46 12.02 2.99 24.49 3.06 24.79 18 3.8 
5.08 b) 3.87 11.53 3.46 12.11 2.99 24.37 3.06 24.71 18 3.7 
5.05 b) 3.87 11.51 3.46 12.20 3.00 24.36 3.06 24.59 19 3.6 
4.95 b) 3.87 11.64 3.46 12.28 3.00 24.28 3.06 24.51 19 3.5 
4.85 b) 3.87 11.68 3.46 12.41 3.00 24.17 3.06 24.30 20 3.4 
4.83 b) 3.86 11.71 3.46 12.42 3.00 24.00 3.07 24.11 20 3.3 
4.76 b) 3.86 11.88 3.46 12.57 3.00 23.98 3.07 24.07 21 3.3 
4.71 b) 3.86 12.04 3.47 12.71 3.01 23.80 3.07 23.90 22 3.1 
4.62 b) 3.86 12.10 3.47 13.03 3.01 23.47 3.08 23.61 23 2.9 
4.58 b) 3.86 12.28 3.47 13.08 3.01 23.36 3.08 23.49 24 2.8 
4.51 b) 3.85 12.50d) 3.47 13.43 3.02 23.21 3.09 23.28 25 2.7 
4.45 b) 3.85 12.70d) 3.48 13.78 3.02 23.08 3.09 23.22 26 2.5 
4.44 b) 3.85 12.90d) 3.48 13.82 3.03 22.92 3.09 23.01 27 2.4 
4.39 b) 3.85 13.00d) 3.48 13.95 3.03 22.68 3.10 22.84 28 2.3 
4.36 b) 3.84 13.20d) 3.48 14.18 3.03 22.37 3.10 22.68 29 2.2 
4.27 b) 3.84 13.50d) 3.49 14.47 3.04 22.14 3.11 22.33 31 2.0 
4.19 b) 3.83 13.70d) 3.49 14.76 3.04 21.78 3.11 22.01 33 1.8 
4.14 b) 3.83 13.90d) 3.49 15.00c) 3.05 21.70c) 3.12 21.89c) 34 1.7 
4.04 b) 3.83 14.27 3.49 15.38 3.05 21.27 3.12 21.61 36 1.4 
4.04 b) 3.82 14.33 3.49 15.40 3.06 21.29 3.13 21.58 36 1.4 
62 
(Table 2 Continued) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD 


























3.90 b) 3.81 14.78 3.50 16.04 3.07 20.62 3.14 20.90 39 1.1 
3.65 b) 3.80 15.52 3.51 17.03 3.08 19.66 3.15 19.90 45 0.5 
3.53 b) 3.79 15.84 3.52 17.41 3.10 19.19 3.17 19.44 47 0.3 
3.19 b) 3.78 16.73 3.52 18.22 3.11 18.59 3.18 18.83 51 -0.1 
2.72 b) 3.77 17.48 3.53 18.88 3.12 18.14 3.19 18.18 55 -0.5 
2.68 b) 3.77 17.55 3.53 19.01 3.13 18.02 3.20 18.11 55 -0.5 
1.91 b) 3.76 18.28 3.53 19.76 3.14 17.31 3.25 17.52 59 -0.9 
1.55 b) 3.76 18.50 3.53 19.90 3.14 17.20 3.25 17.30 60 -1.0 
1.30 b) 3.76 18.50 3.53 19.90 3.14 17.20 3.25 17.30 60 -1.0 





Figure 3.2.  Titration curves for 3g monitored by 1H NMR in CD3OD with (A) as signal width 
































































Initially, although the addition of d-TFA decreased the pD, the conformational flip of 3g 
did not occur.  This is seen by the constant signal widths and the constant chemical shifts of the 
signals between pD 7.5-5.0.  When the pD was in the buffer zone (pD 5.0-3.0), small additions 
of d-TFA did not change the pD significantly.  Consistent with these small additions of d-TFA 
was the slow increase in signal width of H4 (10.9 Hz) and H5 (11.5 Hz) accompanied with the 
slow decrease in signal width of H1 and H2 (25.1 and 25.3 Hz respectively).  This marked the 
beginning of the conformational flip.  The further addition of d-TFA shifted the equilibrium 
towards conformer BD+ with signal width of H4 (18.5 Hz) and H5 (19.9 Hz) and the signal width 
of H1 and H2 (17.2 and 17.3 Hz respectively).  The changes in signal width of all protons on the 
cyclohexane show that the protonation of the 2-mercapto-1-methylimidazole group consequently 
changes the conformational equilibrium by stabilizing conformer BD+ through intramolecular 
hydrogen bonding the type HO...D-N+.  The comparisons of the signal widths to the limiting 
parameters show that there is a substantial amount of conformer AD+.  Evidence of this can be 
seen in the conformation population nB + nBH+(%) where the switch ends at ~60% of conformer 
BD+ (Figure 3.3).   
Another confirmation of the conformational flip was seen in the changes in chemical shift 
(Figure 3.2).  Typically, axial protons’ signals are located more upfield as compared to signals of 
equatorial protons when considering protons geminal to the same substituent.  This is confirmed 
in the chemical shifts of H1, H2 and H4.  With the addition of d-TFA, the signals for H1 (δ 2.99) 
and H2 (δ 3.05) in 3g both shifted downfield to δ 3.14 and δ 3.25 respectively.  This confirms the 
axial-equatorial conformational switch.  The simultaneously occurring equatorial-axial switch 
can only be seen in H4.  The signal for H4 (δ 3.88) shifted upfield to δ 3.76 with the addition of 
d-TFA.  An unexpected reverse trend was seen for signal H5 (δ 3.45) with a downfield shift to δ 
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3.53 during the equatorial-axial switch.  Given that the nitrogen on the imidazole group was 
protonated and the positioning of the nitrogen close to the geminal proton H5 on the cyclohexane 
ring, the deshielding effect of the positive charge may counteract the effect of the equatorial-
axial orientation of the proton.  It is also important to note that chemical shifts are sensitive to 
temperature, types of solvents, complexations with reagents, etc, and this could affect the typical 
trends of H5. 
 
 
Figure 3.3.  Titration curve of 3g in CD3OD monitoring the signal width of H
4 corresponding 
conformer population (nB). 
 
To confirm and follow the conformational flip, the relative population of both conformers 
(nA, nB) in the conformational equilibrium were estimated using the observed signal widths 













































conformational equilibrium was calculated using the formula:  ∆GB-A = -RTln(nB /nA).  The 
results (Table 2) show that the gradual addition of d-TFA produces a protonation-induced 
conformational flip of 3g.  Compound 3g initially showed significant preference for conformer A 
(~88% in CD3OD) compared to conformer B (~12% in CD3OD) (Figure 3.3).  The addition of 
acid resulted in a preference for conformer BD+ (~60% in CD3OD and excess d-TFA) compared 
to conformer AD+ (~40% in CD3OD and excess d-TFA).   
Hence, not only can the titration of azaarylsulfanylcylohexanols be expressed by signal 
width variation, but it can also be monitored by the equilibrium population of conformers with 
further insight given by the calculated ∆GB-A-values in CD3OD from these populations.  Prior to 
addition of d-TFA, conformation equilibrium was initially biased to conformer A at pD 7.10 
(∆GB-A = 4.3 kJ/mol).  With the addition of acid, conformation equilibrium became slightly 
biased to conformer BD+  at pD 1.14 (∆GB-A = -1.0 kJ/mol).  From these ∆GB-A-values, the power 
of this conformational pH-trigger was estimated to be ≥ 5 kJ/mol (Table 2). 




Given the assortment of substituents used in the synthesis of trans-2-(azaarylsulfanyl)-
cyclohexanol derivatives (Scheme 3.3, 3.4 and 3.5) and the variation in characteristics of media 
used in the collection of their parameters, for example, addition of d-TFA, types of solvent and 
temperature, it is important to assess the factors that affect their conformational equilibrium. 
Effect of azaarylsulfanyl groups as a polar-head.  The initial conformational studies of 
azaarylsulfanylcyclohexanol 3g showed similar results to the analogous trans-2-
aminocyclohexanols (TACHs) studied previously.25  These TACHs had structural variations in 
their amino polar-head groups that created variability in conformational switches.  The 
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substituents on the synthesized azaarylsulfanylcyclohexanol derivatives 5a-m (Scheme 3.3, 3.4 
and 3.5) were of different heterocyclic variety and their conformational behavior was analyzed in 
different solvents and in the presence of excess d-TFA (Table 3).  
 
Table 3 
1H NMR Data and Conformational Parameters for 5a-m.a) 
 
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
 5a    
CDCl3 3.33 24.8 2.78 25.7 96 -7.9 
(CD3)2SO 3.32 22.0
g) 3.02 22.2 78 -3.1 
CD3OD 3.40 22.9
 2.92 23.6b) 85 -4.2 
+ CF3COOD 
e) 3.39 23.1 2.91 23.9b) 86 -4.5 
          5b    
CDCl3 3.29 25.0 2.68 25.5 96 -7.9 
(CD3)2SO 3.29 21.5
g) 2.92 21.8 75 -2.7 
CD3OD 3.36 23.1 2.81 23.6 85 -4.3 
+ CF3COOD 
e) 3.36 23.2 2.81 23.7 86 -4.4 
5c    
CDCl3 3.52 24.8 3.42 26.7
d) 99 <-10 
(CD3)2SO 3.44 21.7
g) 3.66 22.3 77 -3.0 
CD3OD 3.51 22.5
b) 3.54 23.0 82 -3.7 
+ CF3COOD 
e) 3.62 24.7 3.56 26.1 97 -8.6 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 





(Table 3 Continued) 
   
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
   5d    
CDCl3 3.49 24.2 3.16 25.6
 94 -6.8 
(CD3)2SO 3.38 22.4
 3.33 23.2 82 -3.7 
CD3OD 3.47 22.5
 3.31 24.3f) 85 -4.3 
+ CF3COOD 
e) 3.58 23.4c) 3.54 24.5f) 89 -5.0 
5e    
CDCl3 3.58 
b) 3.63 26.0 96 -7.8 
(CD3)2SO 3.45 22.2
g) 3.66 22.8 80 -3.4 
CD3OD 3.57 22.9
 3.77 24.2 86 -4.5 
+ CF3COOD 
e) 3.58 23.3 3.79 24.6 89 -5.0 
 5f    
CDCl3 3.52 24.9 2.90 26.3 98 -9.9 
(CD3)2SO 3.30 22.4 3.01 23.7 83 -4.0 
CD3OD 3.36 23.9 2.87 24.6
 90 -5.5 
+ CF3COOD 
e) 3.48 24.5 3.28 26.3b) 97 -8.6 
  5g    
CDCl3 3.53 24.7
 2.99 26.3 98 -9.1 
(CD3)2SO 3.30 23.0
g) 3.00 23.9 86 -4.4 
CD3OD 3.39 23.7 2.93 24.7 90 -5.4 
+ CF3COOD 
e) 3.47 24.4 3.24 26.4 97 -8.6 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved signal 
(a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 





(Table 3 Continued) 
   
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
5h    
CDCl3 3.60 24.8 3.15 26.4 98 -9.9 
(CD3)2SO 3.38 21.8
g) 3.30 23.2 80 -3.4 
CD3OD 3.49 ~23
c) 3.30 24.6 89 -5.0 
+ CF3COOD 
e) 3.53 ~24c) 3.45 25.7 94 -6.6 
     5i   
CDCl3 3.62 24.7 3.20 26.3 98 -9.1 
(CD3)2SO 3.49 22.2
g) 3.39 24.0 84 -4.0 
CD3OD 3.52 23.3
f) 3.36 24.5 88 -5.0 
+ CF3COOD 
e) 3.58 24.2 3.48 25.5 94 -6.7 
                     5j                          
CDCl3 3.59 24.8
f) 3.22 ~26f) 97 -8.6 
(CD3)2SO 3.50 ~22
g) 3.39 24.1 83 -3.4 
CD3OD 3.55 23.5
 3.39 24.8 90 -5.3 
+ CF3COOD 
e) 3.59 24.1 3.51 25.7 94 -6.8 
         5k  
CDCl3 3.65 25.1
d) 3.36 26.7d) 100 <-10 
(CD3)2SO 3.63 22.1
 3.47 23.2 81 -3.6 
CD3OD 3.52 23.6
 3.45 24.6 90 -5.3 
+ CF3COOD 
e) 3.59 24.7 3.67 26.7 99 <-10 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 





(Table 3 Continued) 
   
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
          5l  
CDCl3 3.63 24.0 3.65 25.6 94 -6.6 
(CD3)2SO 3.49 23.1 3.69 23.6 85 -4.3 
CD3OD 3.59 23.4 3.72 24.5 89 -5.0 
+ CF3COOD 
e) 3.71 23.6 3.71 24.5 89 -5.2 
          5m  
CDCl3 3.67 25.0 3.68 26.0 98 -9.2 
(CD3)2SO 3.49 22.6 3.64 24.3 86 -4.4 
CD3OD 3.60 23.3 3.70 24.9 90 -5.2 
+ CF3COOD 
e) 3.60 23.5 3.70 25.1 91 -5.6 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal; g) JHCOH was subtracted.   
 
All the studied trans-2-azaarylsulfanylcyclohexanols 5a-m prefer the diequatorial 
conformation 5B in all solvents (75-100%, Table 4).  In comparison to prior similar models, with 
R = CH3, Ph, that were studied and found to have total conformational preference for 
diequatorial orientation 5B regardless of solvent and temperature73, the found conformational 
preference for 5B in compounds 5a-m was significantly smaller.   
Also, there is a uniform trend in the interaction of the compounds 5a-m with solvents.  
Particularly, the preference for conformer 5B is stronger in relatively non-polar CDCl3 than in 
polar solvents, CD3OD and (CH3)2SO.  A plausible explanation for this difference may be the 
71 
intramolecular hydrogen bonding which stabilizes 5B in CDCl3, but is interrupted by 
intermolecular hydrogen bonding with CD3OD and especially with (CD3)2SO. 
This preference for conformation 5B was useful for comparison with the conformational 
equilibrium of dicarboxylate derivatives 3a-m (Table 4) equipped with ethoxycarbonyl 
counterbalances that would change the conformation preference. 
To explore the possible acid-induced shift of the conformational equilibrium, the CD3OD 
solutions of compound 5a-m were treated with up to a 15-fold excess of d-trifluoroacetic acid.  
Despite the already substantial conformational bias, a noticeable additional shift of equilibrium 
towards the diequatorial conformer 5BD+ was observed, especially for the pyridinyl-derivative 
5c (82 → 97%) which was the most sensitive to d-TFA.  Expectedly, the equilibrium of phenyl-
derivative 5a and tolyl-derivative 5b remained practically insensitive due to the lack of nitrogen 
























        W, Hz 
H5 (S) 
       W, Hz 
H1 
        W, Hz 
H2 






3a   
CDCl3 3.81 (17)
c) 3.24 17.0 3.11 19.9 3.17 20.2 48 0.2 
(CD3)2SO 3.83 9.3
b) 3.49 10.1 2.80 27.1 2.91 27.2 5 7.2 
CD3OD 3.93 10.1 3.44 11.3 3.01 26.1
b) 3.04 26.4b) 10 5.3 
+ CF3COOD 
e) 3.94 10.2 3.43 11.4 3.01 25.9b) 3.04 26.3b) 11 5.1 
3b  
CDCl3 3.77 (20)
c) 3.16 b) 3.12 19.2 3.16 b) 59 -0.9 
(CD3)2SO 3.79 9.5
h) 3.39 9.7 2.81 27.0 2.90 27.2 4 7.4 
CD3OD 3.91 10.0 3.35 11.3 3.01 25.4
b) 3.03 25.6 12 4.8 
+ CF3COOD 
e) 3.91 10.1 3.34 11.3 3.02 b) 3.02 b) 11 5.0 
3c  
CDCl3 3.81 
b) 3.81 b) 3.13 16.2 3.25 16.5 64 -1.4 
(CD3)2SO 3.93 (10.6)
c) 4.19 (11.2)c) 2.73 27.7d) 2.93 27.8d) 0 >10 
CD3OD 4.03 9.9 4.19 11.1 2.89 26.8 3.07 27.0 8 6.1 
+ CF3COOD 
e) 3.92 b) 3.92 b) 3.09 18.2 3.24 18.9 52 -0.2 
3d  
CDCl3 3.89 16.9 3.56 18.6 3.11 18.6 3.25 19.0 52 -0.2 
(CD3)2SO 3.87 ~10.2
h) 3.74 11.0 2.74 26.5 2.94 26.5 8 5.9 
CD3OD 3.97 11.0 3.76 12.3 2.94 25.1 3.10 25.2 15 4.3 
+ CF3COOD 
e) 3.93 15.7 3.91 16.6 3.02 20.1 3.21 20.5 42 0.8 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 









        W, Hz 
H5 (S) 
       W, Hz 
H1 
        W, Hz 
H2 








b) 4.00 b) 3.04 20.6 3.19 20.8 40 1.0 
(CD3)2SO 3.97 (11)
c) 4.12 11.0 2.72 27.7d) 2.94 27.7d) 1 >10 
CD3OD 4.10 ~9.6
b) 4.22 11.0 2.86 27.2 3.08 27.3 6 6.6 
+ CF3COOD 
e) 4.10 ~10.3b) 4.23 11.0 2.86 27.0 3.08 27.2 8 6.1 
3f  
CDCl3 3.85 17.9 3.34 18.9 3.09 18.0 3.20 18.2 55 -0.5 
(CD3)2SO 3.80 ~9.3
g) 3.59 ~10.3b) 2.78 27.1 2.90 27.2 4 8.0 
CD3OD 3.85 10.7 3.46 11.3 2.94 25.4 3.04 25.5 13 4.6 
+ CF3COOD 
e) 3.80 17.0 3.62 18.1 3.08 19.0 3.18 19.1 50 0.0 
3g  
CDCl3 3.85 19.2 3.40 20.4 3.10 16.7 3.23 17.0 63 -1.3 
(CD3)2SO 3.84 (10)
c) 3.58 ~10.1b) 2.80 27.0 2.91 27.0 4 7.5 
CD3OD 3.88 10.9 3.45 11.5 2.99 25.0 3.05 25.2 15 4.3 
+ CF3COOD 
e) 3.76 18.5 3.53 19.9 3.14 17.2 3.25 17.3 60 -1.0 
3h  
CDCl3 4.00 16.6 3.69 17.3 3.05 19.4 3.21 19.6 46 0.3 
C6D6 4.16 (15)
c) 4.03 (16)c) 3.25 22.7 3.43 22.9 34 1.7 
(CD3)2CO 4.00 (12)
c) 4.08 b) 2.91 b) 3.09 26.8 6 6.7 
(CD3)2SO 3.93 ~9.4
g) 3.86 10.2 2.75 27.5 2.92 27.5 4 7.7 
CD3OD 4.02 10.1 3.84 10.6 2.91 26.5 3.06 26.7 8 5.9 
+ CF3COOD 
e) 4.02 11.5 3.90 12.5 2.94 25.0 3.09 25.2 17 3.8 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal; g) JHCOH was subtracted.   
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        W, Hz 
H5 (S) 
       W, Hz 
H1 
        W, Hz 
H2 








c) 3.61 15.7 2.97 21.2 3.14 21.3 39 1.1 
(CD3)2SO 3.92 ~9.3
g) 3.75 10.2 2.74 27.8 2.89 27.8 3 8.5 
CD3OD 4.00 9.6 3.73 10.7 2.89 26.7 3.03 27.0 7 6.4 
+ CF3COOD 
e) 4.01 12.3 3.83 13.1 2.91 24.3 3.11 24.5 21 3.2 
3j  
CDCl3 4.00 ~20.5
f) 3.58 ~21.5f) 3.18 14.7f 3.29 15.1f) 72 -2.3 
(CD3)2SO 3.98 ~9.3
g) 3.92 10.4 2.79 26.9 2.94 27.1 5 6.9 
CD3OD 4.08 10.1 3.96 11.2 2.95 25.7 3.09 25.9 11 5.0 
+ CF3COOD 
e) 4.10 b) 4.03 11.8 2.95 25.2 3.12 25.3 14 4.4 
3k  
CDCl3 4.00 18.5 3.86 19.5 3.10 17.5 3.27 17.7 59 -0.9 
(CD3)2SO 4.22 11.0 4.02 
b) 2.76 27.4 2.95 27.5 7 6.3 
CD3OD 4.03 10.1 4.01 10.6 2.94 26.3 3.08 26.3 9 5.7 
+ CF3COOD 
e) 3.89 18.0 3.96 19.3 3.15 17.6 3.25 17.8 57 -0.7 
3l  
CDCl3 4.08 16.6 4.12 18.3 3.06 19.5 3.24 19.8 48 0.2 
(CD3)2SO 4.05 
b) 4.24 10.4 2.75 26.7 2.96 26.9 6 6.8 
CD3OD 4.16 
b) 4.29 11.6 2.89 26.1 3.11 26.4 10 5.3 
+ CF3COOD 
e) 5.49 10.4 5.64 12.5 4.15 26.0 4.39 26.1 13 4.7 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 









        W, Hz 
H5 (S) 
       W, Hz 
H1 
        W, Hz 
H2 







CDCl3 4.07 16.1 4.12 17.6 3.06 19.6 3.24 19.9 46 0.4 
(CD3)2SO 4.07 
b) 4.26 10.6 2.75 26.8 2.97 26.8 6 6.9 
CD3OD 4.16 
b) 4.29 ~10.2f) 2.89 26.1 3.11 26.3 9 5.7 
+ CF3COOD 
e) 4.17 b) 4.28 ~10.8f) 2.90 26.0 3.11 26.3 9 5.7 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved signal 
(a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to CD3OD 
solution; f) Poorly resolved signal; g) JHCOH was subtracted.   
 
In comparison to the derivatives 5a-m, which prefer conformation 5B in all solvents, the 
conformational equilibrium of dicarboxylate derivatives 3a-m in polar solvents, CD3OD and 
(CD3)2SO, is strongly shifted towards conformation 3A.  The conformation 3A has two 
ethoxylcarbonyl counterbalances in equatorial positions, and the hydroxyl and azaarylsulfanyl 
groups in axial positions.  Nonetheless, the opposite conformation 3B, with both ethoxylcarbonyl 
counterbalances in axial positions and the hydroxyl and RS group in equatorial positions, is 
almost equally populated or even slightly more predominant in non-polar CDCl3.  This is 
apparently due to the stabilization by the intramolecular hydrogen bond that was also seen in 
compounds 5a-m. 
For the dicarboxylate derivatives 3a-m to have a conformational preference for 3A, the 
ethoxylcarbonyl counterbalances need to have more conformational energy than the hydroxyl 
and aminothiol group.  Previously the destabilizing effect of two axial COOEt groups in 
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structures similar to 3B was estimated as 7 to 8 kJ/mol in C6D12 and approximately 10 kJ/mol in 
CDCl3 and (CD3)2CO.
17 A comparison of the GB-A data in Tables 3 and 4, (5 vs 3), gives similar 
values: 7.7-8.9 kJ/mol in CDCl3, 12-15 kJ/mol in (CD3)2SO, and 10-14 kJ/mol in CD3OD. 
To explore the possible acid-induced shift of the conformational equilibrium, CD3OD 
solutions were treated with up to 15-fold excess of d-TFA.  Despite the substantial 
conformational bias towards conformation 3A for all compounds 3, a significant shift of 
equilibrium towards the conformer 3BD+ was observed for the 2-pyridinyl derivative 3c (8 → 
52%), 4-pyridinyl derivative 3d (15 → 42%), imidazolyl derivative 3f (13 → 50%), methyl-
imidazolyl derivative 3g (15 → 60%) and benzimidazolyl derivative 3k (9 → 57%).  The 
structural similarity in all these molecules is basic nitrogen on azaarylsulfanyl group that is in 
proximity with the hydroxyl group and can stabilize the conformation 3BD+ upon protonation.  
This stabilization in the form 3BD+ is due to an intramolecular hydrogen bond of the type 
HO...D-N+ and by electrostatic attraction HO...N+.    
After screening all the compounds 3a-m by treatment with excess d-TFA, the diversity in 
basicity of the derivatives that showed significant sensitivity to acid was evaluated by titration 
(Figure 3.4).  Previously, it was found that  more basic polar head in analogous structures, 
TACHS, showed noticeable changes in conformation in less acidic pD ranges.25 The 
azaarylsulfanyl groups appear to undergo conformational changes at more acidic pD ranges (4.8-
2.6) with the more basic region for 3f and 3g, and surprisingly with the more acid region for 3c.  
Although derivative 3k underwent a conformational switch at a lower pD range as compared to 
other derivatives, the conformational population range span for its switch was the widest (9 → 
57%), about 6-times the population increase of conformer 3BD+.  It is closely followed by 3g (15 
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→ 60%) whose conformational population increase was four-fold with the highest population 
limit of 3BD+ conformers nB (nBD+) at 60 % after the switch. 
 
 
Figure 3.4.  Titration curves of 3c, 3d, 3f, 3g and 3k in CD3OD monitoring the signal width of 
H4 with its corresponding conformer populations (nB). 
 
Previously, it was found that the basicity of a molecule could be estimated by NMR 




the pKa of a protonated base is equal to pH at equilibrium where equal amounts of unpronotated 
and protonated base exist (nL=nHL).  When obtaining the pKa with NMR titrations, the pD is used 
in place of the pH as deuterated acids are commonly used to avoid signal overlap.  As seen in 
Figure 3.5, the pKa of the protonated form of the base can be estimated at the halfway point of 
the changes of NMR parameters (the chemical shift δ, ppm), which coincides with the middle of 






































Figure 3.5.  Sample estimation of pKa based on 
1H NMR Titration curves.74  
 
With the use of this method, the basicity of all trans-2-azaarylsulfanylcyclohexanol 
dicarboxylate derivatives that showed significant sensitivity to d-TFA was obtained using mainly 
the signal width (W), but supported with data from chemical shifts (δ) (Table 5).  As previously 
mentioned, the chemical shift data is not as reliable due to the sensitivity to changes while the 


















1H NMR Titration-Estimated Basicity a) (pKa) of Dicarboxylate Derivatives 3c, 3d, 3f, 3g and 3k. 
RS group Estimated pKa 
Using δ Using W 
3c      
3.3 3.3 
3d,    
4.0 4.0 
3f,    
4.3 4.3 
3g,   
4.4 4.4 
3k,    
3.4 3.4 
a) 600 MHz; 0.02-0.03 M solutions of CD3OD at 294K 
 
The pKA-values estimated from both signal width (W) and chemical shift (δ) were 
consistent for all trans-2-(azaarylsulfanyl)-cyclohexanol dicarboxylate derivatives that showed 
significant sensitivity to d-TFA. 
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Effect of the position of nitrogen on azaarylsulfanyl group.  The positions of the 
nitrogen atomson the araarylsulfanyl groups are important because their proximity to the 
hydroxyl group helps to stabilize conformers B or BD+ through electrostatic attraction HO...N+ 
or by intramolecular hydrogen bonding of the type HO...DN+.  A comparison of derivatives 3c, 
2-pyridinyl, and 3d, 4-pyridinyl, can be used to investigate the influence of nitrogen’s position. 
In non-acidic conditions, compounds 3 (Table 4) and 5 (Table 3) with their 
azaarylsulfanyl groups as 2-pyridine, 3c and 5c, and as 4-pyridine, 3d and 5d, all have similar 
conformational traits and preferences in different solvents.  They all have the highest 
conformational preference for conformer B in CDCl3, and the highest conformational preference 
for conformer A in (CD3)2SO. 
In acidic conditions, the dicarboxylate derivatives 3c and 3d (Table 4 and Figure 3.4) are 
more sensitive to acid as compared to non-dicarboxylate derivatives 5c and 5d (Table 3).  Both 
3c and 3d showed significant response to excess d-TFA and were titrated for further 
investigation (Figure 3.4).  Surprisingly, upon titration the conformational switch of 3d happened 
at a more basic pD than that of 3c although the nitrogen in the 2-pyridinyl group, for 3c, is closer 
in proximity to the hydroxyl group as compared to the 4-pyridinyl group, for 3d.  A possible 
explanation for this is that the nitrogen in both cycles decreases the basicity of the aromatic rings 
and makes them more responsive to d-TFA (compared to phenyl and tolyl derivatives 3a and 3b 
respectively (Table 4)).  But the closer nitrogen on the azaarylsulfanyl group is to the hydroxyl 
group, their stronger the stabilization of the intramolecular hydrogen bond.  Suggesting that 
regardless of the amount of d-TFA used protonate the nitrogen on the 2-pyridinyl group in 3c, 
the conformational changes due to hydrogen bonding cannot be compared to the conformational 
changes in 4-pyridinyl group 3d. 
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Another plausible explanation for this difference is that the conformational switch could 
also be facilitated by electrostatic interactions.  Once the 4-pyridinyl derivative 3d was 
protonated, the charge on the pyridinyl group was able to interact with the lone pair of hydroxyl 
group and form an attraction that aided in the conformational preference for conformer 3BD+.  It 
is also reasonable to say that electrostatic interactions may have a significant contribution in 
other derivatives that were sensitive to acid. 
Effect of R-groups on azaarysulfanyl groups.  In order to alter the electron density of 
an aromatic ring, electron donating groups were used.  It was possible to see the effect of a mild 
electron donating group when an azaarylsulfanyl derivative with an alkyl group, methyl, was 
synthesized and compared to an azaarylsulfanyl derivative without one.   This can be seen in the 
comparison of derivatives 3f and 3g (Table 4 and Figure 3.4) and derivative 5f and 5g (Table 3).   
In non-acidic conditions, compounds 3 (Table 4) and 5 (Table 3) with their RS group as 
imidazole, 3f and 5f, and as 1-methyl-imidazole, 3g and 5g, all have similar conformational traits 
and preferences in different solvents.  They all have the highest conformational preference for 
conformer B in CDCl3, and their highest conformational preference for conformer A in 
(CD3)2SO. 
In acidic conditions, 3f and 3g (Table 4 and Figure 3.4) are more sensitive to acid as 
compared to 5f and 5g (Table 3).  Both 3f and 3g showed similar response to excess d-TFA and 
were titrated for further investigation.  Upon further inspection, it was evident that the two 
compounds underwent conformational changes in the same pD range and hence had similar pKA-
values.  The only major difference between 3f and 3g was the conformational population 
difference that gradually increased between 3.8 – 1.3 (Figure 3.6).   The methyl group on 3g uses 
the inductive donating effect to increase the electron density of the RS group.  This leads to a 
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slight increase in basicity which not only affects the pKa but has a greater effect on the 
conformational switch given the increased pronation ability and hence a stronger intramolecular 
hydrogen bond of the type   HO...D-N+ in conformer 3BD+. 
 
 
Figure 3.6.  Titration curves 3f and 3g in CD3OD monitoring the signal width of H
4 with their 
corresponding conformer populations (nB) and show the pKa for their conformational switch. 
 
Effect of t-butyl counterbalance.  In order to explore the limits of the conformational 
equilibrium, a tert-butyl group was used as a bulky counterbalance.  With such a strong anchor 
directly across the hydroxyl group, in 4-t-butyl-2-azaarylsulfanylcyclohexanol 8, and the RS 
group, in 5-t-butyl-2-azaarylsulfanylcyclohexanol 9, both of these groups on each type of 
compound were forced into a diaxial orientation: conformer A.  The conformational preference 
for 8A and 9A provides the limiting parameters for protons adjacent to H1 (OH) and H2 (RS) 





































models.  Imidazolyl (8a and 9a), 2-pyridinyl (8b and 9b) and benzimidazole (8c and 9c) 
derivatives provided models that were most sensitive for estimating the limiting parameter WA. 
 
Table 6 
1H NMR Data and Conformational Parameters for 8a-m.a) 
 
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
  8a  
CDCl3 4.11 10.4 4.88 (~11)
c) 12 5.0 
(CD3)2SO 3.93 ~9
g) 4.06 9.7f) 4 7.9 
CD3OD 4.07 9.1
 4.05 10.3 6 6.8 
+ CF3COOD 
e) 4.09 ~9f) 3.94 10f) 5 7.4 
8b  
CDCl3 4.10 9.8
b) 3.61 (~11)c) 10 5.4 
(CD3)2SO 3.84 ~9
g) 3.51 10.2f) 5 7.1 
CD3OD 3.94 8.6
f) 3.44 9.4f) 2 9.8 
+ CF3COOD 
e) 4.02 ~9f) 3.56 10f) 5 7.4 
       8c  
CDCl3 4.16 9.1 4.28 9.7
h) 4 7.7 
(CD3)2SO 4.01 (~9)
c) 4.12 (~10)c) 5 7.4 
CD3OD 3.95 (~8)
c) 4.08 9.2h) ~0 >10 
+ CF3COOD 
e) 3.96 (~8)c) 4.08 9.2h) ~0 >10 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WA; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal; g) JHCOH was subtracted; h) 






1H NMR Data and Conformational Parameters for 9a-m.a) 
 
solvent, acid H1 (O) 
           W, Hz 
H2 (S) 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
 9a  
CDCl3 4.05 (~9)
c) 4.23 9.8h) 4 7.7 
(CD3)2SO 3.78 ~9
g) 4.18 10.9 7 6.2 
CD3OD 3.93 8.2 4.16 9.3
h) ~0 >10 
+ CF3COOD 
e) 3.93 b) 4.05 9.3h) ~0 >10 
9b  
CDCl3 4.03 9.0 4.16 9.3
d) 3 8.8 
(CD3)2SO 3.72 ~8
g) 3.61 ~10.7f) 4 8.0 
CD3OD 3.87 8.1
d) 3.58 ~9h) ~0 >10 
+ CF3COOD 
e) 3.81 8.5 3.78 9.1h) ~1 >10 
       9c  
CDCl3 4.29 9.2
b) 4.13 9.8f) 5 7.4 
(CD3)2SO 4.24 (~9)
c) 3.88 9.4f) 3 8.6 
CD3OD 4.08 
b) 3.93 b) 5 7.4 
+ CF3COOD 
e) 4.10 ~9f) 4.02 (~10)c) 5 7.4 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WA; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal; g) JHCOH was subtracted; h) 




The constitutional isomers 4-t-butyl-2-azaarylsulfanylcyclohexanol 8 and 5-t-butyl-2-
azaarylsulfanylcyclohexanol 9 were separated when possible and analyzed by 1H NMR.  Only 
stand-alone well resolved signals were used to determine the limiting parameter WA.   Clear 
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signals of H1 (OH) for 9b in CD3OD (8.1 Hz), and H
2 (RS) for 9b in CDCl3 (9.3 Hz) (Table 7) 
were selected as WA for other studied models.   
The obtained NMR results show a complete preference for conformers 8A and 9A.  Even 
with the presence of d-TFA that was previously seen to change the conformation preference 
towards BD+ and/or the twisted form TD+ in analogous TACH structures,25 no contribution from 
8BD+ or 8TD+ in compounds 8a-c and 9BD+ or 9TD+ in compounds 9a-c was seen in acid 
media.  This means that the conformational power of the tert-butyl group to remain in the 
equatorial position supersedes the attraction (HO…D-N+) due to intramolecular hydrogen 
bonding. 
Effect of OR 
 
 
Scheme 3.10.  Synthesis of Diethyl 4-((1H-benzoimidazol-2-yl)thio)-5-Acetoxycyclohexane-1,2-




The hydroxyl group is important in the conformational equilibria due to its participation 
in intramolecular hydrogen bonding.  This intramolecular interaction (OH...N) is responsible for 
the stabilization of conformer B in the absence of d-TFA, while the intramolecular interaction 
(HO...D-N+) is responsible for the stabilization of conformer BD+ in the presence of d-TFA.   
The influence of this hydroxyl group in both scenarios can be checked by modifying it into an 
acetate group.  Compound 3x was obtained by acetylation using acyl chloride through refluxing 




Figure 3.7.  1H NMR of signal H4 of alcohol 3k and acetate 3x in CDCl3 solvent. 
 
The hydroxyl group is important in the conformational equilibria due to its participation 
in intramolecular hydrogen bonding.  This intramolecular interaction (OH...N) is responsible for 
the stabilization of conformer B in the absence of d-TFA, while the intramolecular interaction 
(HO...D-N+) is responsible for the stabilization of conformer BD+ in the absence of d-TFA.   The 
influence of this hydroxyl group in both scenarios can be checked by modifying it into an acetate 
group.  Compound 3x was obtained by acetylation using acyl chloride through refluxing in dry 
chloroform (Scheme 3.10). 
The conformational equilibrium was estimated as described in previous sections using the 








preference was observed between compounds 3k and 3x in CDCl3.   The alcohol 3k 
demonstrated a slightly higher conformation preference for conformer B than conformer A (H4 
(OH), W = 18.5 Hz, ~59% B) in CDCl3.  The acetate 3x predominantly adopted a conformation 
A (H4 (OAc), W = 9.2 Hz, ~7% B) in CDCl3 (Figure 3.7 and Table 8).   This highlights the 
importance of the hydroxyl group in the stabilization of conformer B through intramolecular 
hydrogen bonding (OH...N), especially in non-polar solvent. 
In conjunction with what was mention before, the intermolecular hydrogen bonding with 
CD3OD and OH effectively interferes with the diequatorial intramolecular hydrogen bonding 
(OH...N), hence shifting the conformational equilibrium from conformer B to conformer A.  
This was consistent with the extracted parameters for 3k, (H4 (OH), W = 10.1 Hz, ~11% B), and 
3x, (H4 (OAc) in CD3OD (Figure 3.8).  Therefore, alcohol 3k and acetate 3x are both stabilized, 
in the form of conformer A, by the intermolecular hydrogen bonding with CD3OD.  In the case 
of acetate 3x, there is no stabilization of conformer BD+ by d-TFA.   But, a difference in 
sensitivity to d-TFA between alcohol 3k, (H4 (OH), W = 18.0 Hz, ~57% B), and acetate 3x, (H4 
(OAc), W = 14.7 Hz, ~34% B) (Table 8), confirms that conformational preference is dictated by 

































1H NMR Data and Conformational Parameters for 3k and 3x.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal; g) JHCOH was subtracted.   
 
Effect of solvent.  Analagous TACHs showed correlation between specific conformers 
and particular solvents depending on the solvents’ polarity and ability participate in 
intermolecular hydrogen bonding.  The solvents that are not able to undergo intermolecular 
hydrogen bonding allow the hydroxyl and azaarylsulfany groups to undergo intramolecular 
hydrogen bonding.  In order to elucidate these concepts further, we evaluated the conformational 
behavior of dicarboxylate derivative 3h (Figure 3.7) in additional solvents and the 1H NMR 
spectra of 3h were compared and contrasted.  The conformer populations (nA, nB) and free energy 





           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 
       % 
GB-A, 
kJ/mol 
3k       R=H 
CDCl3 4.00 18.5
 3.86 19.5 3.10 17.5 3.27 17.7 59 -0.9 
(CD3)2SO 4.22 11.0 4.02 
b) 2.76 27.4 2.95 27.5 7 6.3 
CD3OD 4.03 10.1 4.01 10.6 2.94 26.3 3.08 26.3 9 5.7 
+ CF3COOD 
e) 3.89 18.0 3.96 19.3 3.15 17.6 3.25 17.8 57 -0.7 
3x       R=Ac 
CDCl3 5.35 9.2 4.55 10.6 3.02 
b) 3.03 b) 7 6.3 
(CD3)2SO 5.15 10.0
 4.56 10.9f) 2.86 b) 2.86 b) 10 5.3 
CD3OD 5.29 10.0 4.49 11.3 2.98 
b) 2.98 b) 11 5.0 
+ CF3COOD 
















1H NMR Data and Conformational Parameters for 3h in Different Deuterated Solvents.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other 








           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 




 3.69 17.3 3.05 19.4 3.21 19.6 46 0.3 
C6D6 4.16 ~15
c) 4.03 ~16c) 3.25 22.7 3.43 22.9 34 1.7 
CD3OD 4.02 10.1 3.84 10.6 2.91 26.5 3.06 26.7 8 6.0 
(CD3)2CO 4.00 ~12
c) 4.08 b) 2.91 b) 3.09 26.8 6 6.7 
(CD3)2SO 3.93 ~9.4
h) 3.86 10.2 2.75 27.5 2.92 27.5 4 7.8 
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                     A                B                                          
            ~96%           ~4%  
            ~94%           ~6%
             ~92%           ~8%
            ~66%         ~34%
            ~53%         ~47% 



















Conformational equilibria of 3h are considerably different in the specific solvents.  While 
the conformational preference for conformer A, (ΔGB-A), decreases, the conformational 
preference for conformer B increases.  This depends on the solvents’ ability to hydrogen bond 
with the hydroxyl group.  This can be seen in the trend below and in Table 9;  
(CD3)2SO (7.8kJ/mol) > (CD3)2CO (6.7 kJ/mol) > CD3OD (6.0 kJ/mol) C6D6 (1.7 kJ/mol)> 
CDCl3 (0.3 kJ/mol).                 
In polar solvents (CD3)2SO and (CD3)2CO, intermolecular hydrogen bonding obstructs 
the possibility of intramolecular hydrogen bonding by surrounding the hydroxyl group.  The 
crowding of the hydroxyl due to the intermolecular hydrogen bonding keeps the hydroxyl and 
azaarylsulfanyl groups in diaxial positions thus giving conformational preference to conformer A 
(Scheme 3.11 and Scheme 3.12). 
 
 




Scheme 3.12.  Intermolecular Hydrogen Bonding of 3h in CD3OD. 
 
 
In nonpolar solvents C6D6 and CDCl3, the intramolecular hydrogen bonding is not 
hindered by intermolecular hydrogen bonding of solvent with the hydroxyl group.  This helps to 
stabilize conformer B for 3h (Table 9).  A possible reason for the stronger conformational 
preference in CDCl3 as compared to C6D6 is the mild presence of DCl, acid generated due to 
exposure of CDCl3 to light, that can protonate the azaarylsulfanyl group and aid in the 
intramolecular hydrogen bonding (Scheme 3.13).  This would stabilize conformer B, with a 
small contribution from BD+.  This same limited influence of DCl probably affects the 1H NMR 




Scheme 3.13.  Intramolecular Deuterium Based-Hydrogen Bonding of 3h due to DCl in CDCl3 
and the Partial Stabilization of Conformer B. 
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Library of trans-2-Triazolylcyclohexanol/Cyclohexylacetate Dicarboxylate Derivatives 
Earlier, it was established that trans-2-aminocyclohexanols (TACHs) (Scheme 1.19 and 
3.1) successfully underwent pH-induced conformational switches in acidic media and their 
conformational preference was changed by intramolecular hydrogen bonding.  We expanded this 
concept to include trans-2-(azaarylsulfanyl)-cylohexanols (Scheme 3.2) with nitrogen containing 
heterocycles as the basic amino groups.  With these results in consideration, we expanded our 
assortment of conformational switches by proposing trans-2-triazolylcyclohexanols (Scheme 
3.14) that are analogous to both TACHs and trans-2-(azaarylsulfanyl)-cylohexanols.  The 
conformational switch would be based on protonation of the triazolyl group leading to formation 
of a strong intramolecular hydrogen bond of the type HO...H-N+(Tz) that alters the 
conformational preference from diaxial to diequatorial  for the triazole and hydroxyl substituents.  
Similarly, two ethoxylcarbonyl groups, in trans configuration, were used to counterbalance other 
substituents.   
 
 
Scheme 3.14.  Acid-Induced Shift of the Conformational Equilibrium of trans-2-
Triazolylcyclohexanol Derivatives. 
 
With this idea, different trans-2-triazolylcyclohexanols derivatives were proposed for 
synthesis (Scheme 3.15 and Scheme 3.16).  The hydroxyl and two adjacent ethoxylcarbonyls 
were conserved as in TACHs and trans-2-azaarylsulfanylcylohexanols.  The design allows for 
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change of basicity of the triazole ring by placing different substituents on either C4 (carbon 4) or 
C5 (carbon 5) on the triazole ring, and analysis of the impact of each substituent relative to its 
position.  Replacement of the hydroxyl group with acetate would assess the influence HO has on 
intramolecular hydrogen bonding and stabilization of conformer B and BD+. 
Surprisingly, pathways that allowed for synthesis of disubstituted triazolyl dicarboxylate 
derivatives 16 also allowed for synthesis of and hexahydrobenzo-triazolo-oxazinone 
dicarboxylate derivatives 15 as discussed further.  Compounds 15 provided a diaxial orientation 
of the protons geminal to the triazole and the lactone oxygen.  They could be used for estimation 
of the 1H NMR limiting parameters for conformer B and BD+.   
 
 





   





Synthesis of trans-2-Triazolylcyclohexanol Dicarboxylate Derivatives 
 
 
Scheme 3.17.  Synthesis of trans-2-(1,4)Triazolylcyclohexanol/cyclohexylacetate Dicarboxylate 
Derivatives. 
 
Compounds 11a, 11b, 12a and 12b (Scheme 3.17) were synthesized beginning with 
diethyl 4-cyclohexene-trans-1,2-dicarboxylate 1.  Epoxidation of alken 1 was done with m-
CBPA in DCM to give epoxide 2.The epoxide ring cleavage of compound 2 by azide anion was 
done with sodium azide and ammonium chloride in a 15:1 solution of DI H2O and ethanol to 
give diethyl-5-azido-4-hydroxy-1,2-cyclohexanedicarboxylate 10a.75,76 Azide 10a exposed to 
conditions of copper(I)-catalyzed “click reaction” (CuAAC) with  CuSO4.5H2O, ascorbic acid 
and  1-octyne or phenylacetylene in a 2:7 solution of  dioxane and H2O and gave triazoles 11a 
and 11b 
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Azide 10a was acetylated using acyl chloride through refluxing in dry chloroform 
producing diethyl-5-azido-4-acetoxy-1,2-cyclohexanedicarboxylate 10b after purification.  
Acetyl-azide 10b was treated with the same click reaction conditions as 10a and produced 12a 
and 12b .   
 
 
Scheme 3.18.  Synthesis of trans-2-(1,4 and 1,5)Triazolylcyclohexanol Dicarboxylates. 
 
 
Scheme 3.19.  Synthesis of trans-2-(1,4 and 1,5)Triazolylcyclohexylacetate Dicarboxylates. 
 
Azide 10a (Scheme 3.18) and 10b (Scheme 3.19) were also exposed to 1,3-dipolar 
cycloaddition reactions in different conditions: by refluxing in toluene with 1-octyne or 
phenylacetylene in separate reactions.  Both azides produced triazole derivatives with a hexyl or 
phenyl substituents at C4 or C5, i.e.  11a, 11b and 12a, 12b with the substituents on the former 
and 11c, 11d and 12c, 12d with the substituents on the latter.  Azide 10a and 10b also underwent 
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1,3-dipolar cycloaddition reactions in toluene with diphenylacetylene to produce triazole 13 and 
14. (Scheme 3.20). 
 
 




Scheme 3.21.  Synthesis of trans-2-(4,5)Triazolylcyclohexanol and Hexahydrobenzo-Triazolo-
Oxazinone Dicarboxylate Derivatives. 
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Compounds 15 and 16 were synthesized with azide 10a and a series of 2-alkynyl esters 
through 1,3-dipolar cycloaddition reactions in toluene.  Tricyclic derivatives 15 (Scheme 3.21) 
went through triazole adduct 15*,77,78 with ester at C5 and alkyl group at C4, and forms lactones 
due to esterification at high temperatures.  The compounds 16 with esters at C4 and alkyl groups 
at C5 are stable (Scheme 3.21). 
Conformational Study of trans-2-Triazolylcyclohexanol Dicarboxylate Derivatives 
The fast equilibrium [A + AH+]  [B + BH+] (Scheme 3.22) was examined by 1H 
NMR spectroscopy (600 MHz).  The vicinal coupling constants 3JHH between several protons 
attached to the cyclohexane moiety are strongly conformationally-dependent, which allows an 
assignment of a predominant conformation and an evaluation of the position of conformational 
equilibrium: large vicinal couplings, 9-12 Hz, are observed between the diaxial protons (as H1 
and H2 in A, Scheme 3.22), and small values, 2-5 Hz, are measured for the axial-equatorial and 
equatorial-equatorial vicinal couplings protons (as H4 and H5 in A, Scheme 3.22).71 The 
observation of a single set of well-resolved multiplets with the averaged NMR parameters attests 
to high rates of both conformational and acid-base equilibria on the NMR time scale. 
The conformer populations (nA, nB) in dilute solutions were estimated as described 
previously25–27,30,32,64,65,72 using Eliel’s equation(1)10,13 applied to the averaged signal width W = 
JHH (a sum of spin-spin couplings) of the protons geminal to the substituents: (Wobserved = WA·nA 
+ WB·nB).  The parameter W was measured as a distance between terminal peaks of a multiplet.  
These signals were usually well resolved and had chemical shifts in a region apart from the 




Scheme 3.22.  Limiting Parameters WA and WB for H
4 in Individual Conformers of trans-2-
Triazolylcyclohexanols Dicarboxylates and the Observed Averaged Signal Width W. 
 
The limiting parameters WA and WB for individual conformers were estimated from the 
measurements for the conformationalbiased compounds 19a, 19b and 38b (Scheme 3.23).  WB 
was assumed to equal 25.7 Hz for H(O) geminal to OH and 27.0 Hz for H(Tz) geminal to 
triazole  from 19a and 19b (Table 10), and 10 Hz for H(COOEt) geminal to ethoxycarbonyl 
groups  from previously studied similar structures.25 The limiting parameters due to 
conformational bias towards conformer A,  WA , were set as 9.0 Hz for H(O) geminal to OH and  
10.1Hz  for H(Tz) geminal to triazole  from 38b,  while WA for  H
1 and H2 was set as 27.0 Hz  
100% A
21.5 Hz 27.0 Hz
3.74 3.72 3.70 3.68 PPM
observed
3.74 3.72 3.70 3.68 3.66 PPM
100% B




based on previous data from analogous compounds.25 Analogous data for other protons were 
used when possible to confirm the conformational assignment.  Compounds 15 were initially 
considered for limiting parameters WB for the ethoxycarbonyls, but further inspection showed 
distortion of the cyclohexane rings of these compounds. 
The 1H NMR data and the conformational parameters for compounds 11-14 and 16 are 
present in Table 10.  Prior to acidification, the conformer B is already strongly predominant.  
Upon acidification, the predominance of conformer B (and the form BD+) remains the same.  
The concentration of acid has no significant effect on the position of the equilibrium. 
 
Table 10 
1H NMR Data and Conformational Parameters for 11-14 and 16.a) 
 
solvent, acid H4 (O) 
           W, Hz 
H5 (Tz) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
11a- R=H, R1=H, R2= n-C6H13 
CDCl3 4.24 
b) 4.34 25.1 3.37 b) 3.37 b) 96 -8.0 
CD3OD 4.10 21.3 4.46 22.1 3.33 
b) 3.33 b) 72 -2.3 
+ CF3COOD 
e) 4.11 22.0 4.47 23.2 3.34 b) 3.34 b) 78 -3.1 
11b- R=Ac, R1=H, R2= n-C6H13          
CDCl3 5.23 20.6
 4.63 21.6 3.38 16.1 3.26 16.1 66 -1.7 
CD3OD 5.30 21.1 4.74 22.0 3.38 15.6
 3.29 15.5b) 69 -2.0 
+ CF3COOD 
e) 5.30 21.1 4.75 22.1 3.39 15.6 3.29 15.5b) 70 -2.0 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Poorly resolved signal; e) d-trifluoroacetic acid was added in large excess 




(Table 10 Continued) 
 
solvent, acid H4 (O) 
           W, Hz 
H5 (Tz) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+) 
  % 
GB-A, 
kJ/mol 
11c- R=H, R1= n-C6H13, R2= H 
CDCl3 4.33 25.0
 4.43 23.9 3.44 11.9 3.46 12.0 89 -5.0 
CD3OD 4.27 24.4 4.32 23.2 3.42 12.4
 3.44 12.5 85 -4.3 
+ CF3COOD 
e) 4.27 24.5 4.31 23.2 3.42 12.4 3.44 12.6 85 -4.3 
11d- R=Ac, R1= n-C6H13, R2= H 
CDCl3 5.52 22.6
 4.68 23.4 3.48 13.3 3.41 13.4 80 -3.4 
CD3OD 5.41 22.7 4.75 23.6
d) 3.45 13.1 3.39 13.0 82 -3.7 
+ CF3COOD 
e) 5.41 22.7 4.75 23.6d) 3.45 13.1 3.39 13.0 82 -3.7 
12a- R=H, R1=H, R2= Phenyl 
CDCl3 4.25 
b) 4.41 25.5 3.40 (~12)b) 3.41 (~12)b) 89 -5.1 
CD3OD 4.15 21.9 4.56 22.9 3.39 14.0 3.34 14.2 77 -3.0 
+ CF3COOD 
e) 4.14 22.2 4.58 23.1 3.39 13.0f) 3.35 14.0d) 80 -3.3 
12b- R=Ac, R1=H, R2= Phenyl  
CDCl3 5.29 21.0 4.73 22.1 3.42 15.6 3.29 15.8 70 -2.1 
CD3OD 5.38 21.2 4.84 22.2 3.43 15.2 3.31 ~15
b) 72 -2.3 
+ CF3COOD 
e) 5.38 21.3 4.85 22.3 3.43 15.2 3.31 ~15b) 73 -2.4 
 12c- R=H, R1= phenyl, R2= H 
CDCl3 4.43 24.2 4.33 25.3 3.44 (~11)
b) 3.46 (~11)b) 89 -5.0 
CD3OD 4.32 23.9 4.27 25.1 3.42 11.8 3.44 11.9 85 -4.3 
+ CF3COOD 
e) 4.31 24.0 4.27 25.1 3.42 11.8 3.44 11.8 85 -4.3 
12d- R=Ac, R1= Phenyl, R2= H 
CDCl3 5.59 23.1 4.77 23.8 3.53 12.8 3.44 12.9 83 -3.9 
CD3OD 5.48 23.3 4.83 24.1
b) 3.48 12.5b) 3.42 12.5 85 -4.3 
+ CF3COOD 
e) 5.48 23.3 4.83 24.0b) 3.49 12.5b) 3.42 12.6 85 -4.2 
13- R=H, R1= Phenyl, R2= Phenyl 
CDCl3 4.56 25.1 4.12 25.6 3.35 
b) 3.35 b) 94 -6.9 
CD3OD 4.31 24.4
b) 4.28 25.2 3.40 11.7 3.31 b) 91 -5.6 
+ CF3COOD 
e) 4.31 24.5b) 4.29 25.4 3.40 11.9 3.32 b) 91 -5.6 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Poorly resolved signal; e) d-trifluoroacetic acid was added in large excess 




(Table 10 Continued) 
 
solvent, acid H4 (O) 
           W, Hz 
H5 (Tz) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB 
(nBD+) 
  % 
GB-A, 
kJ/mol 
14- R=Ac, R1= Phenyl, R2= Phenyl 
CDCl3 5.59 24.3
 4.44 25.3d) 3.39 11.3d) 3.22 11.4b) 91 -5.8 
CD3OD 5.52 24.0 4.61 25.0 3.38 11.7
d) 3.36 11.8b) 89 -5.2 
+ CF3COOD 
e) 5.52 24.0 4.61 25.1 3.38 11.7d) 3.36 11.8b) 89 -5.2 
16a- R1= CH3, R2= CH2CH3 
CDCl3 4.29 24.2 5.25 24.8 3.36 11.5
d) 3.42 11.9d) 91 -5.8 
CD3OD 4.12 22.0 5.34 22.8 3.41 13.9 3.32 13.6 77 -3.0 
+ CF3COOD 
e) 4.11 22.0 5.36 23.0 3.41 13.8 3.33 13.4 78 -3.1 
16b- R1= (CH2)2CH3, R2= CH3 
CDCl3 4.34 24.1 5.23 24.8 3.37 11.5 3.41 ~12)
d) 90 -5.3 
CD3OD 4.10 22.2
 5.36 23.0 3.40 13.8 3.34 13.6 78 -3.0 
+ CF3COOD 
e) 4.10 22.2 5.36 23.0 3.40 13.7 3.34 13.6 78 -3.0 
16c- R1= (CH2)4CH3, R2= CH3 
CDCl3 4.36 24.0 5.22 24.9 3.35 11.5 3.42 11.8 90 -5.2 
CD3OD 4.08 22.6
 5.38 23.2 3.38 13.5 3.33 13.3b) 79 -3.3 
+ CF3COOD 
e) 4.08 22.7 5.39 23.3 3.38 13.5 3.33 13.4b) 80 -3.4 
16d- R1= (CH2)5CH3, R2= CH3 
CDCl3 4.36 24.0
 5.25 24.9 3.34 11.8 3.43 (~12)b) 89 -5.1 
(CD3)2SO 4.06 22.8
 5.40 23.5 3.39 13.3 3.33 13.2 80 -3.4 
+ CF3COOD 
e) 4.07 22.9 5.40 23.5 3.39 13.3 3.34 13.3 81 -3.5 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Poorly resolved signal; e) d-trifluoroacetic acid was added in large excess 










Effect of ethoxycarbonyl counterbalances.  All the studied compounds (11-14 and 16) 
showed conformational preference for conformer B (70-95%).  This was unexpected due to the 
observed conformational preference for conformer A seen in analogous TACHs and trans-2-
azaarylsulfanylcylohexanols that had the same ethoxylcarbonyl groups as counterbalances.  
From previously studied cyclohexane structures, we estimated the destabilizing effect of  two 
axial ethoxylcarbonyl groups as 7-8 kJ/mol in C6D6 and ~10 kJ/mol in (CD3)2CO.  
65 Adding the 
energy difference between conformer B and A (∆GB-A) (Table 10), we can estimate the 
preference of the triazolyl group and hydroxyl groups for the diequatorial arrangement in B as 
10-14 kJ/mol depending on the substituent on the triazole ring and the type of solvent.  Such a 
strong preference was unexpected and very different from the properties of TACHs with 5 and 
even 6-membered cyclic amino-substituents. 
Effect of R-groups on triazole ring.  The existence of weak electron donating groups, 
hexyl for compounds 11 and phenyl for compounds 12, or moderate electron withdrawing 
groups, esters for compounds 16, on the triazole ring, has no effect on the conformational 
preference of these structures.  This was unfortunate because analogous TACHs and trans-2-
azaarylsulfanylcylohexanols showed that adding substituents to the amino group or RS group 
(Table 4) would alter the basicity of the group and have an effect on the conformation 
equilibrium upon acidification.  It is also noted that the existence of two bulky groups on C4 and 
C5 of the triazole ring (compound 13 with both R1 and R2 = phenyl) and derivatives with 
substituents at C5 only, significantly shifts the conformational equilibrium towards conformer B 
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as compared to all other triazolyl derivatives.  Apparently, this is due to the repulsion between 
the substituents at C5 and the atoms of the cyclohexane ring. 
Effect of solvent.  In solutions of nonpolar solvent CDCl3 and polar solvent CD3OD, all 
the studied compounds (11-14 and 16) showed conformational preference for conformer B.  The 
derivatives with a substituent on C4 only showed slighly higher presence of conformer B because 
the none polar solvents do not interfere with the intramolecular hydrogen bonding (OH...N(Tz)).  
The dissimilarity is seen in CD3OD for the derivatives that have a substituent on C5 only and 
derivatives with a substituent on both C4 and C5.  These compounds do not show different 
conformational preference in CD3OD because the force due to the repulsion between the 
substituents at C5 and the cyclohexane ring is stronger than the intermolecular hydrogen bonding 
with the solvent. 
Effect of change in pH.  The unfortunate preexisting bias for conformer B means that 
these trans-2-triazolylcylohexanols are not efficient as conformational switches.  This is 
exacerbated by the low pKa of the triazole which makes protonation of the group difficult, thus 
leading to relatively low stabilization of conformer BH+ from conformer B.  With the addition of 
10-15 fold excess d-TFA (pD ≈ 1.1), there was little to no effect on the conformer BH+’s 








Library of trans-2-Triazolyl-Cyclohexanol/-Cyclohexyl Acetate Derivatives 
 
 
Scheme 3.23.  Library of trans-2-Triazolylcyclohexanol/cyclohexyl Acetate Derivatives with and 
without Counterbalances. 
 
As seen from the results in Table 10, trans-2-triazolylcyclohexanol dicarboxylates 
already have a conformational bias towards conformer B where the hydroxyl and triazolyl 
groups are in equatorial positions and the trans-ethoxylcarbonyl groups are in axial positions.  
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This unexpected result led us to attempt to understand the interaction between the hydroxyl and 
triazolyl groups, and the importance of hydrogen bonding to this interaction.  This was done 
using such counterbalances as methyl, phenyl and t-butyl groups, and altering the hydroxyl 
group with acetate while maintaining the triazolyl group.  The varying conformational energy for 
each of these counterbalances to prefer the equatorial position, also known as A-Value, can be 
used to assess the energy needed to changes the orientation of the hydroxyl/acetate and triazolyl 
groups from diequatorial to diaxial positions.  This is only possible if the counterbalances are cis 
to the hydroxyl/acetate and triazolyl groups.  Compounds of this design were suggested for 
synthesis.  (Scheme 3.23). 
Synthesis of trans-2-Triazolylcyclohexanol Derivatives 
Compounds 18 and 19 (Scheme 3.24 and 3.25) were synthesized beginning with 
commercially available cyclohexene oxide 4.  The ensuing epoxide ring cleavage by azide anion 
was done with sodium azide and ammonium chloride in a 15:1 solution of H2O and ethanol to 
produce azide 17a.  Azide 17a was acetylated using acyl chloride through refluxing in dry 
chloroform to produce Acetyl-azide 17b.  Both azides 17a and 17b were exposed to copper(I)-
catalyzed “click reaction” (CuAAC) conditions with CuSO4.5H2O, ascorbic acid and 1-octyne or 
phenylacetylene in a 2:7 solution of dioxane and DI H2O to give triazoles 18a,b and 19a,b 
respectively (Scheme 3.24).  Azide 17a was also exposed to other “click reaction” conditions by 




Scheme 3.24.  Synthesis of trans-2-Triazolylcyclohexanols/cyclohexyl Acetates. 
 
 
Scheme 3.25.  Synthesis of trans-2-(4,5-diphenyl)Triazolylcyclohexanol 18c. 
 
Compounds 24-29 (Scheme 3.26) were synthesized beginning with commercially 
available 4-methyl/pheny/t-butylcyclohexene.  Each of these alkenes was epoxidized with m-
CPBA in DCM to produce an inseparable mixture of as syn and anti epoxides (20a, 20b and 20c) 
with each counterbalance.  Epoxide ring cleavage by azide anion was done with sodium azide 
and ammonium chloride in a 15:1 solution of H2O and ethanol to give azide mixtures as 
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constitutional isomer pairs 21a,b , 22a,b and 23a,b.  Compounds 21a,b , 22a,b and 23a,b were 
exposed to copper(I)-catalyzed “click reaction” (CuAAC) conditions with  CuSO4.5H2O, 




Scheme 3.26.  Synthesis of trans-2-Triazolyl-4/5-Methyl/Phenyl/t-Butyl-Cyclohexanols. 
 
Constitutional isomer pairs 21a,b , 22a,b and 23a,b were acetylated using acyl chloride 
through refluxing in dry chloroform to produce Acetyl-azido constitutional isomer pairs 30a,b , 
31a,b and 32a,b.  Compounds 30a,b , 31a,b and 32a,b were exposed to copper(I)-catalyzed 
“click reaction” (CuAAC) conditions with  CuSO4.5H2O, ascorbic acid and  1-octyne or 
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phenylacetylene in a 2:7 solution of  dioxane and H2O to give triazoles 33-38 whose isomers 
were separated when possible (Scheme 3.27).   
 
 
Scheme 3.27.  Synthesis of trans-2-Triazolyl-4/5-Methyl/Phenyl/t-Butyl-Cyclohexyl Acetates. 
 
Conformational Study of trans-2-Triazolylcyclohexanol Derivatives with Counterbalances 
A similar fast equilibrium in [A + AH+]  [B + BH+] (Scheme 3.22) was examined for 
trans-2-triazolylcyclohexanols with counterbalances (compounds 24-29 and 33-38) by 1H NMR 
spectroscopy (600 MHz).  The conformer populations (nA, nB) in dilute solutions were estimated 
using the same limiting parameters (WA, WB) and the signal width W for signals of interest. 
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Table 11 
1H NMR Data and Conformational Parameters for trans-2-Triazolyl-5-Methyl/Phenyl/t-Butyl-
Cyclohexanols 
 
solvent, acid H1 (OR) 
           W, Hz 
H2 (Tz) 
           W, Hz 
nB (nBD+) 





18a- R = H, R1 = n-C6H13, R2  = H  
CDCl3 3.88 25.2 4.32 25.7 95 -7.0 -1.68 
CD3OD 3.86 24.7
 4.20 26.4 95 -7.3 -1.75 
+ CF3COOD 
e) 3.85 24.7 4.20 26.4 95 -7.3 -1.75 
18b- R = H, R1 = phenyl, R2  = H 
CDCl3 4.06 24.9
b) 4.15 25.9 94 -6.9 -1.65 
CD3OD 3.92 24.9
b) 4.29 26.5 96 -7.9 -1.88 
+ CF3COOD 
e) 3.92 24.8b) 4.32 26.5 96 -7.7 -1.83 
18c- R = H, R1(C4 and C5) = phenyl, R2 = H 
CDCl3 4.48 24.9 3.85 25.8
 94 -6.8 -1.61 
CD3OD 4.21 25.6
 3.90 26.2 97 -8.8 -2.10 
+ CF3COOD 
e) 4.21 25.6 3.91 26.2 97 -8.8 -2.10 
19a- R = Ac, R1 = n-C6H13, R2  = H 
CDCl3 5.05 25.6 4.48 27.0
d) 100 -14.2 -3.40 
CD3OD 5.11 25.6 4.59 27.0
d) 100 -14.2 -3.40 
+ CF3COOD 
e) 5.11 25.6 4.59 27.0d) 100 -14.2 -3.40 
19b- R = Ac, R1 = phenyl, R2  = H 
CDCl3 5.15 25.7
d) 4.58 26.9 100 -14.2 -3.40 
CD3OD 5.19 25.7
d) 4.60 27.0d) 100 -14.2 -3.40 
+ CF3COOD 
e) 5.19 25.7d) 4.61 27.0d) 100 -14.2 -3.40 
25a- R = H, R1 = n-C6H13, R2  = CH3 
CDCl3 4.26 24.8 4.35 25.7 93 -6.5 -1.55 
CD3OD 4.03 23.9 4.42 25.8 91 -5.7 -1.36 
+ CF3COOD 
e) 4.02 24.0 4.42 25.8 91 -5.8 -1.38 
25b- R = H, R1 = phenyl, R2  = CH3 
CDCl3 4.12 24.4 4.39 25.6 92 -6.0 -1.42 
CD3OD 3.93 24.1 4.53 25.8 92 -5.9 -1.40 
+ CF3COOD 
e) 3.94 24.1 4.53 25.8 92 -5.9 -1.40 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 
CD3OD solution; f) Poorly resolved signal. 
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(Table 11 Continued) 
 
solvent, acid H1 (OR) 
           W, Hz 
H2 (Tz) 
           W, Hz 
nB (nBD+) 





27a- R = H, R1 = n-C6H13, R2  = phenyl 
CDCl3 4.31 24.7 4.34 
b) 94 -6.7 -1.61 
CD3OD 4.27 18 4.43 19.4 56 -0.4 -0.10 
+ CF3COOD 
e) 4.27 18 4.44 b) 54 -0.4 -0.09 
27b- R = H, R1 = phenyl, R2  = phenyl 
CDCl3 4.40 25.0 4.41 
b) 96 -7.7 -1.83 
CD3OD 4.29 18.7 4.54 
b) 58 -0.8 -0.19 
+ CF3COOD 
e) 4.29 18.8 4.54 b) 59 -0.9 -0.21 
29a- R = H, R1 = n-C6H13, R2  = C(CH3)3 
CDCl3 4.52  (~11)
c) 4.58 (~12)c) 14 5.0 1.19 
CD3OD 4.37 9.1
 4.57 10.6 5 9.8 2.34 
+ CF3COOD 
e) 4.38 9.3 4.58 10.7 6 8.8 2.10 
29b- R = H, R1 = phenyl, R2  = C(CH3)3 
CDCl3 4.58 10.2 4.66 12.0
b) 12 5.6 1.34 
CD3OD 4.42 9.8
 4.66 10.8 7 7.5 1.79 
+ CF3COOD 
e) 4.41 10.1 4.69 11.2 9 6.5 1.55 
34a- R = Ac, R1 = n-C6H13, R2  = CH3                         
CDCl3 5.32 23.1
 4.45 23.8 83 -3.8 -0.92 
CD3OD 5.37 24.1 4.55 ~26
f) 92 -6.1 -1.45 
+ CF3COOD 
e) 5.37 24.1 4.55 ~26f) 92 -6.1 -1.45 
34b- R = Ac, R1 = phenyl, R2  = CH3  
CDCl3 5.40 23.0
 4.53 23.9 83 -3.8 -0.92 
CD3OD 5.45 24.4 4.60 25.1 91 -5.5 -1.32 
+ CF3COOD 
e) 5.45 24.4 4.60 25.1 91 -5.5 -1.32 
36a- R = Ac, R1 = n-C6H13, R2  = phenyl 
CDCl3 5.39 16.7 4.63 17.5 47 0.5 0.12 
CD3OD 5.42 19.3 4.75 20.0 61 -1.0 -0.24 
+ CF3COOD 
e) 5.41 20.2 4.79 20.6 66 -1.5 -0.35 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 






(Table 11 Continued) 
 
36b- R = Ac, R1 = phenyl, R2  = phenyl 
CDCl3 5.48 16.7 4.71 17.4 46 0.5 0.13 
CD3OD 5.53 19.3 4.79 19.9 61 -1.0 -0.23 
+ CF3COOD 
e) 5.52 20.1 4.81 20.3 65 -1.3 -0.32 
38a- R = Ac, R1 = n-C6H13, R2  = C(CH3)3 
CDCl3 5.35 (~11)
c) 4.62 (~12)c) 17 4.3 1.03 
CD3OD 5.44 9.6 4.71 10.3 5 9.1 2.17 
+ CF3COOD 
e) 5.44 9.6 4.71 10.3 5 9.1 2.17 
38b- R = Ac, R1 = phenyl, R2  = C(CH3)3 
CDCl3 5.50 9.8 4.57 10.2 5 9.8 2.34 
CD3OD 5.58 (~11)
c) 4.67 (~11)c) 12 5.8 1.38 
+ CF3COOD 
e) 5.58 10.5 4.69 10.7 9 6.6 1.58 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 

























1H NMR Data and Conformational Parameters for trans-2-Triazolyl-4-Methyl/Phenyl/t-Butyl-
Cyclohexanols 
 
solvent, acid H1 (OR) 
           W, Hz 
H2 (Tz) 
           W, Hz 
nB (nBD+) 





24a- R = H, R1 = n-C6H13, R2  = CH3 
CDCl3 3.98 24.2
f) 4.07 25.4 91 -5.6 -1.34 
CD3OD 3.92 23.8 4.24 25.7
 91 -5.5 -1.32 
+ CF3COOD 
e) 3.91 23.9 4.25 25.8 91 -5.7 -1.36 
24b- R = H, R1 = phenyl, R2  = CH3 
CDCl3 4.08 24.4
 4.44 25.6 92 -6.0 -1.42 
CD3OD 3.91 24.0 4.52 25.9 92 -5.9 -1.40 
+ CF3COOD 
e) 3.90 24.1 4.53 26.0 92 -6.1 -1.45 
26a- R = H, R1 = n-C6H13, R2  = phenyl 
CDCl3 4.24 24.4 4.34 
b) 92 -6.0 -1.44 
CD3OD 4.15 19.5 4.46 20.3 63 -1.2 -0.28 
+ CF3COOD 
e) 4.15 19.5 4.47 b) 63 -1.3 -0.31 
26b- R = H, R1 = phenyl, R2  = phenyl 
CDCl3 4.31 25.5 4.41 
b) 99 -10.8 -2.58 
CD3OD 4.18 20.0 4.54 
b) 66 -1.6 -0.38 
+ CF3COOD 
e) 4.18 20.2 4.54 b) 67 -1.7 -0.42 
28a- R = H, R1 = n-C6H13, R2  = C(CH3)3 
CDCl3 4.44 11.6 4.57 11.7
b 15 4.8 1.14 
CD3OD 4.43 10.2 4.48 10.3 7 7.7 1.83 
+ CF3COOD 
e) 4.41 10.3 4.50 10.4 8 7.3 1.75 
28b- R = H, R1 = phenyl, R2  = C(CH3)3 
CDCl3 4.53 11.8 4.66 12.0 17 4.4 1.06 
CD3OD 4.52 9.7 4.55 10.3 6 8.8 2.10 
+ CF3COOD 
e) 4.53 (~10)c) 4.56 (~10)c) 6 8.8 2.10 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved 
signal (a width at 1/3 of its height is shown); d) Used as WA; e) d-trifluoroacetic acid was added in large excess (x10
-15) to 











        W, Hz 
H2 (Tz) 







33a- R = Ac, R1 = n-C6H13, R2  = CH3 
CDCl3 5.07 23.1
f) 4.70 25.6 88 -4.9 -1.17 
CD3OD 5.14 23.3 4.78 ~25
f) 87 -4.6 -1.11 
+ CF3COOD 
e) 5.14 23.3 4.78 ~25f) 87 -4.6 -1.11 
33b- R = Ac, R1 = phenyl, R2  = CH3 
CDCl3 5.15 23.3
f) 4.78 24.5 86 -4.3 -1.03 
CD3OD 5.22 23.8
f) 4.83 25.3 90 -5.2 -1.24 
+ CF3COOD 
e) 5.22 23.8f) 4.84 25.3 90 -5.2 -1.24 
35a- R = Ac, R1 = n-C6H13, R2  = phenyl 
CDCl3 5.24 18.0 4.73 18.9 54 -0.3 -0.07 
CD3OD 5.34 18.5 4.69 19.5 58 -0.6 -0.15 
+ CF3COOD 
e) 5.33 18.7 4.70 19.6 58 -0.7 -0.17 
35b- R = Ac, R1 = phenyl, R2  = phenyl 
CDCl3 5.37 16.5 4.74 17.9 47 0.4 0.10 
CD3OD 5.63 18.9 4.79 19.3 58 -0.7 -0.16 
+ CF3COOD 
e) 5.62 19.0 4.80 19.3 59 -0.7 -0.17 
37a- R = Ac, R1 = n-C6H13, R2  = C(CH3)3 
CDCl3 5.25 (~10)
c) 4.77 (~12)c) 11 5.8 1.38 
CD3OD 5.52 10.4
f) 4.58 10.5f) 8 7.0 1.68 
+ CF3COOD 
e) 5.52 10.4f) 4.58 10.5f) 8 7.0 1.68 
37b- R = Ac, R1 = phenyl, R2  = C(CH3)3 
CDCl3 5.43 9.0
d) 4.70 10.1d) 0 >13 >3.5 
CD3OD 5.48 (~10)
c) 4.81 (~11)c) 9 6.9 1.64 
+ CF3COOD 
e) 5.49 9.4 4.82 10.6 6 8.8 2.10 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Unresolved signal 
(a width at 1/3 of its height is shown); d) Used as WA; e) d-trifluoroacetic acid was added in large excess (x10
-15) to CD3OD 










Effect of counterbalances.  The conformational preference of the compounds studied 
varied depending on the strength of the counterbalances.  With the A-value for the methyl, 
phenyl and t-butyl groups listed as 1.75 kcal/mol, 2.80 kcal/mol and 4.50 kcal/mol respectively,10  
the variation in energy from each of these groups alters the conformation of the triazole and 
hydroxyl/acetate groups on the cyclohexane ring.  The conversion of Gibbs free energy (∆G) 
from kJ/mol to kcal/mol allows for direct comparison of the A-values and energy from the 
experimental data.    
As expected, all the compounds without a counterbalance (18a,b,c and 19a,b) showed 
complete preference for conformer B in acid and non-acidic environments (Table 11).  This is 
supported by the wide signal widths for the axial protons geminal to the triazole and 
hydroxyl/acetate groups that are in axial positions.  This diequatorial orientation is also 
supported by the crystal structure of 18b (Figure 3.10).  The signal widths in 1H NMR from these 
models were used as limiting parameters, WB, for the triazole and hydroxyl/acetate groups in the 




Figure 3.10.  X-ray crystal structure of 18b. 
 
With the methyl group as the counterbalance (compounds 24a,b, 25a,b, 33a,b and 34a,b) 
(Table 11 and 12), there is still a strong conformational preference for B in acid and non-acidic 
environments.  This means that the conformational energy of the methyl group is not sufficient to 
alter the position of the triazole and hydroxyl/acetate groups and interruption the interaction 
between the groups. 
With the phenyl group as the counterbalance (compounds 26a,b, 27a,b, 35a,b and 36a,b) 
(Table 11 and 12), the conformational preference for B varies.  In CDCl3, the preference for B is 
significantly higher compared to CD3OD for compounds 26a,b and 35a,b that have triazole and 
hydroxyl substituents.  Compounds with triazole and acetoxy substituents (27a,b and 36a,b) 
have a stronger preference for A in CDCl3 as compared to CD3OD apparently due to lack of 
intramolecular hydrogen bonding.  Hence, conformational energy of the phenyl group is 
sufficient to partially alter the position of the triazole and hydroxyl/acetate groups and break the 
interaction between the groups in CD3OD, i.e., the A-value of the phenyl and the strength based 
on the interaction and conformational energy of the triazole and hydroxyl/acetate substituents are 










environments of CD3OD.  The bulky t-butyl counterbalance in compounds 28a,b, 29a,b, 37a,b 
and 38a,b (Table 11 and 12) alters the conformational preference to conformer A regardless of 
solvent.  This preference does not change in acid or non-acidic environments.  It means that the 
conformational strength of the t-butyl group is sufficient to alter the position of the triazole and 
hydroxyl/acetate groups and break the interaction between the groups. 
Effect of solvent.  The variation in conformation is clearly seen in compounds 26a,b, 
27a,b, 35a,b and 36a,b (Table 11 and 12).   In nonpolar solvent CDCl3, compounds 26a,b, 27a,b 
have a high preference for conformer B.  The hydroxyl group in these compounds is able to 
participate in intramolecular hydrogen bonding (OH...N(Tz)) with no interference from the 
solvent.  For these same compounds, polar solvent CD3OD disrupts the intramolecular hydrogen 
bonding by hydrogen bonding with the hydroxyl group intermolecularly and increases preference 
for conformer A.  The same intermolecular interactions are present for compounds 35a,b and 
36a,b in CD3OD even though they have an acetate group.  But in CDCl3, the acetate group has 
no significant attraction with the triazolyl group and the phenyl counterbalance is able to force a 
preference for conformer A. 
Library of cis/transtriazolylcyclohexanes 
The results in Table 11-12 show that trans-2-triazolylcyclohexanol derivatives have a 
conformational bias towards conformer B with the hydroxyl/acetoxy and triazolyl groups in 
equatorial positions.  The results also showed that any counterbalance with an A-value of 
approximately 2.80 kcal/mol (phenyl) or more can start to affect the conformational bias and 
increase preference for conformer A.  Furthermore, the conformational anchoring of the t-butyl 
group was sufficient to alter the positions of the hydroxyl/acetate and triazolyl groups from 
equatorial to axial, thus altering the bias from conformer B to A.   
120 
These results prompted us to estimate the so far unknown conformational energy of the 
triazolyl group independently.  With no data reported on the A-value of the triazole and its 
growing synthetic use in the pharmaceutical and chemical industries, it is important to know the 
rating for the bulkiness of this group and its preference of position on a cyclohexane ring.  This 
was done in a classical way by using the same counterbalances of methyl, phenyl and t-butyl 
groups, and placing them directly across the triazolyl group on a cyclohexane ring.  The varying 
conformational energy of the counterbalances would cause “haggling” with the triazole for the 
equatorial position on the cyclohexane ring and the energetic preference for this position would 
go to the substituent with a higher A-value.   
Synthesis of the compounds necessary to satisfy this approach meant availability of both 
cis and trans configurational isomers to show the limiting parameters for all counterbalances and 
the triazolyl group when monitoring their conformational dependence.   Compounds of this 




Scheme 3.28.  Library of cis/transTriazolylcylcohexanes. 
 
Synthesis of Triazolylcyclohexanes 
 
 
Scheme 3.29.  Synthesis of Triazolylcyclohexanes. 
122 
Compounds 40a,b were synthesized beginning with commercially available 
bromocyclohexane (Scheme 3.29).  A nucleophilic substitution (Sn2) was done with azide anion 
using sodium azide in DMSO by way of reflux to produce azidocylohexane 39.79 Azide 39 was 
exposed to copper(I)-catalyzed “click reaction” (CuAAC) conditions with  CuSO4.5H2O, 
ascorbic acid and  1-octyne or phenylacetylene in a 2:7 solution of  dioxane and DI H2O to give 
triazoles 40a and 40b respectively (Scheme 3.29). 
Compounds 43-45 (Scheme 3.30) were synthesized beginning with commercially 
available 4-methyl/pheny/t-butylcyclohexanols.  All alcohols were tosylated in chloroform with 
pyridine and p-toluenesulfonyl chloride to produce compounds 41a-c.80 A nucleophilic 
substitution (Sn2) was done with compounds 41a-c and azide anion using sodium azide in 
DMSO by way of reflux to produce azides 42a-c.  Azides 42a-c were exposed to copper(I)-
catalyzed “click reaction” (CuAAC) conditions with CuSO4.5H2O, ascorbic acid and 1-octyne or 
phenylacetylene in a 2:7 solution of dioxane and DI H2O to give triazoles 43a,b, 44a,b and 45a,b 
respectively (Scheme 3.30).  When possible, the configurational isomers were separated by 




                            




Figure 3.11.  1H NMR confirming separation of configuration isomers of 43b. 
 
Conformational Study of cis/trans-Triazolylcyclohexanes 
 
 
Scheme 3.31.  Conformational Equilibrium in trans-Triazolylcyclohexanes. 
 
The fast equilibrium [B]  [BH+] (Scheme 3.31) was examined by 1H NMR 
spectroscopy (600 MHz) for the with trans configuration isomers.  It is important to note that 
these isomers don’t have any preference for conformer A due to repulsion of both substituents 
with the cyclohexane ring.  The conformation is biased towards conformer B in nonacidic media 




















































X : parts per Million : 1H
4.69 4.68 4.67 4.66 4.65 4.64 4.63 4.62 4.61 4.6 4.59 4.58 4.57 4.56 4.55 4.54 4.53 4.52 4.51 4.5 4.49 4.48 4.47 4.46 4.45 4.44 4.43 4.42 4.41 4.4




Scheme 3.32.  Conformational Equilibrium in cis-Triazolylcyclohexanes. 
 
For the cis configuration isomer, the fast equilibrium [A + AH+]  [B + BH+] (Scheme 
3.32) was considered.  With the variations of the counterbalance conformational energy, the 
preference for conformer A is an option in the case of a strong anchor like t-butyl.  Both 
conformers A and B can be protonated to give AH+ and BH+, and both protonated conformers 
should be considered during conformational analysis.    
The conformer populations (nA, nB) in dilute solutions were estimated from the averaged 
signal width W = JHH (a sum of spin-spin couplings) of the protons geminal to the triazole:  
Wobserved = WA·nA + WB·nB.  The limiting parameters WA and WB for individual conformers were 
obtained from the measurements for compounds 45a and 45b (Scheme 3.28).  WB was assumed 
to equal 32.4 Hz for H(Tz) geminal to triazole  from 45a and 45b (Table 13).The limiting 
parameters due to conformational bias towards conform A,  WA , was set 12 HZ for H(Tz) 
geminal to triazole  based on analogous compounds.81  
126 
Table 13 
1H NMR Data and Conformational Parameters for trans-Triazolyl-4-Methyl/Phenyl/t-Butyl-
Cyclohexanes 
 
solvent, acid H2 (Tz) 
                    W, Hz 
nB (nBD+) 
  % 




40a- R = n-C6H13, R1  = H 
CDCl3 4.41 31.2 94 -6.8 -1.62 
CD3OD 4.43 31.3 95 -7.0 -1.67 
+ CF3COOD 
e) 4.46 31.3 95 -7.0 -1.67 
40b- R = phenyl, R1  = H 
CDCl3 4.50 31.5
 96 -7.5 -1.80 
CD3OD 4.53 31.3 95 -7.0 -1.67 
+ CF3COOD 
e) 4.55 31.3 95 -7.0 -1.67 
43a (trans)- R = n-C6H13, R1  = CH3 
CDCl3 4.36 32.1 99 -10.3 -2.46 
CD3OD 4.40 31.6
c) 96 -7.8 -1.87 
+ CF3COOD 
e) 4.42 31.6c) 96 -7.8 -1.87 
43b (trans)- R = phenyl, R1  = CH3 
CDCl3 4.47 32.1 99 -10.3 -2.46 
CD3OD 4.50 31.6 96 -7.8 -1.87 
+ CF3COOD 
e) 4.52 31.6b) 96 -7.8 -1.87 
44a (trans)- R = n-C6H13, R1  = Phenyl 
CDCl3 4.52 32.1 99 -10.3 -2.46 
CD3OD 4.64 32.0
 98 -9.6 -2.29 
+ CF3COOD 
e) 4.65 32.1 99 -10.3 -2.46 
44b (trans)- R = phenyl, R1  = Phenyl 
CDCl3 4.63 32.1 99 -10.3 -2.46 
CD3OD 4.72 31.9 98 -9.0 -2.15 
+ CF3COOD 
e) 4.73 32.0 98 -9.6 -2.29 
45a (trans)- R = n-C6H13, R1  = C(CH3)3 
CDCl3 4.33 32.4
d) 100 -13.0 -3.11 
CD3OD 4.35 32.3 100 -13.0 -3.11 
+ CF3COOD 
e) 4.37 32.3 100 -13.0 -3.11 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Poorly resolved 
signal; d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10





(Table 13 Continued) 
 
 
45b (trans)- R = phenyl, R1  = C(CH3)3 
CDCl3 4.45 32.3
 100 -13.0 -3.11 
CD3OD 4.49 32.4
d) 99 -11.3 -2.70 
+ CF3COOD 
e) 4.50 32.4d) 100 -13.0 -3.11 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Poorly resolved 
signal; d) Used as WB; e) d-trifluoroacetic acid was added in large excess (x10





1H NMR Data and Conformational Parameters for cis-2-Triazolyl-4-Methyl/Phenyl/t-Butyl-
Cyclohexanols 
 
solvent, acid H1 (Tz) 
                    W, Hz 
nB (nBD+) 





43a (cis)- R = n-C6H13, R1  = CH3 
CDCl3 4.43 24.7 62 -1.2 -0.29 
CD3OD 4.49 24.2 60 -1.0 -0.23 
+ CF3COOD 
d) 4.51 24.3 60 -1.0 -0.24 
43b (cis)- R = phenyl, R1  = CH3 
CDCl3 4.55 24.5 61 -1.1 -0.27 
CD3OD 4.59 24.3 60 -1.0 -0.24 
+ CF3COOD 
d) 4.62 24.3b) 60 -1.0 -0.24 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Poorly resolved 







(Table 14 Continued) 
 
 
44a (cis)- R = n-C6H13, R1  = Phenyl 
CDCl3 4.64 17.1 25 2.7 0.64 
CD3OD 4.84 16.2
 21 3.3 0.79 
+ CF3COOD 
d) 4.87 16.2 21 3.3 0.79 
44b (cis)- R = phenyl, R1  = Phenyl 
CDCl3 4.76 16.7 23 2.9 0.71 
CD3OD 4.83 16.2
 21 3.3 0.79 
+ CF3COOD 
d) 4.85 16.3 21 3.2 0.77 
45a (cis)- R = n-C6H13, R1  = C(CH3)3 
CDCl3 4.57 13.3
 6 6.6 1.57 
CD3OD 4.57 12.8 4 7.8 1.87 
+ CF3COOD 
d) 4.60 12.8 4 7.8 1.87 
45b (cis)- R = phenyl, R1  = C(CH3)3 
CDCl3 4.67 13.2
 6 6.8 1.62 
CD3OD 4.69 12.7 3 8.2 1.95 
+ CF3COOD 
d) 4.70 12.7 3 8.2 1.95 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Poorly resolved 











Factors Affecting Conformational Equlibrium of trans-2-Triazolylcyclohexanes 
 
                   
Figure 3.12.  1H NMR signal (H1) for 44b. 
 
Effect of counterbalances.  The compounds 40a and 40b (Table 13), that have no 
counterbalance, showed an expected preference for the diequatorial conformer B.  Acidic media 
had no effect on the conformational equilibrium.  All the trans isomers showed total preference 
for conformer B regardless of the counterbalance and acidity of the environment.  This 
arrangement was used to determine the limiting parameter, WB, for these triazolylcylohexanes. 
The variation in conformer population for the cis isomers was used to estimate the 
conformational energy of the triazolyl group.  As the A-value increases for the counterbalances 
on the cyclohexane ring, the preference for conformer A increases.  The equilibrium Gibbs free 
energy, ∆GB-A, and the A-value for the counterbalance can be used to estimate the 
conformational energy of the triazolyl group. 
   
 
 
J1,6a   = J1,2a   =  12.0 Hz 
J1,6e   = J1,2e   =  4.0 Hz 
 
J1,6a   = J1,2a    
J1,6e   = J1,2e   
130 
Table 15 
1H NMR Data and Conformational Parameters for cis-Triazolyl-4-Methylcyclohexanols 43a and 
43b a) 
 
solvent, acid H1 (Tz) 
                    W, Hz 
nB (nBD+) 





43a (cis)- R = n-C6H13 
CDCl3 4.43 24.7 62 -1.2 -0.29 
CD3OD 4.49 24.2 60 -1.0 -0.23 
+ CF3COOD 
d) 4.51 24.3 60 -1.0 -0.24 
43b (cis)- R = phenyl 
CDCl3 4.55 24.5 61 -1.1 -0.27 
CD3OD 4.59 24.3 60 -1.0 -0.24 
+ CF3COOD 
d) 4.62 24.3b) 60 -1.0 -0.24 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) Partially or completely overlapped with other signals; c) Poorly resolved 





With the methyl group as the counterbalance, the 1.74 kcal/mol A-value is able to change 
the conformational preference towards conformer A while still keeping conformer B as the major 
conformer in the equilibrium.  Addition of excess d-TFA has no effect on the population of 
either conformer.  The conformational energy was determined in CD3OD because the values 
from ∆GB-A were consistent as compared to CDCl3.  With the use of the A-value and -0.24 
kcal/mol for ∆GB-A (Table 13 and 14), the conformational energy of the triazolyl group was 
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1H NMR Data and Conformational Parameters for cis-Triazolyl-4-Phenylcyclohexanols 44a and 
44b a) 
 
solvent, acid H1 (Tz) 
                    W, Hz 
nB (nBD+) 





44a (cis)- R = n-C6H13 
CDCl3 4.64 17.1 25 2.7 0.64 
CD3OD 4.84 16.2
 21 3.3 0.79 
+ CF3COOD 
b) 4.87 16.2 21 3.3 0.79 
44b (cis)- R = phenyl 
CDCl3 4.76 16.7 23 2.9 0.71 
CD3OD 4.83 16.2
 21 3.3 0.79 
+ CF3COOD 
b) 4.85 16.3 21 3.2 0.77 






The phenyl group alters the conformational equilibrium to give preference to A while 
keeping B as the minor population.  Addition of excess d-TFA has no effect on the population of 
either conformer.  With the use of the A-value for phenyl (2.80 kcal/mol) and 0.79 kcal/mol 
∆GB-A (Table 15 and 16), conformational energy of the triazolyl group was estimated again to be 
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significant preference for conformer A with the triazole preferring the axial position due to the 
higher conformational energy of the phenyl group. 
The conformational results from cis-triazolyl-4methycylohexanes (43a and 43b) and cis-
triazolyl-4phenylcylohexanes (44a and 44b) show that the conformational energy of the triazolyl 
group is between 1.74 and 2.80 kcal/mol because of the preference for B in the former and the 
preference for A in the latter.  The compounds 45a and 45b (Table 14), with the t-butyl 
counterbalance, showed total preference for conformer A.  This is expected because of the 
conformational energy of the t-butyl ‘anchor” (4.50 kcal/mol) is large and firmly holds the 
triazolyl group in the axial position.  This result shows that the A-value of the triazole is 
significantly lower than that of t-butyl. 
Calculations for the Conformational Energy of the Triazolyl Group 
In order to support the results in Tables 13, 14 and 15, calculations were done on model 
compounds to determine the conformational energy of the triazolyl group on a cyclohexane ring.  
Initial training calculations were done on simple cyclohexane models with methyl (Aeq and Aax) 
and phenyl(Beq and Bax) (Figure 3.13) substituents in reference to previously obtained 
conformational energies in gas phase and in methanol.82,83 
All the calculations were done using Gaussian 09 program package and carried out by the 
group of Dr. Hyun Joo.  Initially the models were optimized to obtain geometry with the lowest 
potential energy.  This optimization included rotation of the substituents along a particular bond 
while allowing the rest of the molecule to accommodate the changes.  This would ensure that the 
lowest energy structure was obtained with the consideration of all rotamers of each model.  The 
geometry optimizations were performed at MP2 level with 6-311+G(d,p) basis set.84 
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To confirm that the geometry of each optimized structure was at the true minimum, 
vibration frequency calculations were carried out.  From these calculations, thermodynamic 
correction terms including zero point vibration energy, thermal correction (Cp) to enthalpy (∆H
o), 
and entropy (∆So) were attained.  For more accurate description of thermodynamics of the axial 
and equatorial conformers, coupled cluster CCSD(T) method was used for single point energy 
calculation based on the MP2 optimized geometries of each structure.  This was done to find the 
lowest potential energy for the already optimized structures while accounting for all excitations, 
i.e.  up to triple excitations (T).  These excitations included interactions of the molecules in gas 
phase and in methanol which was the experimental environment. 
 
 
                                                 
                                    
 
Figure 3.13.  Optimized structures of substituted model cyclohexanes. 
 
Aeq    Aax   
Beq    Bax   
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Figure 3.14.  Optimized structures of triazolylcyclohexanes. 
 
40Tz-eq    40
Tz-ax
   
43Tz-eq    43Tz-ax   
44Tz-eq    44Tz-ax   
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The results from the simple models agreed with the previous studies of calculated ∆Go in 
the gas phase for the methyl and phenyl groups as 1.99 kcal/mol and 3.06 kcal/mol respectively 
(Table 16).82,83 In methanol the calculated ∆Gosol for the methyl and phenyl groups, 1.96 
kcal/mol and 3.20 kcal/mol respectively, agree with the gas phase results.  The same calculations 
were done for the triazolylcycohexanes with these same substituents to estimate the A-value of 
the triazolyl group. 
 
Table 17 
Calculated Conformational Enthalpy (∆Ho), Free Energy (∆Go) and Free Energy of Solvation in 
Methanol (∆Gsol





















(Aax  -  Aeq) 1.90 1.84 1.94 1.88 
(Bax  -  Beq) 3.02 2.40 3.32 2.70 
(40Tz-ax  -  40Tz-eq) 1.32 1.44 1.57 1.69 
(43Tz-ax  -  43Tz-eq) -0.47 -0.59 -0.23 -0.35 






(Aax  -  Aeq) 2.01 1.95 2.05 1.99 
(Bax  -  Beq) 3.38 2.76 3.68 3.06 
(40Tz-ax  -  40Tz-eq) 1.49 1.41 1.85 1.76 
(43Tz-ax  -  43Tz-eq) -0.41 -0.54 -0.17 -0.28 
(44Tz-ax  -  44Tz-eq) -1.87 -1.24 -1.84 -1.20 
∆Gsolo 




(Aax  -  Aeq) 1.98 1.92 2.02 1.96 
(Bax  -  Beq) 3.52 2.90 3.82 3.20 
(40Tz-ax  -  40Tz-eq) 2.14 2.06 2.50 2.41 
(43Tz-ax  -  43Tz-eq) 0.18 0.09 0.50 0.42 
(44Tz-ax  -  44Tz-eq) -1.04 -0.70 -1.01 -0.68 
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The results from the triazolyl models (Table 16 and Figure 3.14) show agreement with 
the 1H NMR conformational studies with these same counterbalances (Tables 15 and 16).  In 
methanol specifically, the calculated ∆Gosol for the triazolyl group (2.41 kcal/mol) is between 
that of the methyl and phenyl groups.  This would mean that for the cis-triazolyl-4-
methylcyclohexane models, the conformer with the triazolyl group in the equatorial position and 
methyl group in the axial position (43Tz-eq) is more stable than the conformer with the triazolyl 
group in the axial position and methyl group in the equatorial position (43Tz-ax) by 0.42 kcal/mol.  
This energy difference was seen experimentally in the conformer population distribution of 
~60% for conformer B (43Tz-eq) and ~40% for conformer A (43Tz-ax) as 0.24 kcal/mole from cis 
derivative 43. 
The results from the cis-triazolyl-4-phenylcyclohexane models also comply with the 1H 
NMR conformational studies.  The conformer with the triazolyl group in the equatorial position 
and phenyl group in the axil position (44Tz-eq) is less stable than the conformer with the triazolyl 
group in the axial position and phenyl group in the equatorial position (44Tz-ax) by 0.68 kcal/mol.  
This significant energy difference was also seen in the conformer population distribution of 
~21% for conformer B (44Tz-eq) and ~71% for conformer A (44Tz-ax) as 0.79 kcal/mole from cis 
derivative 44.  Thus, the experimental data from 1H NMR conformational studies and the 
calculations approximate the conformational energy of the triazolyl group in methanol to ~2.0 
kcal/mol. 
Glycosidase Inhibitors and Activators 
The effect of small molecules on glycosidases can result in inhibition, activation or have 
no effect on the enzymes activity.  As mentioned before, these small molecules need to be 
structurally similar to the substrate or transition state especially if they are to have any inhibitory 
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effect on an enzyme.56,57 Polar groups, like hydroxyl, amino, amide, carboxylic or carboxylate 
groups, around a molecule analogous to a carbohydrate usually produced significant inhibition to 
glycosidases.57 Recently our group demonstrated the effect of 4-hydroxy-5-alkoxy-1,2-
cyclohexanedicarboxylic acids on activity of β-D-glucosidases and  β-D-galactosidases isolated 
from fungi Aspergillus and Penicillium sp.  85,86 The results showed that the presence of two 
carboxylic groups and one hydroxyl group is important for efficient inhibition.  The magnitude 
of inhibition depends on the configuration of the substituents, with preference for configuration 
in B (Scheme 3.33).  The length of the alkoxy group OR was important for inhibition of β-D-
glucosidases for both Aspergillus oryzae and Penicililum canenscens.85,86 
 
 
Scheme 3.33.  4-Hydroxy-5alkoxy-1,2-Cyclohexanedicarboxylic Acids-Glycosidase Inhibitors.  
85,86  
 
With the increased use of the triazole moiety  in drug synthesis, 87,88 specifically as 
glycosidase inhibitors,62,88–90 combined with the glycosidase activity seen in 4-hydroxy-5-
alkoxy-1,2-cyclohexanedicarboxylic acid derivatives, new triazolyl-1,2-cyclohexanedicarboxylic 
acids (Scheme 3.34), triazolyl-cyclohexanol and hexahydrobenzo-triazolo-ozazinone derivatives 
(Scheme 3.37) are of interest and they were  synthesized for the first time through click 
chemistry91 and checked for glycosidase activity. 
R = H, n-alkyl
cis cis trans
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Library of 2-Triazolylcyclohexanol Dicarboxylic acids  
 
 
Scheme 3.34.  Library of trans-5-Triazolyl-4-Cylohexanol-trans/cis1-2-Dicarboxylic Acids. 
 
A library of trans-5-triazolyl-4-cyclohexanol-trans-1-2-dicarboxylic acid derivatives 47a 
and 47b and trans-5-triazolyl-4-cyclohexanol-cis-1-2-dicarboxylic acid derivatives 55a, 55b, 
56a and 56b were proposed for synthesis and studied as potential glycosidase activity.  
Compounds 55 and 56 were designed with cis carboxylic groups and trans hydroxyl and triazolyl 
groups.  This is analogous to the 4-hydroxy-5-alkoxy-1,2-cyclohexanedicarboxylic acid 
derivatives that showed the most glycosidase inhibition in the previous study (Scheme 3.33).85,86 
Synthesis of all dicarboxylic acids derivatives was proposed with hexyl and phenyl groups on the 
carbon 4 (C4) of the triazole.  The hexyl long chain was proposed due to structural similarity to 
alkoxy groups in the previous study.  In contrast to the long chain long chain alkoxy groups, a 





Synthesis of trans/cis-2-Triazolylcyclohexanol Dicarboxylic acid 
 
 
Scheme 3.35.  Synthesis of trans-5-Triazolyl-1-2-Cylohexanol Dicarboxylic Acids.  
 
Compounds 47a and 47b (Scheme 3.35) were synthesized beginning with diethyl 4-
cyclohexene-trans-1,2-dicarboxylate 1.  Diethyl 4-cyclohexene-trans-1,2-dicarboxylate 1 was 
previously synthesized19,29,30 through Diels-Alder reaction between butadiene sulfone and diethyl 
fumarate.  The product had a trans orientation of the ethoxylcarbonyl groups.  The ensuing 
epoxidation of alkene 1 was done with m-CBPA in DCM to give epoxide 2.  The subsequent 
epoxide ring cleavage by azide ion was done with sodium azide and ammonium chloride in a 
15:1 solution of H2O and ethanol.  Diethyl-5-azido-4-hydroxy-1,2-cyclohexanedicarboxylate 10a 
was obtained as a yellow oil without purification.  Azide 10a was used in a copper(I)-catalyzed 
“click reaction” with CuSO4.5H2O, ascorbic acid and 1-octyne or phenylacetylene in a 2:7 
solution of dioxane and H2O to give 1,2,3-triazolyl derivatives 11a and 11b respectively.  
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Compounds 11a and 11b were hydrolyzed with potassium hydroxide to yield diacids 47a and 
47b. 
Cis dicarboxylic acids 55a, 55b, 56a and 56b (Scheme 3.36) were synthesized beginning 
with dimethyl-4-cyclohexene-cis-1,2-dicarboxylate 50.  Compound 50 was synthesized through 
the alcoholysis of cis-1,2,3,6-tetrahydrophthalic anhydride in methanol with sulfuric acid.85 This 
was followed by epoxidation with m-CBPA in DCM to give dimethyl 7-
oxabicyclo[4.1.0]heptane-cis-3,4-dicarboxylates (50-syn), yellow oil, and (50-anti), white 
crystals, that were separated by column chromatography.  The ensuing azido-epoxide ring 
cleavage was done with sodium azide and ammonium chloride in the same conditions as azide 
10 for both epoxides 50-syn and 50-anti.  This dimethyl (1R*, 2S*, 4R*, 5R*)-5-azido-4-
hydroxy-1,2-cyclohexanedicarboxylate 51 and dimethyl (1R*, 2S*, 4S*, 5S*)-5-azido-4-
hydroxy-1,2-cyclohexanedicarboxylate 52 respectively.  Azides 51 and 52 were treated with 
“click reactions” conditions, similar to azide 10a, and produced dimethyl (1S*, 2R*, 4S*, 5S*)-
5-(4-hexyl/phenyl-1,2,3-triazolyl)-4-hydroxy-1,2-cyclohexanedicarboxylate 53a and 53b, and 
dimethyl (1S*, 2R*, 4R*, 5R*)-5-(4-hexyl/phenyl-1,2,3-triazolyl)-4-hydroxy-1,2-
cyclohexanedicarboxylate 54a and 54b respectively.  Compounds 53 and 54 were hydrolyzed 
with potassium hydroxide to yield diacids 55 and 56. 
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Scheme 3.36.  Synthesis of cis-2-Triazolylcylohexanol Dicarboxylic Acids. 
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The configuration of the structures and their predominant conformations were determined 
using 1H NMR, 13C NMR, and 2D NMR techniques that include COSY, HMQC and HMBC.  1H 
NMR helped to elucidate the equatorial and/or axial orientations of the vicinal protons, for all 
substituents on each compound.   
 
 
Figure 3.15.  1H NMR signals of trans-5-triazolyl-4-cyclohexanol-trans-1-2-dicarboxylic acid 
47a (in (CD3)2CO). 
 
The structural assignment of the trans-1-2-dicarboxylic acid derivatives, like 47a (Figure 
3.15), was relatively straightforward.  The large spin-spin coupling constants support the trans-
diaxial orientation of protons H4 and H5, i.e., implying a diequatorial orientation for the hydroxyl 
and triazolyl groups.  The small spin-spin coupling constants support the trans-diequatorial 
orientation of protons H1 and H2 in which both carboxylic groups are in a diaxial orientation. 
H5 H4 H2 H1
J5,6e = 4.25 Hz 
J5,4   = 9.15 Hz 
J5,6a = 11.43 Hz 
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The structural assignment of the cis-1-2-dicarboxylic acid derivatives, like 55a (Figure 
3.16), differs from that of trans-1-2-dicarboxylic acid derivatives due the axial-equatorial 
orientation of the carboxylic groups.  Two small spin-spin coupling constants of H2 to H1 and 
H3e, and one large spin-spin coupling constant of H2 to H3a support the orientation of the 
carboxylic groups.   
 
  
Figure 3.16.  1H NMR signals of trans-5-triazolyl-4-cyclohexanol-trans-1-2-dicarboxylic acid 
55a (in CDCl3). 
 
Library of trans-2-Triazolylcyclohexanol and Hexahydrobenzo-Triazolo-Oxazinone  
 
Derivatives for Glycosidase Assays 
 
With interest in the design of previously studied 4-hydroxy-5-alkoxy-1,2-
cyclohexanedicarboxylic acid, it was evident that the carboxylic groups, hydroxyl group and 
alkoxy chain were of importance in the inhibition of glycosidases.  With the design of a library 
of cis and trans dicarboxylic acid derivatives in Scheme 3.34, trans-2-triazolylcyclohexanol 
derivatives (Scheme 3.37) were proposed because they would help show whether glycosidase 
activity is affected by the absence of the carboxylic groups.  While synthesizing these trans-2-
H5 H4 H2H1
J2,1   = 4.04 Hz 
J2,3e = 4.04 Hz 
J2,3a = 12.91 Hz 
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triazolylcyclohexanols, hexahydrobenzo-triazolo-oxazinone derivatives 57 were produced and 


















Scheme 3.38.  Synthesis of trans-2-Triazolylcylohexanols and Hexahydrobenzo-Triazolo-
Oxazinone Derivatives. 
 
Lactones 57 and trans-2-triazolylcylohexanols 58 were synthesized beginning with 
commercially available cyclohexene oxide 4.  Epoxide ring cleavage of compound 4 was done in 
similar condition for epoxide 2 and produced 2-azidocyclohexanol 24a.  Azide 24 was obtained 
as a yellow oil without purification.  Azide 24 was exposed to “click” 1,3-dipolar cycloaddition 
reactions by refluxing in toluene with a series of 2-alkynyl esters.  Tricyclic derivatives 57 
(Scheme 3.38) goes through triazole adduct 57*,77,78 with ester at C5 and hydrocarbon at C4, 
which are unstable at high temperatures and further reacts through esterification to form lactones.  
The triazole adducts with ester at C4 and hydrocarbon at C5 is stable and affords compounds 58 
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(54-70% yield).  (Scheme 3.38).  Similar to the synthesis of derivatives 57a-d (Scheme 3.38), 
azide 24a was treated with dimethyl/ethyl acetylenedicarboxylate by refluxing in toluene.  These 
click reaction conditions resulted into lactones 57e and 57f (Scheme 3.39). 
 
 
Scheme 3.39.  Synthesis of Hexahrdrobenzo-Triazolo-Oxazinone-4-Carboxylate Derivatives. 
 
 
Scheme 3.40.  Synthesis of trans-2-Triazolylcyclohexanol Derivatives. 
 
Azide 24a was also used in ‘click reaction” conditions with CuSO4.5H2O, ascorbic acid 
and 2-alkynyl esters in a 2:7 solution of dioxane and H2O.  These conditions facilitated the 
decarboxylation of the alkyne, which is also catalyzed by Cu+,92–96 leaving a terminal alkyne to 
react with 24a and give trans-2-triazolychexanol derivative 59a-c (Scheme 3.40).   
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NMR Analysis of trans-2-Triazolylcyclohexanols 
The diequatrorial orientation of the hydroxyl and triazolyl groups has already been 
confirmed by 1H NMR for trans-2-triazolylcyclohexanols (compounds 18 and 19: Table 11).  
The signal widths (~23-26Hz) and shape of the signals (ddd or td) for the axial protons geminal 
to either functional group accounts for two large couplings and one small coupling for each of 
the signals.  But to confirm the substituents on 1,4-disubstituted and 1,4-5-trisubstituted 1,2,3-
triazoles, Nuclear Overhauser Effect Spectroscopy (NOESY) NMR experiment was used.  
NOESY is useful in identifying which protons are close to each other in space irrespective of 
bonding connectivity.  This is done by irradiating the signal for the proton/s of interest on the 1H 
NMR spectrum and a response will be seen by the signals present within a given spatial 
environment.   
 
 
Figure 3.17.  NOE experiment for 58b in CDCl3. 
 
In order to solve the structural connectivity problem of 1,4-disubstituted and 1,4&5-
trisubstituted 1,2,3-triazoles with NOE, 1,4-disubtituted triazole 59c (Figure 3.17) and 1,4&5-
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trisubstituted triazole 58b (Figure 3.18) were explored.  By irradiating the protons on the α-
carbon (-CH2), a response is expected from signals on the hydrocarbon chain and any other 
protons within the vicinity.    
For the NOE of 58b (-CH2 at 2.95ppm, Figure 3.17), a response was seen from the 
protons on the hydrocarbon chain as expected.  The notable response from proton geminal to the 
triazole on the cyclohexane ring supports the proposed structure.  The absence of response from 
the methoxy protons attached to C5 on the triazole ring also supports the proposed structure.  For 
the NOE of 59c (-CH2 at 2.68ppm, Figure 3.18), besides the expected response from the protons 
on the hydrocarbon chain, there was only a response from the proton on C4 of the triazole ring.  









NMR Confirmation of Hexahydrobenzo-Triazolo-Oxazinone Derivatives 
 
 
Figure 3.19.  NOE experiment for 57f in CDCl3. 
 
The structures of the lactones 57 are different from the other synthesized compounds 
because of the lactone locks the structure into a tricyclic ring.  With the carbonyl attached at C4 
and a hydrocarbon chain or ester group at C5 on the triazole ring, there is separation of the 
protons on the triazole and cyclohexane rings.  To confirm the structure of these tricyclic 
compounds, an NOE experiment was done for 57f (Figure 3.19).  By irradiating the protons on 
the α-carbon on the ethoxy group (-CH2), a response was seen from signals on the β-carbon (-
CH3).  This coupled with the absence of a response from any protons on the cyclohexane ring 
supports the proposed structure.   
The orientation of the substituents on hexahydrobenzo-triazolo-oxazinone derivatives can 
also be seen in the Xray crystal structure of 57e (Figure 3.20).  The fused planer lactone and 
triazole rings separate the cyclohexane ring from ester further confirming the results from the 
NOE experiment of 57f that has the same structure.  The x-ray structure also shows the planar 
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nature of the methoxycarbonyl and triazole ring that a fused to the heterocylic ring of the lactone 
in a half-chair conformation. 
 
 
Figure 3.20.  X-ray crystal structure for 57e.  
 
Inhibition Assay for trans/cis-2-Triazolylcyclohexanol Dicarboxylic Acid, trans-2- 
 
Triazolylcyclohexanol and Hexahydrobenzo-Triazolo-Oxazinone Derivatives 
 
The synthesized compounds 47, 55, 56, 57, 58 and 59 were assayed for glycosidase 
activity against glycosidases in multi-enzyme complexes isolated from Penicillium Canescens 
and Aspergilus Oryzae.  The complex from P.canescens contained α-D galactosidase, β-D-
galactosidase and β-D-glucosidase.  The complex from A.oryzae contained α-D galactosidase, β-
D-galactosidase, α-D-glucosidase and β-D-glucosidase.  These assays were performed under 
direct supervision of.  Dr. Natalyia Samoshina. 
The experiments were performed in a standard way 97 by monitoring the release of p-
nitrophenol from its related p-nitrophenyl glycosides.  The released p-nitrophenol’s 





N2-N1-C6-C5    56.8o
C7-O1-C1-C6    27.3o
C9-C8-C7-O2 13.0o










of enzymes and substrate combinations were chosen so that the degree of hydrolysis was 
between 10% and 20% over the course of the assay.  The assumption for these conditions is that 
the amount of substrate is high enough to give a linear relationship within a given amount of 
time for the first stage of the reaction.98 After a fixed period of time, the reaction was stopped by 
adding 0.5M Na2CO3 which makes the solution basic leading to inactivation of the enzymes and 
the deprotonation of p-nitrophenol, hence producing a yellow color.  The color intensity 
correlates with the amount of p-nitrophenol produced when the enzyme acts on the substrate.  All 
synthesized compounds underwent a preliminary screening and the results are reported in 
Figures 3.21, 3.22 and 3.23. 
 
 





Figure 3.21.  Effect of trans-5-triazolylcyclohexanol-1-2-dicarboxylic acids 47a,b, 55a,b and 
56a,b (1mM) on the activity of glycosidases from Aspergillus Oryzae (A) and Penicillium 
Canenscens (B). 
 
Trans-dicarboxylic acid derivatives 47 were assayed against the enzymes from A.oryzae 
and p.canescens in Figure 3.21 A and B respectively.  Compounds 47a and 47b showed no 
inhibition of any of the enzymes in A.oryzae or P.canescens.  But, both 47a and 47b 
unexpectedly showed the highest activation for β-D-galactosidase from A.oryzae.  This rare 















































galactosidase for the treatment of gangliosidosis (CDC 2019).  Both compounds also showed 
weak activation for β-D-glucosidase from A.oryzae. 
Cis-Dicarboxylic acid derivatives 55 were assayed against the same enzymes and their 
results were specific for each of the enzymes.  The results found in α-D-galactosidase, β-D-
galactosidase, α-D-glucosidase and β-D-glucosidase from A.oryzae showed weak inhibition in 
most enzyme, but strong inhibition specifically for 55a in α-D galactosidase (Figure 3.21A).  
Compound 55b only showed weak inhibition for all the same enzymes.  In P.canescens, both 
55a and 55b showed strong inhibition in α-D galactosidase and β-D-glucosidase respectively 
(Figure 3.21B).   Weak activation was noticed for 55b in β-D-galactosidase. 
Cis-Dicarboxylic acid derivatives 56 underwent similar assays to their diastereomers 55   
and their results were not as significant.  In β-D-galactosidase from A.oryzae, 56a showed weak 
activation while 56b showed strong activation (Figure 3.21A).  56b also showed weak inhibition 
in α-D-galactosidase from A.oryzae.  Apart from the weak activation by 56b in β-D-glucosidase, 






Figure 3.22.  Effect of hexahydrobenzo-triazolo-oxazinones 57a-f (1mM) on the activity of 
glycosidases from Aspergillus Oryzae (A) and Penicillium Canenscens (B). 
 
Lactones 57a-f underwent similar assays to compounds 47, 55 and 56 (Figure 3.21).  
Consistent trends were seen in the results of these compounds.  In the enzymes from A.oryzae, 
all derivatives showed weak inhibition for α-D-glucosidase and α-D galactosidase while the 
results for β-D-glucosidase and β-D galactosidase were insignificant (Figure 3.22A).  In the 
enzymes from P.canescens, all derivatives weak to strong activation for β-D-glucosidase and β-
















































Figure 3.23.  Effect of trans-2-triazolylcyclohexanols 58a-d and 59a-c (1mM) on the activity of 
glycosidases from Aspergillus Oryzae (A) and Penicillium Canenscens (B). 
 
Trans-2-Triazolylcyclohexanol derivatives 58a-d and 59a-c underwent similar assays to 
compounds 47, 55 and 56 (Figure 3.21) and lactones 57 (Figure 3.22).  Consistent trends were 
seen in the results of these compounds.  In the enzymes from A.oryzae, all derivatives showed 
weak inhibition for α-D-glucosidase and α-D galactosidase (Figure 3.23A).  Interesting, 
increased activation was noticed with the lengthening of the hydrocarbon chain at C5 on the 
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Furthermore, the reverse effect was seen the lengthening of the hydrocarbon chain at C4 on the 
triazole ring for compounds 59a-c for the same enzymes.  In the enzymes from P.canescens, all 
derivatives weak to strong activation for β-D-glucosidase and β-D galactosidase while the results 













CHAPTER 4: CONCLUSION 
 
Trans-2-(azaarylsulfanyl)-cylohexanols, analogous to trans-2-aminocyclohexanols 
(TACHs), underwent pH-induced conformational switches in acidic media.  The range of 
switching varied based on the basicity of the azaarylsulfanyl groups and the intramolecular 
interactions of these groups with the hydroxyl group.   
Trans-2-triazolylcyclohexanols, also analogous to trans-2-aminocyclohexanols (TACHs), 
showed initial conformational bias that decreased the efficiency of these compounds as potential 
conformational switches.  The interactions between the triazolyl and hydroxyl groups were 
studied to quantify their effects on the bias.  The unknown conformational energy of the triazolyl 
group was estimated. 
The glycosidase studies showed some activity of carbohydrate hydrolytic enzymes (β-D-
glucosidase and β-D-galactosidase) in both A.oryzae and P.canescens for trans-5-
triazolylcyclohexanol-1-2-dicarboxylic acid derivatives, triazolyl-lactones and trans-2-
triazolylcyclohexanols.  Selective inhibition for β-D-glucosidase and α-D-galactosidase in both 
P.canescens and A.oryzae was seen certain cis-5-triazolylcyclohexanol-1-2-dicarboxylic acid 
derivatives. 
The results of our research have been partially published in journals and presented at 
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CHAPTER 5: EXPERIMENTAL 
 
Synthesis 
General procedure for epoxidation of alkynes (Diethyl 7-oxabicyclo[4.1.0]heptane-3,4-
dicarboxylate (2)) 
 
m-CPBA (5.7 g, 33 mmol) was dissolved in 150 mL of dry CH2Cl2 at 0
oC.  Diethyl 4-
cyclohexene-trans-1,2-dicarboxylate (22 mmol) was added in small portions at 00 C while 
stirring.  The stirring continued at 00C for 13 h.  After consumption of the starting material (TLC, 
hexane/EtOAc 7:3), 50 mL of CHCl3.  Reaction mixture was washed 2 x 25 mL of 0.4 M sodium 
sulfite solution, 2 x 25 mL of saturated Na2CO3 and 2 x 25 mL of brine by.  The organic phase 
was separated dried for 12 h over anhyd Na2SO4, and all solvent was removed on rotary 
evaporator to yield a crude product.  Initial ratio adjustments were made for other epoxidations. 
Diethyl 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate (2) 
 
A yellow oil of the crude product initially of 3.8 g was obtained.  Product was purified by 
column chromatography (hexane/EtOAc 3:1) to give 3.4 g (60%) of a colorless oil of pure 
epoxide. Rf: 0.56 (Hexane: EtOAc, 10:1).  1H NMR (600 MHz, CDCl3): δ 1.23 (t, J = 7.1 Hz, 
3H; CH3), 1.24 (t, J = 7.1 Hz, 3H; CH3), 1.89 (ddd, J = 14.9, 10.7, 2.1 Hz, 1H; H5a), 2.05 (dd, J 
= 15.3, 10.9 Hz, 1H; H2a), 2.31 (ddd, J = 15.5, 6.7, 4.7 Hz, 1H; H2e), 2.46 (ddd, J = 14.8, 4.8, 
1.9 Hz, H5e), 2.59 (dt, J = 10.8, 6.6 Hz, 1H; H3), 2.82 (dt, J = 10.7, 4.8 Hz, H4), 3.18 (t, J = 4.4 
Hz, H1), 3.25 (m, H6), 4.13 (m, 4H, OCH2).  
13C NMR (150 MHz, CDCl3): δ 14.15 (2CH3, Et), 
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26.40 (C2), 27.30 (C5), 37.80 (C3), 40.11 (C4), 50.34 (C1), 51.94 (C6), 60.74 (2C, OCH2), 
173.79, 174.71 (C=O).  HMRS: C12H19O5
+ [M+H]cal m/z 243.1227; [M+H]exp m/z 243.1231.   
Dimethyl 7-oxabicyclo[4.1.0]heptane-cis-3,4-dicarboxylates (49-syn) and (49-anti) 
Epoxides 49-syn and 49-anti were prepared from dimethyl 4-cyclohexene-cis-1,2-
dicarboxylate 7 (12.6 g , 63 mmol) as described in the epoxidation procedure and separated by 
column chromatography (Hex:EtOAc/1:1).   
(1R,3S,4R,6S)-dimethyl 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate(49-syn) 
 
Yielded a yellow oil of 4.4 g (37%).  1H NMR (600 MHz, CDCl3): δ 2.12 (dd, J=15.2, 
4.7 Hz, 2H; H2eq, H5eq), 2.67 (dd, J=15.5, 6.7 Hz, 2H; H2ax, H5ax), 2.74 (m, 2H; H3, H4), 
3.16 (m, 2H, H1, H6), 3.67 (s, 6H, OCH3).  
13C NMR (150 MHz, CDCl3): δ 24.84 (C2, C5), 
37.59 (C3, C4), 51.02 (C1, C6), 51.95 (OCH3), 173.08 (C=O).  C10H15O5 [M+H]cal m/z 
215.0914; [M+H]exp m/z 215.0922. 
(1R,3R,4S,6S)-dimethyl 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate(49-anti) 
 
Yielded a colorless oil of 6.0 g (48%).  1H NMR (600 MHz, CDCl3): δ 2.24 (m, 4H; 
H2ax, H2eq, H5ax, H5eq), 2.91 (m, 2H; H3, H4), 3.23 (m, 2H; H1, H6), 3.68 (s, 6H, OCH3).  
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13C NMR (150 MHz, CDCl3): δ 24.82 (C2, C5), 37.70 (C3, C4), 51.62 (C1, C6), 52.11 (OCH3), 
173.57 (C=O).  C10H15O5 [M+H]cal m/z 215.0914; [M+H]exp m/z 215.0942 
3-(methyl)-7-oxabicyclo[4.1.0]heptane (20a) 
 
The product was isolated as a colorless oil by column chromatography (silica gel; Hex: 
EtOAc, 40:1): yield 925mg (84%).  Rf: 0.49 (Hex: EtOAc, 10:1).  1H NMR (600 MHz, CDCl3): 
δ 0.84 (d, J = 7.0 Hz, 3H; CH3), 0.87 (m, 1H; H4), 1.22-1.33 (m, 1H; H3), 1.38 (m, 1H; H4), 
1.70 ( dddd, J = 14.8, 12.5, 5.2, 1.5 Hz, H2ax), 1.81 (ddd, J = 15.6, 11.4, 6.6 Hz, H5ax), 1.96 (m, 
H5eq), 2.10 (ddd, J = 14.9, 4.2, 2.0 Hz, H2eq), 3.10 (m, 2H; H1, H6); 13C NMR (150 MHz, 
CDCl3): δ 21.71 (CH3), 23.47 (C5), 25.26 (C4), 29.04 (C3), 33.62 (C2), 51.56 (C1), 53.23 




The product was isolated as a colorless oil by column chromatography (silica gel; 
Hexane: EtOAc, 7:3): yield 853 mg (78%).  Rf: 0.25 (Hex: EtOAc, 7:3).1H NMR (600 
MHz,CDCl3): δ 1.47 (m, 1H, H4), 1.52 (m, H4eq),  1.69 (m, 2H, H5eq,H5ax), 1.88 (m, 1H; 
H2ax), 2.11 (ddd, J = 14.9, 4.1.  2.1 Hz, 1H; H2eq), 3.21 (t, J = 4.4 Hz, H6), 3.32 (m, H1), 7.29 
(m, 2H; Ph), 7.34 (m, 2H; Ph), 7.37 (m, 1H; Ph). 13C NMR (150 MHz, CDCl3): δ 24.13 (C4), 
25.86 (C5), 28.30 (C2), 39.59 (C3), 51.99 (C1), 53.73 (C6) 124.24, 124.36, 124.94, 125.04, 
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The product was isolated as a colorless oil by column chromatography (silica gel; 
Hexane: EtOAc, 40:1): yield 0.52 g (84%).  Rf: 0.25 (Hex: EtOAc, 40:1).  1H NMR (600 MHz, 
CDCl3): δ 0.81 (s, 9H, CH3), 1.07 (ddd, J = 4.1, 12.5, 25.1 Hz, 1H, H4ax), 1.22 (m, 1H, H3), 
1.37 (m, 1H, H4eq), 1.50 (m, 1H, H2ax), 1.75 (ddd, J = 15.4, 12.9, 6.3 Hz, H5ax), 2.04 (dtd, J = 
15.5, 5.9, 1.7 Hz, H5eq), 2.16 (m, 1H; H2), 3.11 (m, 1H; H6), 3.21 (m, 1H; H1).  13C NMR (150 
MHz, CDCl3): δ 19.1 ((CH3)3), 25.4 (C5), 26.7 (C3), 27.3 (C6), 43.1 (C(CH3)3), 52.6 (C2), 54.5 
(C1).  HMRS: C10H19O
+ [M+H]cal m/z 155.1430; [M+H]exp m/z 155.1445. 
General procedure for epoxide cleavage with azaaryl groups 
Epoxide (1.11 mmol) and sodium tetraborate (1.30 mmol) were dissolved in 10 mL of 
THF and/or H2O solution at r.t.   Under Ar, azaaryl (1.70 mmol) was added while stirring at r.t.  
Reaction was monitored (TLC) until the consumption of epoxide.  Reaction was diluted with 7 
mL of H2O and washed with 3 X 15 mL CH2Cl2.  The combined organic layer was dried for 12 h 







Diethyl cis-4-hydroxy-trans-5-(phenylthio)cyclohexane-trans-1,2-dicarboxylate (3a) 
 
Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as colorless oil 
by column chromatography (silica gel; DCM:EtOAc, 9:1) to give a yield 296 mg (79%).  Rf; 
0.50 (DCM:EtOAc, 9:1).  1H NMR (600 MHz, CDCl3): δ 1.20 (t, J = 7.1 Hz, 3H; CH3), 1.21 (t, J 
= 7.1 Hz, 3H; CH3), 1.83 (m, 1H; H3eq), 1.88 (m, 1H; H6eq), 2.27 (ddd, J = 13.9, 8.5, 3.1 Hz, 
1H; H3ax), 2.35 (ddd, J = 14.0, 8.4, 4.1 Hz, 1H; H6ax), 2.42 (s, 1H; OH), 3.11 (td, J = 8.1, 4.2 
Hz, 1H; H1), 3.16 (td, J = 8.2, 4.4 Hz, 1H; H2), 3.24 (m, 1H; H5), 3.81 (m, 1H; H4),  4.12 (m, 
4H; OCH2), 7.24 (m, 1H; Ph), 7.29 (m, 2H; Ph), 7.42 (m, 2H; Ph).  
13C NMR (150 MHz, 
CDCl3): δ 14.21 (2CH3, Et), 29.02 (C6), 31.24 (C3), 39.93 (C2), 40.52 (C1), 50.33 (C5), 60.94, 
60.96 (OCH2), 68.12 (C4), 99.98 (C, Ph), 127.54 (CH, Ph), 129.18 (2CH, Ph), 132.31 (2CH, Ph), 
173.87, 174.03 (C=O).  HMRS: C18H25O5S
+ [M+H]cal m/z 353.1417; [M+H]exp m/z 353.1432. 
Diethyl cis-4-hydroxy-trans-5-(-p-tolylthio)cyclohexane-trans-1,2-dicarboxylate (3b) 
 
Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as colorless oil 
by column chromatography (silica gel; DCM:EtOAc, 9:1) to give a of yield 293 mg (81%).  Rf; 
0.54 (DCM:EtOAc, 9:1).  1H NMR (600 MHz, DMSO-d6): δ 1.14 (t, J = 7.1 Hz, 3H; CH3), 1.15 
(t, J = 7.1 Hz, 3H; CH3), 1.83 (m, 3H; H3ax, H3eq, H6eq), 2.11 (ddd, J = 13.4, 12.9, 4.1 Hz, 1H; 
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H6ax), 2.81 (ddd, J = 12.2, 11.1, 3.7 Hz, 1H; H1), 2.90 (td, J = 11.3, 4.4 Hz, 1H; H2), 3.34 (s, 
3H; CH3, tolyl), 3.39 (q, J = 3.3 Hz, H5), 3.79 (quin, J = 3.2 Hz, H4), 4.04 (m, 4H; OCH2), 5.30 
(d, J = 3.5 Hz, 1H; OH), 7.17 (m, 2H; tolyl), 7.32 (m, 2H; tolyl).  13C NMR (150 MHz, DMSO-
d6): δ 14.52, 14.54 (2CH3; Et), 21.11 (CH3; tolyl), 28.00 (C6), 30.92 (C3), 39.16 (C2), 39.89 
(C1), 48.69 (C5), 60.64, 60.71 (OCH2), 66.25 (C4), 130.46 (2CH; tolyl), 131.02 (C, tolyl), 
131.75 (2CH; tolyl), 137.28 (C, tolyl), 174.27, 174.77 (C=O).  HMRS: C19H27O5S
+ [M+H]cal m/z 
367.1574; [M+H]exp m/z 367.1398. 
Diethyl cis-4-hydroxy-trans-5-(pyridine-2-yl-thio)cyclohexane-trans-1,2-dicarboxylate (3c) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 7:3) to give a yield of 293 mg (65%).  Rf; 0.20 
(hexane:EtOAc, 7:3).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.0 Hz, 3H; CH3), 1.25 (t, J = 
7.1 Hz, 3H; CH3), 1.92 (m, 1H; H2ax), 2.02 (m, 2H; H2eq, H6eq), 2.35 (ddd, J = 13.8, 12.4, 4.1 
Hz, 1H; H6ax), 2.90 (ddd, J = 12.0, 10.9, 3.8 Hz, 1H; H1), 3.07 (ddd, J = 12.0, 10.8, 4.1 Hz, 1H; 
H2), 4.03 (q, J = 3.5 Hz, H4), 4.13 (m, 4H; OCH2), 4.19 (q, J = 3.5 Hz, 1H; H5), 7.11 (m , 1H; 
pyridinyl), 7.30 (m , 1H; pyridinyl), 7.62 (td , J = 8.0, 2.0 Hz, 1H; pyridinyl), 8.41 (m , 1H; 
pyridinyl).  13C NMR (150 MHz, CD3OD): δ 13.12 (2CH3, Et), 28.11 (C6), 31.15 (C3), 39.09 
(C2), 40.84 (C1), 44.14 (C5), 60.50, 6055 (OCH2), 67.42 (C4), 120.06, 122.76, 136.64, 146.27 
(CH, pyridinyl), 157.45 (C, pyridinyl), 174.41, 174.52 (C=O).  HMRS: C17H24NO5S
+ [M+H]cal 
m/z 354.1370; [M+H]exp m/z 354.1371. 
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Diethyl cis-4-hydroxy-trans-5-(pyridine-4-yl-thio)cyclohexane-trans-1,2-dicarboxylate  (3d) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as yellow oil by column 
chromatography (silica gel; EtOAc) to give a yield of 280 mg (72%).  Rf; 0.34 (EtOAc).  
1H 
NMR (600 MHz, CD3OD): δ 1.24 (t, J = 7.0 Hz, 3H; CH3), 1.25 (t, J = 7.1 Hz, 3H; CH3), 1.99 
(m, 3H; H3ax, H3eq, H6eq), 2.41 (ddd, J = 14.2, 11.4, 4.1 Hz, 1H; H6ax), 2.94 (ddd, J = 11.2, 
10.1, 3.8 Hz, 1H; H1), 3.10 (td, J = 10.2, 4.4 Hz, 1H; H2), 3.76 (q, J = 4.1 Hz, H5), 3.97 (q, J = 
3.9 Hz, H4), 4.14 (m, 4H; OCH2), 7.37 (m, 2H; pyridinyl), 8.34 (m, 2H; pyridinyl).  13C NMR 
(150 MHz, CD3OD): δ 13.13 (2CH3, Et), 27.81 (C6), 30.99 (C3), 39.30 (C2), 40.41 (C1), 44.97 
(C5), 60.60, 60.72 (OCH2), 66.71 (C4), 121.62 (2CH; pyridinyl), 148.48 (2CH; pyridinyl), 
174.14, 174.66 (C=O).  HMRS: C17H24NO5S
+ [M+H]cal m/z 354.1370; [M+H]exp m/z 354.1382. 
Diethyl cis-4-hydroxy-trans-5-(pyrimidin-2-yl-thio)cyclohexane-trans-1,2-dicarboxylate (3e) 
 
Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as yellow oil by 
column chromatography (silica gel; Hex:EtOAc, 7:3) to give a yield of 0.184 mg (47%).  Rf; 
0.13 (hexane:EtOAc, 7:3).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.25 
(t, J = 7.0 Hz, 3H; CH3), 1.88 (m, 1H; H2ax), 2.04 (dtd, J = 14.1, 4.0, 1.5 Hz, 1H; H3eq), 2.10 
(dt, J = 13.9, 3.5 Hz, H6eq), 2.37 (ddd, J = 13.6, 12.8, 4.2 Hz, 1H; H6ax), 2.86 (ddd, J = 12.3, 
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11.0, 3.8 Hz, 1H; H1), 3.08 (ddd, J = 12.1, 11.1, 4.0 Hz, 1H; H2), 4.10 (q, J = 3.7 Hz, 1H; H4), 
4.13 (m, 4H; OCH2), 4.22 (q, J = 3.6 Hz, 1H; H5), 7.16 (t , J = 4.9 Hz, 1H; pyrimidinyl), 8.58 (d 
, J = 4.9 Hz, 2H; pyrimidinyl).  13C NMR (150 MHz, CD3OD): δ 13.10 (2CH3, Et), 27.89 (C6), 
31.23 (C3), 39.03 (C1), 40.96 (C2), 44.60 (C5), 60.50, 60.58 (OCH2), 67.07 (C4), 117.13 (CH; 
pyrimidinyl), 157.65 (2C, CH; pyrimidinyl), 170.61 (C; primidinyl) 174.53 (C=O), 175.09 
(C=O).  HRMS: C16H23N2O5S+ [M+H]Cal m/z 355.1322 ; [M+H]exp m/z  355.1334. 
Diethyl cis-4-hydroxy-trans-5-((1H-imidazol-2-yl)thio)cyclohexane-trans-1,2-dicarboxylate (3f) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as yellow oil by column 
chromatography (silica gel; DCM:MeOH, 9:1) to give a yield of 0.305 mg (80%).  Rf; 0.13 
(DCM:MeOH, 9:1).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.25 (t, J = 
7.1 Hz, 3H; CH3), 1.90 (m, 2H; H3eq, H6eq), 2.08 (m, 1H; H3ax), 2.22 (ddd, J = 13.1, 11.5, 4.1 
Hz, 1H; H6ax), 2.96 (ddd, J = 11.4, 10.2, 3.8 Hz, 1H; H1), 3.04 (ddd, J = 11.0, 10.5, 4.0 Hz, 1H; 
H2), 3.46 (q, J = 3.8 Hz, H5), 3.85 (q, J = 3.7 Hz, H4), 4.12 (m, 4H; OCH2), 4.88 (s, OH), 7.12 
(s, 2H; imidazolyl).  13C NMR (150MHz, CD3OD): δ 13.14, 13.17 (2CH3, Et), 27.94 (C6), 30.37 
(C3), 39.30 (C2), 39.97 (C1), 49.74 (C5), 60.53, 60.61 (OCH2), 66.96 (C4), 124.12 (C, 
imidazolyl), 137.37 (2CH, imidazolyl), 174.33, 174.84 (C=O).  HMRS: C15H23N2O5S
+ [M+H]cal 








Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 1:4) to give a yield of 481 mg (79%).  Rf; 0.23 
(hexane:EtOAc, 1:4).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.25 (t, J = 
7.0 Hz, 3H; CH3), 1.88  (dt, J = 14.1, 3.9 Hz, 1 1H; H6eq), 1.94 (dt, J = 14.0, 4.0 Hz, 1H; H3eq), 
2.06 (m, 1H; H3ax), 2.22 (ddd, J = 14.1, 11.3, 4.0 Hz, 1H; H6ax), 2.99 (ddd, J = 11.1, 10.1, 3.8 
Hz, 1H; H2), 3.05 (td, J = 11.1, 4.0 Hz, 1H; H1), 3.45 (q, J = 4.0 Hz, 1H; H5), 3.77 (s, 3H; CH3-
imidazolyl), 3.88 (q, J = 3.8 Hz, 1H; H4), 4.13 (m, 4H; OCH2), 7.04 (d, J = 1.4 Hz, 1H; H; 
imidazolyl), 7.24 (d, J = 1.4 Hz, 1H; H; imidazolyl).  13C NMR (150 MHz, CD3OD): δ 13.11, 
13.12 (2CH3, Et), 28.02 (C6), 30.64 (C3), 32.90 (CH3; imidazolyl) 39.30 (C2), 40.12 (C1), 49.99 
(C5), 60.55, 60.61 (OCH2), 66.98 (C4), 123.76, 128.56 (2C, CH; imidazolyl), 139.08 (C; 
imidazolyl) 174.19, 174.77 (C=O).  HRMS: C16H25N2O5S+ [M+H]Cal m/z 357.1479 ; [M+H]exp 












Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 1:4) to give a yield of 251 mg (69%).  Rf; 0.46 
(hexane:EtOAc, 1:4).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.24 (t, J = 
7.1 Hz, 3H; CH3), 1.97 (m, 2H; H3ax, H3eq), 2.05 (dt, J = 14.0, 3.6 Hz, 1H; H6eq), 2.31 (ddd, J 
= 14.0, 12.2, 4.0 Hz, 1H; H6ax), 2.91 (ddd, J = 12.0, 10.7, 3.8 Hz, 1H; H1), 3.06 (td, J = 10.6, 
5.4 Hz, 1H; H2), 3.86 (q, J = 3.6 Hz, H5), 4.02 (q, J = 3.3 Hz, H4), 4.13 (m, 4H; OCH2), 8.36 (s, 
1H; triazolyl).  13C NMR (150 MHz, CD3OD): δ 13.12 (2CH3, Et), 27.98 (C6), 30.56 (C3), 39.13 
(C2), 40.22 (C1), 47.36 (C5), 60.52, 60.60 (OCH2), 67.02 (C4), 146.43 (CH, triazolyl), 157.62 
(C, triazolyl), 174.38, 174.92 (C=O).  HMRS: C14H21N3O5S






Reaction occurred in 10 mL of H2O.  The residue was isolated as light yellow oil by 
column chromatography (silica gel; Hex:EtOAc, 1:4) to give a yield of 141 mg (43%).  Rf; 0.1 
(hexane:EtOAc, 1:4).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.24 (t, J = 
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7.1 Hz, 3H; CH3), 1.95 (m, 2H; H3ax, H3eq), 2.04 (dt, J = 14.0, 3.6 Hz, 1H; H6eq), 2.26 (ddd, J 
= 13.9, 12.3, 4.1 Hz, 1H; H6ax), 2.89 (ddd, J = 12.0, 10.9, 3.8 Hz, 1H; H1), 3.03 (m, 1H; H2), 
3.73 (q, J = 3.6 Hz, H5), 4.00 (q, J = 3.3 Hz, H5), 4.12 (m, 4H; OCH2).  13C NMR (150 MHz, 
CD3OD): δ 13.10 (2CH3, Et), 27.94 (C6), 30.46 (C3), 39.12 (C2), 40.18 (C1), 47.24 (C5), 60.48, 
60.54 (OCH2), 67.10 (C4), 155.54, 158.87 (C, triazolyl), 174.52, 174.99 (C=O).  HMRS: 
C14H23N4O5S





Reaction occurred in H2O:THF (1:1).  The residue was isolated as white crystals by 
column chromatography (silica gel; DCM:MeOH, 19:1) to give a yield of 281 mg (63%).  Rf; 
0.45 (DCM:MeOH, 19:1).  1H NMR (600 MHz, CD3OD): δ 1.23 (t, J = 7.1 Hz, 3H; CH3), 1.24 
(t, J = 7.1 Hz, 3H; CH3), 2.00 (m, 2H; H3ax, H3eq), 2.11 (dt, J = 14.1, 3.9 Hz, 1H; H6eq), 2.37 
(ddd, J = 14.0, 11.8, 4.1 Hz, 1H; H6ax), 2.95 (ddd, J = 11.6, 10.3, 3.8 Hz, 1H; H1), 3.09 (m, 1H; 
H2), 3.96 (q, J = 3.8 Hz, H5), 4.08 (q, J = 3.7 Hz, H5), 4.13 (m, 4H; OCH2) 7.56 (m, 1H; 
pyridinyl), 8.41 (m, 1H; pyridinyl), 8.61 (m, 1H; pyridinyl), 9.17 (m, 1H; pyridinyl).  13C NMR 
(150 MHz, CD3OD): δ 13.11, 13.12 (2CH3, Et), 28.11 (C6), 30.72 (C3), 39.22 (C2), 40.32 (C1), 
47.88 (C5), 60.56, 60.66 (OCH2), 67.08 (C4), 124.13 (CH, pyridinyl), 125.97 (C, pyridinyl), 
134.25, 146.60, 149.68 (CH, pyridinyl), 149.71, 160.11 (C, triazolyl), 174.21, 174.83 (C=O).  
HMRS: C19H25N4O5S






Reaction occurred in 10 mL of H2O.  The residue was isolated as white crystals by 
column chromatography (silica gel; Hex:EtOAc, 1:1) to give a yield 361 mg (61%).  Rf; 0.37 
(hexane:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.22 (t, J = 7.1 Hz, 3H; CH3), 1.24 (t, J = 
7.1 Hz, 3H; CH3), 1.90 (m, 1H; H3ax), 1.98 (m, 1H; H6ax), 2.32 (m, 1H; H3eq), 2.52 (m, 1H; 
H6eq), 3.10 (m, 1H; H1), 3.27 (m, 1H; H2), 3.86 (m, 1H; H5), 4.00 (dt, J = 7.5, 3.3 Hz, 1H; H4), 
4.15 (m, 4H; OCH2), 7.18 (m, 2H; Ph), 7.47 (s, 2H; Ph).  13C NMR (150 MHz, CDCl3): δ 14.23 
(2CH3, Et), 29.12 (C6), 32.52 (C3), 40.19 (C2), 41.01 (C1), 49.12 (C5), 61.21, 61.30 (OCH2), 
70.31 (C4), 121.63 (4CH, Ph), 149.57 (C, Ph), 163.55 (C, imidazolyl), 173.48, 174.15 (C=O).  
HMRS: C19H25NO5S
+ [M+H]cal m/z 393.1479; [M+H]exp m/z 393.1483. 
Diethyl cis-4-hydroxy-trans-5-((benzothiazol-2-yl)thio)cyclohexane-trans-1,2-dicarboxylate (3l) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 1:1) to give a yield of 309 mg (68%).  Rf; 0.54 
(hexane:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.25 (t, J = 7.1 Hz, 3H; CH3), 1.26 (t, J = 
7.1 Hz, 3H; CH3), 1.95 (m, 1H; H3ax), 2.11 (m, 1H; H6ax), 2.27 (m, 1H; H3eq), 2.54 (m, 1H; 
H6eq), 3.06 (m, 1H; H1), 3.24 (dt, J = 7.6, 4.4 Hz, 1H; H2), 3.66 (br.  s, 1H; OH), 4.08 (m, 1H; 
171 
H4), 4.12 (m, 1H; H5), 4.17 (m, 4H; OCH2), 7.31 (m, 1H; Ph), 7.41 (m, 1H; Ph), 7.75 (m, 1H; 
Ph), 7.84 (m, 1H; Ph).  13C NMR (150 MHz, CDCl3): δ 14.25 (2CH3, Et), 28.80 (C6), 32.21 
(C3), 39.84 (C2), 40.98 (C1), 49.79 (C5), 61.06, 61.15 (OCH2), 69.56 (C4), 121.15, 121.64, 
124.76, 126.31 (CH, Ph), 134.49, 152.75 (C, Ph), 165.90 (C, thiazolyl), 173.41, 173.91 (C=O).  
HMRS: C19H24NO4S2
+ [M+H]cal m/z 410.1090; [M+H]exp m/z 410.1105. 
Diethyl cis-4-hydroxy-trans-5-((benzoxazol-2-yl)thio)cyclohexane-trans-1,2-dicarboxylate (3m) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 1:1) to give a yield of 265 mg (56%).  Rf; 0.45 
(hexane:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.25 (t, J = 7.0 Hz, 3H; CH3), 1.26 (t, J = 
7.1 Hz, 3H; CH3), 1.95 (m, 1H; H3eq), 2.12 (m, 1H; H6eq),  2.26 (m, 1H; H3ax),  2.55 (m, 1H; 
H6ax), 3.06 (dt, J = 7.7, 4.3 Hz, 1H; H1), 3.24 (dt, J = 7.6, 4.4 Hz, 1H; H2), 3.67 (s, 1H; OH), 
4.07 (m, 1H; H4), 4.12 (m, 1H; H5), 4.17 (m, 4H; OCH2), 7.31 (m , 1H; Ph), 7.41 (m , 1H; Ph), 
7.75 (m , 1H; Ph), 7.84 (m , 1H; Ph).  13C NMR (150 MHz, CDCl3): δ 14.26 (2CH3, Et), 28.80 
(C6), 32.20 (C3), 39.84 (C2), 40.98 (C1), 49.79 (C5), 61.05, 61.14 (OCH2), 69.53 (C4), 121.15, 
121.64, 124.76, 126.32 (CH, Ph), 135.49, 152.76 (C, Ph), 165.89 (C, oxazolyl) 173.44, 173.41 
(C=O).  HMRS: C19H24NO6S








Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as colorless oil 
by column chromatography (silica gel; DCM:Hex, 4:1) to give a yield of 199 mg (87%).  Rf; 
0.52 (DCM:hexane, 4:1).  1H NMR (600 MHz, CDCl3): δ 1.28 (m, 4H; H4eq, H4ax, H5eq, 
H5ax), 1.70 (m, 2H; H3eq, H3ax), 2.11 (m, 2H; H6eq, H6ax), 2.78 (ddd, J = 12.8, 8.9, 3.0 Hz, 
1H; H2), 3.33 (ddd, J = 15.0, 7.3, 2.5 Hz, 1H, H1), 7.30 (m, 3H; Ph), 7.48 (m, 2H; Ph).  13C 
NMR (150MHz, CDCl3): δ 24.23 (C4), 26.18 (C5), 32.86 (C3), 33.94 (C6), 56.74 (C2), 72.15 
(C1), 99.68 (C, Ph), 127.74 (CH; Ph), 129.02 (2CH; Ph), 133.91 (2CH; Ph).  HMRS: 
C12H17NOS
+ [M+H]cal m/z 209.0995; [M+H]exp m/z 209.0962. 
Trans-2-(p-tolylthio)cyclohexanol (5b) 
 
Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as colorless oil 
by column chromatography (silica gel; DCM:Hex, 9:1) to give a yield of 182 mg (85%).  Rf; 
0.50 (DCM:hexane, 9:1).  1H NMR (600 MHz, CDCl3): δ 1.26 (m, 4H; H4eq, H4ax, H5eq, 
H5ax), 1.76 (m, 2H; H3eq, H3ax), 2.07 (m, 2H; H6eq, H6ax), 2.35 (s, 3H; CH3), 2.12 (m, 1H; 
H2), 3.29 (dt, J = 10.3, 4.4 Hz, 1H, H1), 7.12(m, 2H; tolyl), 7.37 (m, 2H; tolyl).  13C NMR (150 
MHz, CDCl3): δ 21.34 (CH3), 23.53 (C4), 26.19 (C5), 31.42 (C3), 33.27 (C6), 57.24 (C2), 72.82 
(C1), 98.24 (C; tolyl), 129.86 (2C; tolyl), 134.19 (2C; tolyl) 138.25 (C; tolyl).  HMRS: 
C13H19NOS





Reaction occurred in 10 mL of H2O.  The residue was isolated as a yellow oil by column 
chromatography (silica gel; DCM:EtOAc, 9:1) to give a yield of 180 mg (78%).  Rf; 0.27 
(DCM:EtOAc, 9:1).  1H NMR (600 MHz, CDCl3): δ 1.33 (m, 3H; H3, H4, H5), 1.49 (m, 1H; 
H6ax), 1.77 (m, 2H; H4, H5), 2.14 (m, 1H; H6eq), 2.22 (m, 1H; H3eq), 3.42 (ddd, J = 12.8, 9.9, 
4.0 Hz, 1H; H1), 3.51 (td, J = 10.1, 4.3 Hz, 1H; H2), 6.13 (s, 1H; OH), 7.03 (ddd, J = 7.3, 5.1, 
1.1 Hz, 1H; H; pyridinyl), 7.29 (dt, J = 8.1, 1.0 Hz, 1H; H; pyridinyl), 7.51 (ddd, J = 7.9, 7.5, 1.9 
Hz, 1H; H; pyridinyl), 8.35 (m, 1H; H; pyridinyl).  13C NMR (150 MHz, CDCl3): δ 24.26 (C5), 
26.38 (C4), 32.50 (C6), 36.28 (C3), 52.41 (C2), 76.09 (C1), 120.16, 123.44, 136.66, 148.76 (CH; 
pyridinyl), 159.62 (C; pyridinyl).  HRMS: C11H16NOS
+ [M+H]Cal m/z 210.0947 ; [M+H]exp m/z  
210.0954.   
Trans-2-(pyridin-4-ylthio)cyclohexanol (5d)  
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as white crystals by 
column chromatography (silica gel; EtOAc:MeOH, 9:1) to give a yield of 209 mg (83%).  Rf; 
0.38 (EtOAc:MeOH, 9:1).  1H NMR (150 MHz, CDCl3): δ 1.39 (m, 4H; H4eq, H4ax, H5eq, 
H5ax), 1.77 (m, 2H; H3ax, H3eq), 2.17 (m, 2H; H6eq, H6ax), 2.14 (m, 1H; H6eq), 2.22 (m, 1H; 
H3eq), 3.16 (ddd, J = 12.8, 8.8, 3.2 Hz, 1H; H2), 3.49 (td, J = 10.0, 4.3 Hz, 1H; H1), 7.24 (m, 
2H; pyridinyl), 8.39 (m, 2H; pyridinyl).  13C NMR (600 MHz, CDCl3): δ 24.07 (C4), 26.08 (C5), 
174 
32.54 (C3), 34.28 (C6), 53.68 (C2), 73.15 (C1), 122.69 (C; pyridinyl), 147.66, 149.84 (CH; 
pyridinyl).  HRMS: C11H16NOS
+ [M+H]Cal m/z 210.0947 ; [M+H]exp m/z  210.0931. 
Trans-2-(pyrimidin-2-ylthio)cyclohexanol (5e) 
 
Reaction occurred in 10 mL of H2O.  The residue was purified as colorless oil by column 
chromatography (silica gel; Hex:EtOAc, 1:1) to give a yield of 0.162 mg (70%).  Rf; 0.21 
(hexane:EtOAc, 1:1).  1H NMR (150 MHz, CD3OD): δ 1.47 (m, 4H; H3, H4, H5, H6), 1.68 (m, 
1H; H4ax), 1.78 (m, 1H; H5ax), 2.08 (m, 1H; H6ax), 2.27 (m, 1H; H3ax), 3.57 (td, J = 9.4, 4.0 
Hz, 1H; H1), 3.77 (ddd, J = 10.6, 9.5, 4.1 Hz, 1H; H2), 7.11 (t, J = 4.9 Hz, 1H, H; pyrimidinyl), 
8.54 (d, J = 4.9 Hz, 2H, H; pyrimidinyl).  13C NMR (600 MHz, CD3OD): δ 23.64 (C5), 25.17 
(C4), 31.72 (C3), 34.64 (C6), 50.51 (C2) 71.58 (C1), 116.63 (CH; pyrimidinly), 157.31 (2C, CH; 
pyrimidinly), 172.36 (C; pyrimidinly).  HRMS: C10H15N2OS
+ [M+H]Cal m/z 211.0900 ; 
[M+H]exp m/z  211.0915.   
Trans-2-((1-H-imidazol-2-yl)thio)cyclohexanol (5f)  
 
Reaction occurred in 10 mL of H2O:THF (1:1).  The residue was isolated as white 
crystals after recrystallization in EtOH to give a of yield 312 mg (69%).  Rf; 0.28 (EtOAc).  
1H 
NMR (150 MHz, CD3OD): δ 1.39 (m, 4H; H3, H4, H5, H6), 1.68 (m, 2H; H4, H5), 1.99 (m, 2H; 
H3, H6), 2.87 (m, 1H; H2), 3.35 (td, J = 9.8, 4.3 Hz, 1H; H1), 7.10 (s, 2H; imidazolyl).  13C 
NMR (600 MHz, CD3OD): δ 23.92 (C5), 25.35 (C4), 32.11 (C3), 34.57 (C6), 54.91 (C2), 72.52 
175 
(C1), 123.92(2CH; imidazolyl), 137.85 (C; imidazolyl).  HRMS: C9H15N2OS
+ [M+H]Cal m/z 
199.0900 ; [M+H]exp m/z  199.0853.   
Trans-2-((1-methyl-1-H-imidazol-2-yl)thio)cyclohexanol 5g 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as colorless oil by column 
chromatography (silica gel; EtOAc) to give a of yield 168 mg (27%).  Rf; 0.34 (EtOAc).  
1H 
NMR (600 MHz, CD3OD): δ 1.30 (m, 4H; H3, H4, H5, H6), 1.64 (m, 1H; H4), 1.72 (m, 1H; 
H5), 1.94 (m, 1H; H3), 2.02 (m, 1H; H6), 2.94 (ddd, J = 11.1, 9.5, 4.0 Hz, 1H; H2), 3.39 (td, J = 
9.7, 4.2 Hz, 1H; H1), 3.75 (s, 3H; CH3-imidazolyl), 7.02 (d, J = 1.3 Hz, 1H; H; imidazolyl), 7.21 
(d, J = 1.3 Hz, 1H; H; imidazolyl).  13C NMR (150 MHz, CD3OD): δ 23.90 (C5), 25.30 (C4), 
32.26 (C3), 33.02 (CH3; imidazolyl), 34.82 (C6), 55.41 (C2), 72.78 (C1), 123.46, 128.13 (CH; 
imidazolyl), 139.72 (C; imidazolyl).  HRMS: C10H17N2OS
+ [M+H]Cal m/z 213.1063 ; [M+H]exp 
m/z  213.1056.   
Trans-2-((1-H-1,2,4-triazol-3-yl)thio)cyclohexanol (5h) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as light yellow oil by 
column chromatography (silica gel; Hex:EtOAc, 1:9) to give a yield of 169 mg (34%).  Rf; 0.27 
(Hex:EtOAc, 1:9).  1H NMR (600 MHz, CDCl3): δ 133 (m, 4H; H3, H4, H5, H6), 1.75 (m, 2H; 
H4, H5), 2.16 (m, 2H; H3, H6), 3.15 (ddd, J = 13.1, 9.2, 3.5 Hz, 1H; H2), 3.59 (td, J = 10.2, 4.4 
Hz, 1H; H1), 8.07 (s, 1H; H; triazolyl).  13C NMR (150 MHz , CDCl3): δ 24.26 (C4), 26.13 (C5), 
176 
32.82 (C3), 35.26 (C6), 54.60 (C2), 75.12 (C1), 126.81 (CH; triazolyl), 137.14 (C; triazolyl).  
HRMS: C8H14N3OS
+ [M+H]Cal m/z 200.0852 ; [M+H]exp m/z  200.0942. 
Trans-2-((3-amino-1-H-1,2,4-triazol-5-yl)thio)cyclohexanol (5i)  
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as white crystals by 
column chromatography (silica gel; EtOAc) to give a yield of 269 mg (63%).  Rf; 0.32 (EtOAc).  
1H NMR (600 MHz, CDCl3): δ 131 (m, 4H; H3, H4, H5, H6), 1.76 (m, 2H; H4, H5), 2.13 (m, 
2H; H3, H6), 3.20 (ddd, J = 13.0, 8.8, 3.9 Hz, 1H; H2), 3.62 (td, J = 10.5, 4.0 Hz, 1H; H1), 7.92 
(s, 1H; H; triazolyl), 8.14 (br.s, 2H; H, triazolyl).  13C NMR (150 MHz, CDCl3): δ 23.54 (C4), 
27.28 (C5), 33.04 (C3), 34.97 (C6), 56.87 (C2), 77.26 (C1), 131.28 (CH; triazolyl), 138.27 (C; 
triazolyl).  HRMS: C8H15N4OS
+ [M+H]Cal m/z 215.0961 ; [M+H]exp m/z  215.1123. 
Trans-2-((5(pyridine-4-yl)-4H-1,2,4-triazol-3-yl)thio)cyclohexanol (5j) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as light yellow oil by 
column chromatography (silica gel; DCM:MeOH, 9:1) to give a yield of 169 mg (51%).  Rf; 0.36 
(DCM:MeOH, 9:1).  1H NMR (600 MHz, CD3OD): δ 1.40 (m, 4H; H3, H4, H5, H6), 1.68 (m, 
1H; H4), 1.75 (m, 1H; H5), 2.08 (m, 1H; H3ax), 2.17 (m, 1H; H6ax), 3.39 (ddd, J = 12.4, 8.4, 
2.9 Hz, 1H; H2), 3.55 (td, J = 9.7, 4.2 Hz, 1H; H1), 7.55 (m, 1H; H; pyridinyl), 8.40 (dt, J = 8.0, 
1.9 Hz, 1H; H; pyridinyl), 8.60 (m, 1H; H; pyridinyl), 9.16 (m, 1H; H; pyridinyl).  13C NMR 
(150 MHz, CD3OD): δ 23.78 (C5), 25.20 (C4), 32.24 (C3), 34.81 (C6), 54.02 (C2), 72.87 (C1), 
177 
124.14, 125.08, 126.62, 128.59 (CH; pyridinyl) 134.50, 146.72 (C; triazolyl), 149.81 (C; 
triazolyl).  HRMS: C13H17N4OS
+ [M+H]Cal m/z 277.1118 ; [M+H]exp m/z  277.1159.   
Trans-2-(benzoimidazol-2-ylthio)cyclohexanol (5k) 
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as light yellow oil by 
column chromatography (silica gel; Hex:EtOAc, 4:1) to give a yield of 169 mg (34%).  Rf; 0.51 
(Hex:EtOAc, 4:1).  1H NMR (600 MHz, CDCl3): δ 1.30 (m, 3H; H3, H4, H5), 1.45 (m, 1H; 
H6ax), 1.76 (m, 2H; H4, H5), 2.19 (m, 2H; H6eq, H3eq), 3.36 (m, 1H; H1), 3.65 (td, J = 10.4, 
4.4 Hz, 1H; H2), 7.19 (m, 2H; H; Ph), 7.49 (m, 2H; H; Ph).  13C NMR (150 MHz, CDCl3): δ 
24.17 (C5), 26.14 (C4), 32.72 (C6), 35.86 (C3), 52.62 (C2), 76.18 (C1), 114.31, 122.63 (4CH; 
Ph), 150.71 (2C; Ph), 159.62 (C; imidazolyl).  HRMS: C13H17N2OS
+ [M+H]Cal m/z 249.1056 ; 
[M+H]exp m/z  249.1101.   
Trans-2-(benzothiazol-2-ylthio)cyclohexanol (5l)  
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as light yellow oil by 
column chromatography (silica gel; Hex:EtOAc, 4:1) to give a yield of 329 mg (62%).  Rf; 0.31 
(Hex:EtOAc, 4:1).  1H NMR (600 MHz, CD3OD): δ 1.41 (m, 3H; H3, H4, H5), 1.59 (m, 1H; 
H6eq), 1.70 (m, 1H; H4eq), 1.78 (m, 1H; H5eq), 2.08 (m, 1H; H6ax), 2.34 (m, 1H; H3ax), 3.59 
(td, J = 9.5, 4.2 Hz, 1H; H1), 3.72 (ddd, J = 12.3, 8.2, 2.8 Hz, 1H; H1), 7.31 (m,1H; H; Ph), 7.43 
(m, 1H; H; Ph), 7.82 (m,2H; H; Ph).  13C NMR (150 MHz, CDCl3): δ 23.55 (C5), 25.29 (C4), 
178 
32.12 (C6), 34.80 (C3), 54.76 (C2), 71.99 (C1), 120.59, 121.03, 124.26, 126.04 (4CH; Ph), 
135.27 (C; thiazolyl), 152.91, 167.74 (2C; Ph).  HRMS: C13H16NOS2
+ [M+H]Cal m/z 266.0668 ; 
[M+H]exp m/z  266.0712.   
Trans-2-(benzoxazol-2-ylthio)cyclohexanol (5m)  
 
Reaction occurred in 10 mL of H2O.  The residue was isolated as brown crystals by 
column chromatography (silica gel; Hex:EtOAc, 1:2) to give a yield of 144 mg (29%).  Rf; 0.48 
(Hex:EtOAc, 1:2).  1H NMR (600 MHz, DMSO-d6): δ 1.39 (m, 3H; H3, H4, H5, H6), 1.64 (m, 
2H; H4, H5), 2.06 (m, 1H; H3eq), 2.13 (m, 1H; H6eq), 2.31 (br.s, 1H; OH), 3.50 (td, J = 9.3, 4.0 
Hz, 1H; H1), 3.64 (td,  J = 10.1, 3.6 Hz, 1H; H2), 7.07 (m,2H; Ph), 7.13 (m, 1H; H; Ph), 7.30 
(m,2H; H; Ph).  13C NMR (150 MHz, CDCl3): δ 19.54 (C5), 24.44 (C4), 25.56 (C6), 32.21 (C3), 
54.15 (C2), 70.93 (C1), 119.00, 121.85, 131.02, 141.79 (4CH; Ph), 151.30, 155.13 (C; Ph), 









Compounds 8a and 9a were prepared in the same reaction.  Reaction occurred in 10 mL 
of H2O.  Products were separated by column chromatography (silica gel; DCM:EtOAc, 9:1)  to 
give a colorless oil for 8a and white crystals for 9a.   
(1R,2R,5S)-4-(tert-butyl)-2-(pyridin-2-ylthio)cyclohexanol (8a) 
  
Reaction yielded 103 mg (44%) of 8a.  Rf: 0.48 (DCM:EtOAc, 9:1).  1H NMR (600 
MHz, CD3OD): δ 0.88 (s, 9H; C(CH3)3 ), 1.30 (m, 2H; H5eq, H5ax), 1.53 (m, 1H; H3ax), 1.64 
(m, 2H; H3eq, H6ax), 1.84 (m, 1H; H6eq), 2.26 (tt, J = 13.8, 4.0 Hz, 1H; H4), 4.05 (m, 1H; H2), 
4.07 (q, J = 3.1 Hz, 1H; H1),  7.08 (m, 1H; H; pyridinyl), 7.26  (m,  1H; H; pyridinyl), 7.61 (m,  
1H; H; pyridinyl),8.38 (m,  1H; H; pyridinyl).  13C NMR (150 MHz, CD3OD): δ 22.18 (C5), 
25.41 (3C, C(CH3)3), 26.49(C3), 27.42 (C, t-butyl), 32.26 (C6), 40.38 (C4), 44.80 (C2), 69.44 
(C1), 119.81, 122.63, 136.37, 149.43 (CH; pyridinyl), 158.57 (C; pyridinyl).  HRMS: 
C16H26NOS
+ [M+H]Cal m/z 280.1730 ; [M+H]exp m/z  280.1762.   
(1S,2S,5R)-5-(tert-butyl)-2-(pyridin-2-ylthio)cyclohexanol (9a) 
 
Reaction yielded 118 mg (47%) of 9a.  Rf: 0.46 (DCM:EtOAc, 9:1).  1H NMR (600 
MHz, CD3OD): δ 0.85 (s, 9H; C(CH3)3), 1.26 (m, 2H; H4eq, H4ax), 1.62 (m, 2H; H3eq, H3ax), 
1.94 (m, 2H; H6eq, H6ax), 2.26 (m, 1H; H4), 3.93 (q, J = 3.0 Hz, 1H; H1), 4.16 (m, 1H, H2).  
7.01 (m, 1H; H; pyridinyl), 7.24 (m, 1H; H; pyridinyl), 7.72 (m, 1H; H; pyridinyl),8.27 (m, 1H; 
180 
H; pyridinyl).  13C NMR (150 MHz, CD3OD): δ 23.57 (C5), 25.32 (3C, C(CH3)3), 25.87(C3), 
28.13 (C; t-butyl) 32.20 (C6), 40.12(C4), 45.27 (C2), 69.19 (C1), 118.54, 121.98, 134.21, 150.28 
(CH; pyridinyl), 156.94 (C; pyridinyl).  HRMS: C16H26NOS
+ [M+H]Cal m/z 280.1730 ; [M+H]exp 
m/z  280.1755.   
Compounds 8b and 9b were prepared in the same reaction.  Reaction occurred in 10 mL 
of H2O.  Products were separated by column chromatography (silica gel; EtOAc) to give white 
crystals for both products. 
(1R,2R,4S)-2-((imidazol-2-yl)thio)-4-(t-butyl)cyclohexanol (8b) 
 
Reaction yielded 95 mg (28%) of 8b.   Rf: 0.27 (EtOAc).  1H NMR (600 MHz, CD3OD): 
δ 0.85 (s, 9H; C(CH3)3), 1.38 (m, 2H; H5eq, H5ax), 1.55 (m, 2H; H3eq, H3ax), 1.70 (m, 2H; 
H6eq, H6ax), 2.11 (m, 1H; H4), 3.44 (m, 1H; H2), 3.94 (m, 1H; H1), 7.92 (m, 2H; H; 
imidazolyl).  13C NMR (150 MHz, CD3OD): δ 20.34 (C4), 26.23 (3C, C(CH3)3), 26.30 (C3), 
27.66 (C, t-butyl), 3.150 (C5), 41.92 (C2), 51.65 (C1), 115.62, 116.11 (CH, imdazolyl), 
139.24(C, imidazolyl).  HRMS: C13H23N2OS
+ [M+H]Cal m/z 255.1526 ; [M+H]exp m/z  255.1546.   
(1S,2S,5R)-2-((imidazol-2-yl)thio)-5-(tert-butyl)cyclohexanol (9b) 
 
Reaction yielded 111 mg (42%) of 9b.  Rf: 0.31 (EtOAc).  1H NMR (600 MHz, CD3OD): 
δ 0.85 (s, 9H; C(CH3)3), 1.40 (m, 2H; H4eq, H4ax), 1.53 (m, 1H; H3ax), 1.72 (m, 2H; H3eq, 
H6ax), 1.88 (m, 1H; H6eq), 2.04 (m, 1H; H5), 3.58 (sextet, J = 2.3 Hz, 1H; H2), 3.87 (q, J = 2.8 
181 
Hz, 1H; H1), 7.08 (m, 2H; H; imidazolyl).  13C NMR (150 MHz, CD3OD): δ 20.34 (C4), 26.18 
(3C, C(CH3)3), 26.30 (C3), 27.66 (C, t-butyl), 3.150 (C5), 41.92 (C2), 51.65 (C1), 115.77, 
116.28 (CH, imdazolyl), 139.24(C, imidazolyl).  HRMS: C13H23N2OS
+ [M+H]Cal m/z 255.1526 ; 
[M+H]exp m/z  255.1534.   
Compounds 8c and 9c were prepared in the same reaction.  Reaction occurred in 10 mL 
of H2O.  Products could not be separated by column chromatography (silica gel; Hexane: EtOAc, 




Product appeared as white crystals.  1H NMR (600 MHz, CD3OD): δ 0.85 (s, 9H; 
C(CH3)3), 1.23 (m, 2H; H5eq, H5ax),1.59 (m, 2H; H3eq, H3ax), 1.68 (m, 1H; H6), 2.08 (m, 1H; 
H6), 2.31 (tt, J = 13.6, 4.1 Hz, 1H; H4), 3.95 (m 1H; H1), 4.08 (m, 1H, H2).  7.20 (m, 4H; Ph).  
13C NMR (150 MHz, CD3OD): δ 23.57 (C4), 25.32 (3C, C(CH3)3), 25.87(C5), 32.14 (C; t-butyl) 
32.20 (C6), 40.12(C3), 49.28 (C2), 60.25 (C1), 112.38, 116.28, 125.36, 135.47 (CH; Ph), 159.25, 
161.59 (C; imidazolyl).  HRMS: C17H25N2OS
+ [M+H]Cal m/z 305.1682 ; [M+H]exp m/z  305.1665 








Product appeared as white crystals.  1H NMR (600 MHz, CD3OD): δ 0.87 (s, 9H; 
C(CH3)3), 1.24 (m, 2H; H4eq, H4ax),1.59 (m, 2H; H3eq, H3ax), 1.80 (m, 2H; H6eq, H6ax), 2.09 
(m, 1H; H5), 3.93 (m 1H; H2), 4.08 (m, 1H, H1).  7.49 (m, 4H; Ph).  13C NMR (150 MHz, 
CD3OD): δ 23.57 (C4), 25.32 (3C, C(CH3)3), 25.87(C5), 32.14 (C; t-butyl) 32.20 (C6), 
40.12(C3), 49.28 (C2), 60.25 (C1), 112.38, 116.28, 125.36, 135.47 (CH; Ph), 159.25, 161.59 (C; 
imidazolyl).  HRMS: C17H25N2OS
+ [M+H]Cal m/z 305.1682 ; [M+H]exp m/z  305.1665 (8c and 














General procedure for acetylation of trans-2-(azaarylsulfanyl)-cyclohexanols 
Compound 3k (0.4 g, 1.0 mmol) was dissolved 20 ml of dried CHCl3.  Excess acetyl 
chloride (2 ml) was added to the solution and allowed to reflux.  Upon consumption of the 3k, 
reaction was diluted with 20 ml of CHCl3 and neutralized with Na2CO3 crystals.  Na2CO3 was 
filtered off and organic solution was dried for 12 h over anhyd Na2SO4.  Organic solution was 
filtered and removed by rotary evaporator to give the crude product that was purified by column 
chromatography (silica gel; Hex:EtOAc, 4:1) to give a yield 239 mg (60%) as a yellow oil 3x. 
Diethyl-4-((1H-benzoimidazol-2-yl)thio)-5-acetoxycyclohexane-1,2-dicarboxylate (3x) 
 
1H NMR (600 MHz, CDCl3): δ 1.24 (t, J = 7.1 Hz, 3H; CH3), 1.25 (t, J = 7.1 Hz, 3H; 
CH3), 2.23 (m, 2H; H3eq, H3ax), 2.36 (m, 2H; H6eq, H6ax), 3.02 (m, 2H; H1, H2), 4.15 (m, 4H; 
OCH2), 4.55 (m, 1H; H4), 5.35 (q, J = 3.0 Hz, 1H; H4), 7.31 (m, 2H; Ph), 7.63 (m, 2H; Ph).  
13C 
NMR (150 MHz, CDCl3): δ 14.15 (2CH3, Et), 28.54 (C6), 31.69 (C3), 39.57 (C2), 41.28 (C1), 
49.23 (C5), 61.37, 61.54 (OCH2), 71.39 (C4), 122.34, 122.84, 123.50, 123.71 (4CH, Ph), 149.95, 
150.28 (C, Ph), 162.15 (C, imidazolyl), 168.25, 172.18, 174.73 (C=O).  HMRS: C21H27N2O6S
+ 






General procedure for tosylation of alcohols 
Alcohol (20 mmol) was dissolved in pyridine (25 mL) and cooled in an ice bath (0-5 oC). 
Methanesulfonyl chloride or 4-Toluenesulfonyl chloride (24 mmol) was then added in small 
portions with constant stirring. The reaction was completed in 3 h (monitored by TLC). Ether (30 
mL) and water (7 mL) were added and the organic layer was washed successively with 2 N HCl, 
5% NaHCO3, and water and dried for 12 h over anhyd Na2SO4. Organic solution was filtered and 
solvent removed by rotary evaporator to give the crude product.  
4-methylcyclohexyl methanesulfonate (41a) 
 
The reaction gave 2.89 g (75%) of the crude product 41a as a colorless oil containing 
both cis and trans isomers that could not be separated by column chromatography (cis:trans: = 
1:3):  Rf: 0.39 (Hex:EtOAc, 10:1); trans-41a: 
1H NMR (600 MHz, CDCl3): δ 0.86 (s, 3H; CH3), 
1.01 (m, 2H; H3, H5), 1.24 (m, 1H; H4), 1.27 (m, 2H; H3, H5), 1.77 (m, 2H; H2eq, H6eq), 2.09 
(m,2H; H2ax, H6ax), 2.97 (m, 3H; CH3), 4.55 (m, 1H; H1). 
13C NMR (150 MHz, CDCl3): δ 
20.21 (CH3), 25.68 (C2), 25.87 (C6), 28.64 (C3), 28.78 (C5), 32.64 (C4), 35.06 (CH3). cis-41a:  
1H NMR (600 MHz, CDCl3): δ 0.88 (s, 3H; CH3), 1.01 (m, 2H; H3, H5), 1.31 (m, 3H; H4, H3, 
H5), 1.75 (m, 2H; H2eq, H6eq), 2.00 (m,2H; H2ax, H6ax), 2.98 (m, 3H; CH3), 4.92 (m, 1H; H1). 
13C NMR (150 MHz, CDCl3): δ 20.21 (CH3), 26.34(C2), 26.87 (C6), 27.02 (C3), 28.04 (C5), 
32.51 (C4), 35.13 (CH3). HRMS: C8H17O3S




4-phenylcyclohexyl p-toluenesulfonate (41b) 
 
The reaction gave 3.02 g (88%) of the crude product 41b as a colorless oil containing 
both cis and trans isomers that could not be separated by column chromatography (cis:trans: = 
1:4):  Rf: 0.39 (Hex:EtOAc, 10:1); trans-41b: 
1H NMR (600 MHz, CDCl3): δ 1.49 (m, 2H; H2eq, 
H6eq),  1.62 (m, 2H; H3eq, H5eq), 1.90 (m, 2H; H2ax, H6ax), 2.08 (m, 2H; H3ax, H5ax), 2.44 
(m, 3H; CH3), 2.47 (m, 1H; H4), 4.49 (m, 1H; H1), 7.27 (m, 1H; Ph), 7.29 (m, 2H; Ph), 7.32 (m, 
2H; Ph), 7.84 (m, 2H; p-tol), 7.92 (m, 2H; p-tol).  13C NMR (150 MHz, CDCl3): δ 21.72 (CH3), 
27.10 (C3), 27.19 (C5), 29.98 (C2), 30.08 (C6), 40.19 (C4), 74.48 (C1), 124.35, 124.97, 125.84 
(CH; pH), 127.51, 127.43 (CH; p-tol), 128.48, 129.02 (CH; pH), 129.87, 129.99 (CH; p-tol), 
140.06, 144.47 (C; p-tol), 149.44 (C; pH). cis-41a δ 1.49 (m, 2H; H2eq, H6eq), 1.62 (m, 2H; 
H3eq, H5eq), 1.90 (m, 2H; H2ax, H6ax), 2.08 (m, 2H; H3ax, H5ax), 2.42 (m, 1H; H4), 2.44 (m, 
3H; CH3), 4.87 (m, 1H; H1), 7.27 (m, 1H; Ph), 7.29 (m, 2H; Ph), 7.32 (m, 2H; Ph), 7.84 (m, 2H; 
p-tol), 7.92 (m, 2H; p-tol).   13C NMR (150 MHz, CDCl3): δ 21.84 (CH3), 27.19 (C3), 27.42 
(C5), 29.98 (C2), 30.08 (C6), 40.19 (C4), 74.48 (C1), 124.35, 124.97, 125.84 (CH; pH), 127.51, 
127.43 (CH; p-tol), 128.44, 129.37 (CH; pH), 129.71, 129.99 (CH; p-tol), 140.06, 144.17 (C; p-
tol), 144.34 (C; pH).  HRMS: C19H23O3S






4-(tert-butyl)-cyclohexyl p-toluenesulfonate (41c) 
 
The reaction gave 4.37 g (73%) of the crude product 41c as a colorless oil containing 
both cis and trans isomers that could not be separated by column chromatography (cis:trans: = 
1:3):  Rf: 0.34 (Hex:CHCl3, 3:2); trans-41c: 
1H NMR (600 MHz, CDCl3): δ 0.80 (s, 9H; CH3), 
1.21 (m, 2H; H3, H5), 1.29 (m, 1H; H4), 1.34 (m, 2H; H3, H5), 1.72 (m, 2H; H2eq, H6eq), 1.84 
(m,2H; H2ax, H6ax), 2.48 (m, 3H; CH3), 4.72 (m, 1H; H1), 7.31 (m, 2H; p-tol), 7.94 (m, 2H; p-
tol). 13C NMR (150 MHz, CDCl3): δ 21.34 (CH3), 24.64 (C3), 24.79 (C5), 26.45 ((CH3)3), 28.78 
(C6), 32.01 (C2), 33.94 (C(CH3)3), 38.01 (C4), 87.84 (C1), 120.17, 120.87, 121.49, 121.67 (CH: 
p-tol), 141.32, 143.25 (C: p-tol).  cis-41c: 1H NMR (600 MHz, CDCl3): δ 0.82 (s, 9H; CH3), 1.23 
(m, 2H; H3, H5), 1.27 (m, 2H; H3, H5), 1.30 (m, 1H; H4), 1.81 (m, 2H; H2eq, H6eq), 1.83 
(m,2H; H2ax, H6ax), 2.43 (m, 3H; CH3), 4.33 (m, 1H; H1), 7.43 (m, 2H; p-tol), 7.77 (m, 2H; p-
tol). 13C NMR (150 MHz, CDCl3): δ 21.34 (CH3), 24.64 (C3), 24.79 (C5), 26.45 (CH3)3), 28.78 
(C6), 32.01 (C2), 33.94 (C(CH3)3), 38.01 (C4), 87.84 (C1), 120.17, 120.87, 121.49, 121.67 (CH: 
ph), 141.32, 143.25 (C: ph).   HRMS: C17H27O3S
+ [M+H]cal m/z 311.1675; [M+H]exp m/z 
311.1800. 
General procedure for azido epoxide cleavage 
Epoxide (0.3 g, 2 mmol) was dissolved in 32 mL mixture of EtOH/H2O (15:1), NH4Cl 
(0.2 g, 3 mmol) was added while stirring.  NaN3 (0.2 g, 3 mmol) was dissolved in the reaction 
mixture and reaction mixture was heat to reflux for 24 h while monitoring the consumption of 
epoxide (TLC, Hex:EtOAc/ 7:3).  All solvent was removed on rotary evaporator.  The crude 
187 
product was dissolved in 25 mL of EtoAc and washed with x3 10 mL of DI H2O.  The organic 
solution was separated and dried for 12 h over anhyd Na2SO4.  Organic solution was filtered and 
removed by rotary evaporator to give the crude product. 
Diethyl-5-azido-4-hydroxy-1,2-cyclohexanedicarboxylate (10a) 
 
Azide 10a was synthesized from epoxide 2.  Reaction yielded a yellow oil of 399 mg 
(84%) with no purification needed.  Rf: 0.46 (Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 
1.24 (t, J =7.0 Hz, 3H; CH3), 1.25 (t, J =7.1 Hz, 3H; CH3), 1.80 (ddd, J =13.9, 7.0, 4.3 Hz, 1H; 
H3ax), 1.84 (ddd, J =13.8, 7.1, 4.4 Hz, 1H; H6ax), 2.07 (m, 2H; 1H, H3eq), 2.19 (ddd, J =13.6, 
8.6, 3.8 Hz, 1H; H6eq), 2.25 (br.s, OH), 3.03 (dt, J =4.4, 7.9 Hz, 1H; H1), 3.11 (dt, J =4.4, 7.9 
Hz,1H; H2), 3.60 (dt, J =6.6, 3.7 Hz, 1H; H5), 3.77 (m, 1H; H4), 4.14 (m, 4H; OCH2).  
13C NMR 
(150 MHz, CDCl3): δ 14.22 (CH3), 14.23 (CH3), 27.42 (C3), 30.74 (C6), 39.41 (C2), 39.66 (C1), 
60.10, 61.04 (OCH2), 61.59(C5), 68.22 (C4), 173.44, 173.66 (C=O).  HRMS: C12H19N3O5 
[M+H]cal m/z 286.1397; [M+H]exp m/z 286.1404.   
Trans-2-Azidocyclohexanol (17a) 
 
Azide 17a was synthesized from epoxide 4.  Reaction yielded a light-yellow oil of 1.24 g 
(81%) with no purification needed.  Rf: 0.33 (Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 
1.28 (m, 4H; H3ax, H4ax, H5ax, H6ax), 1.74 (m, 2H; H4eq, H5eq), 2.02 (m, 2H; H3ax, H6ax), 
2.46 (s, 1H, OH), 3.16 (ddd, J = 12.4, 8.0, 3.2 Hz, 1H; H2), 3.38 (m, 1H; H1).  13C NMR (150 
188 
MHz, CDCl3): δ 23.82 (C4), 24.20 (C5), 29.70 (C3), 32.95 (C6), 67.15 (C2), 73.62 (C1).  
HRMS: C6H12N3O
+ [M+H]cal m/z 142.0975; [M+H]exp m/z 142.0981. 
Compounds 21a and 21b were prepared in the same reaction. Reaction occurred in a 
reflux of epoxide 20a and NaN3. Products remained a mixture and were NOT separated by 
column chromatography to give a colorless oil of both 21a and 21b with a yield of 0.82 g 




1H NMR (600 MHz, CDCl3): δ 0.83 (m, 3H; CH3), 1.17 (m, 2H; H3eq, H5eq), 1.40 (m, 
1H; H6eq), 1.51 (m, 1H; H5ax), 1.53 (m, 1H; H3ax), 1.63 (m, 1H; H4), 1.79 (m, H6ax), 2.72 (s, 
1H, OH), 3.09 (ddd, J = 12.2, 7.8, 3.5 Hz, 1H; H2), 3.63 (m, 1H; H1).  13C NMR (150 MHz, 
CDCl3): δ 18.83 (CH3), 25.72 (C4), 27.74 (C6), 28.44 (C5), 33.42 (C3), 66.47 (C2), 74.69 (C1).  
HRMS: C7H14N3O
+ [M+H]cal m/z 156.1131; [M+H]exp m/z 156.1152. 
(1R,2R,5S)-2-azido-5-methylcyclohexanol (21b) 
 
1H NMR (600 MHz, CDCl3): δ 0.87 (m, 3H; CH3), 1.16 (m, 1H; H4eq), 1.19 (m, 1H; 
H6eq), 1.34 (m, 1H; H4ax), 1.40 (m, 1H; H3ax), 1.59 (m, 2H; H3eq, H6ax), 1.69 (m, 1H; H5), 
2.99 (s, 1H, OH), 3.01 (ddd, J = 12.3, 7.7, 3.5 Hz, 1H; H2), 3.82 (m, 1H; H1).  13C NMR (150 
MHz, CDCl3): δ 18.69 (CH3), 25.78 (C5), 26.47 (C4), 28.44 (C6), 36.87 (C3), 67.89 (C2), 78.61 
(C1).  HRMS: C7H14N3O
+ [M+H]cal m/z 156.1131; [M+H]exp m/z 156.1152. 
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Compounds 22a and 22b were prepared in the same reaction. Reaction occurred in a 
reflux of epoxide 20b and NaN3. Products remained a mixture and were NOT separated by 
column chromatography to give a colorless oil of both 22a and 22b with a yield of 0.71 g 




1H NMR (600 MHz, CDCl3): δ 1.70 (m, 2H; H3eq, H5eq), 1.86 (m, 1H; H6eq), 1.92 (m, 
1H; H5ax), 2.09 (m, 1H; H6ax), 2.20 (m, 1H, H3ax), 3.04 (m, 1H; H4), 3.86 (m, 1H, H2), 3.95 
(q, J = 2.6 Hz, 1H; H1), 7.21 (m, 1H; Ph), 7.26 (m, 2H; Ph), 7.30 (m, 2H; Ph).  13C NMR (150 
MHz, CDCl3): δ 23.64 (C5), 27.65 (C6), 30.54 (C3), 41.01 (C4), 62.84 (C2), 69.34 (C1), 123.45, 
123.97, 124.09, 125.11, 125.67 (CH; Ph), 134.02 (C; Ph).  HRMS: C12H16N3O
+ [M+H]cal m/z 
218.1288; [M+H]exp m/z 218.1302. 
(1R,2R,5S)-2-azido-5-phenylcyclohexanol (22b) 
 
1H NMR (600 MHz, CDCl3): δ 1.70 (m, 1H; H4eq), 1.80 (m, 1H; H3eq), 1.83 (m, 2H; 
H6ax, H6eq), 1.92 (m, 1H; H4ax), 2.09 (m, 1H, H3ax), 2.94 (m, 1H; H5), 3.69 (m, 1H, H2), 3.76 
(q, J = 2.7 Hz, 1H; H1), 7.21 (m, 1H; Ph), 7.26 (m, 2H; Ph), 7.30 (m, 2H; Ph).  13C NMR (150 
MHz, CDCl3): δ 22.36 (C3), 26.45 (C4), 28.46 (C6), 40.54 (C5), 61.64 (C2), 70.34 (C1), 122.34, 
190 
123.04, 123.48, 125.19, 125.81 (CH; Ph), 134.29 (C; Ph).  HRMS: C12H16N3O
+ [M+H]cal m/z 
218.1288; [M+H]exp m/z 218.1302. 
Compounds 23a and 23b were prepared in the same reaction. Reaction occurred in a 
reflux of epoxide 20c and NaN3. Products remained a mixture and were NOT separated by 
column chromatography to give a colorless oil of both 23a and 23b with a yield of 1.17 g 




1H NMR (600 MHz, CDCl3): δ 0.86 (m, 9H; CH3), 1.27 (m, 1H; H5eq), 1.32 (m, 1H; 
H3eq), 1.47 (m, 1H; H6eq), 1.56 (m, 2H; H3ax, H5ax), 1.79 (m, 1H, H4), 1.83 (m,1H; H6ax), 
2.03 (s, 1H, OH), 3.67 (q, J = 2.8 Hz, 1H; H2), 3.80 (m, 1H; H1).  13C NMR (150 MHz, CDCl3): 
δ 20.19 (C5), 24.90 (C6), 27.40 ((CH3)3), 32.24 (C(CH3)3), 40.23 (C4), 60.72 (C2), 68.71 (C1).  
HRMS: C10H20N3O
+ [M+H]cal m/z 198.1601; [M+H]exp m/z 198.1616. 
(1R,2R,5S)-2-azido-5-(tert-butyl)-cyclohexanol (23b) 
 
1H NMR (600 MHz, CDCl3): δ 0.89 (m, 9H; CH3), 1.27 (m, 2H; H4ax, H4eq), 1.49 (m, 
1H; H6eq), 1.60 (m, 2H; H3eq, H6ax), 1.88 (tt, J = 3.7, 13.8 Hz, 1H; H5), 1.91 (m,1H; H3ax), 
2.05 (s, 1H, OH), 3.80 (m, 1H; H2), 3.94 (q, J = 2.9 Hz, 1H; H1).  13C NMR (150 MHz, CDCl3): 
191 
δ 20.19 (C4), 24.90 (C3), 27.40 ((CH3)3), 29.29 (C6), 32.28 (C(CH3)3), 41.39 (C5), 61.86 (C2), 
67.25 (C1).  HRMS: C10H20N3O
+ [M+H]cal m/z 198.1601; [M+H]exp m/z 198.1616. 
Dimethyl(1R*, 2S*, 4S*, 5S*)-5-azido-4-hydroxy-1,2-cyclohexanedicarboxylate (51) 
 
51 was synthesized from epoxide 50-anti. Reaction yielded a light-yellow oil 234 mg 
(77%) with no purification needed.  1H NMR (600 MHz, CD3OD): δ 1.62 (ddd, J =13.6, 11.7, 
5.0 Hz, 1H; H6ax), 1.87 (quintet, J = 12.2 Hz, 1H; H3ax), 2.22 (dt, J = 13.5, 4.2 Hz: 1H, H3eq), 
2.33 (dt, J =13.8, 4.1 Hz, 1H; H6eq), 2.75 (dt, J =11.9, 4.2 Hz, 1H; H2), 3.22 (q, J = 3.8 Hz, 1H; 
H1), 3.29 (m, 1H; H5), 3.48 (ddd, J =10.6, 9.2, 4.2 Hz, 1H; H4), 3.66 (s,3H; CH3), 3.69 (s, 3H; 
CH3).  
13C NMR (600 MHz, CD3OD): δ 30.29 (C6), 31.56 (C3), 40.43 (C1), 41.08 (C2), 51.03, 
51.14 (OCH3), 63.71 (C5), 72.22 (C4), 173.22, 173.39(C=O).  HRMS: C10H16N3O5 [M+H]Cal m/z 
258.1084; [M+H]exp m/z 258.1062. 
Dimethyl(1R*,2S*,4R*,5R*)-5-azido-4-hydroxy-1,2-cyclohexanedicarboxylate (52) 
 
51 was synthesized from epoxide 50-syn. Reaction yielded a yellow oil of 0.4 g (78%) 
with no purification needed.  1HNMR (600 MHz, CDCl3): δ 1.70 (ddd, J = 13.7, 10.9, 5.0 Hz, 
H6ax), 1.83 (quintet, J = 12.3 Hz, H3ax), 2.26 (dt, J = 13.7, 4.2 Hz: H3eq), 2.32 (dt, J = 13.7, 4.1 
Hz: H6eq), 2.80 (dt, J =11.7, 4.1 Hz: H2), 3.25 (q, J =4.2 Hz, H1), 3.30 (m, 1H, H5), 3.45 (ddd, 
192 
J = 9.8, 9.5, 4.3 Hz, H4), 3.66 (s, 3H; CH3), 3.69 (s, 3H; CH3).  
13C NMR (150 MHz, CD3OD): δ 
28.15 (C6), 33.26 (C3), 40.55 (C1), 40.95 (C2), 51.06, 51.10 (OCH3), 64.87 (C5), 69.66 (C4), 
173.25, 173.49(C=O).  HRMS: C10H16N3O5 [M+H]Cal m/z 258.1084; [M+H]exp m/z 258.1192. 
General procedure for acetylation of azidocyclohexanols 
Alcohol (2.0 mmol) was dissolved 20 ml of dried CHCl3.  Excess acetyl chloride (2 ml) 
was added to the solution and allowed to reflux.  Upon consumption of the alcohol, reaction was 
diluted with 20 ml of CHCl3 and neutralized with Na2CO3 crystals.  Na2CO3 was filtered off and 
organic solution was dried for 12 h over anhyd Na2SO4.  Organic solution was filtered and 
removed by rotary evaporator to give the crude product. 
Diethyl-5-azido-4-acetoxy-1,2-cyclohexanedicarboxylate (10b)  
 
10b was synthesized from alcohol 10a.  Reaction yielded a yellow oil of 530 mg (81%) 
with no purification needed.  Rf: 0.77 (Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 1.24 (t, 
J =7.1 Hz, 3H; CH3), 1.25 (t, J =7.1 Hz, 3H; CH3), 1.98 (m, 4H; H3eq, H3ax, H6eq, H6ax), 2.08 
(s, 3H; CH3-Acetyl), 2.94 (dt, J = 9.8, 4.7 Hz, 1H; H2), 2.98 (dt, J = 9.2, 5.7 Hz, 1H; H1), 3.79 
(q, J =4.4 Hz, 1H; H5), 4.15 (m, 4H; OCH2), 4.91 (q, J =4.3 Hz, 1H; H4).  
13C NMR (600 MHz, 
CDCl3): δ 14.10 (CH3), 14.12 (CH3), 21.08 (CH3-Acetyl), 27.79 (C3), 27.93 (C6), 39.01 (C2), 
39.50 (C1), 57.81(C5), 61.00 (2C, OCH2), 69.07 (C4), 169.72, 173.43, 173.71 (C=O).  HRMS: 






20b was synthesized from alcohol 20a.  Reaction yielded a light-yellow oil of 133 mg 
(79%) with no purification needed.  1H NMR (600 MHz, CDCl3): δ 1.27(m, 4H; H3, H4, H5, 
H6), 1.71 (m, 2H; H4, H5), 2.02 (m, 2H; H3, H6), 2.08 (s, 3H; CH3), 3.36 (dt, J = 10.4, 4.5 Hz, 
1H; H2), 4.65 (dt, J = 9.9, 4.6 Hz, 1H; H1).  13C NMR (600 MHz, CDCl3): δ 21.20 (CH3), 23.46 
(C4), 23.82 (C5), 30.37 (C3), 30.63 (C6), 63.17 (C2), 75.54 (C1), 170.48 (C=O).  HRMS: 
C8H13N3O2 [M+H]cal m/z 184.1086; [M+H]exp m/z 184.1098. 
Compounds 30a and 30b were prepared in the same reaction. Reaction occurred in a 
reflux of azides 21a and 21b with acetyl chloride. Products remained a mixture and were NOT 
separated by column chromatography to give a yellow oil of both 30a and 30b with a yield of 
0.342 g (91.2%). Rf: 0.79 (Hex:EtOAc, 7:3).  Products 30a and 30b exist in a 1:1 ratio in the 
reaction mixture. 
(1R,2R,4S)-2-azido-4-methylcyclohexyl acetate (30a) 
 
1H NMR (600 MHz, CDCl3): δ 0.91 (s, 3H; CH3), 1.13 (m, 1H; H5eq), 1.27 (m, 2H; 
H3ax, H5ax), 1.47 (m, 1H; H6eq), 1.54 (m, 1H; H3eq), 1.65 (m, 1H, H4), 1.83 (m, 1H; H6ax), 
2.06 (s, 3H; CH3), 3.58 (m, 1H; H2), 4.74 (m, 1H; H1).  
13C NMR (150 MHz, CDCl3): δ 20.13, 
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21.74 (CH3), 24.47 (C6), 26.53 (C4), 27.49 (C5), 32.43 (C3), 61.55 (C2), 76.14 (C1), 170.31 
(C=O).  HRMS: C9H16N3O2
+ [M+H]cal m/z 198.1237; [M+H]exp m/z 198.1245. 
(1R,2R,5S)-2-azido-5-methylcyclohexyl acetate (30b) 
 
1H NMR (600 MHz, CDCl3): δ 0.97 (s, 3H; CH3), 1.134 (m, 1H; H4eq), 1.22 (m, 2H; 
H4ax, H6eq), 1.59 (m, 1H; H5), 1.67 (m, 1H; H6ax), 1.69 (m, 1H, H3eq), 1.94 (m, 1H; H3ax), 
2.08 (s, 3H; CH3), 3.69 (m, 1H; H2), 4.89 (m, 1H; H1).  
13C NMR (150 MHz, CDCl3): δ 20.74, 
21.87 (CH3), 22.97 (C3), 27.24 (C4), 30.21 (C5), 34.24 (C6), 62.04 (C2), 76.81 (C1), 170.54 
(C=O).  HRMS: C9H16N3O2
+ [M+H]cal m/z 198.1237; [M+H]exp m/z 198.1245. 
Compounds 31a and 31b were prepared in the same reaction. Reaction occurred in a 
reflux of azides 22a and 22b with acetyl chloride. Products remained a mixture and were NOT 
separated by column chromatography to give a yellow oil of both 31a and 31b with a yield of 
0.609 g (81.0%). Rf: 0.78 (Hex:EtOAc, 7:3).  Products 31a and 31b exist in a 1:1 ratio in the 
reaction mixture. 
(1R,2R,4S)-2-azido-4-phenylcyclohexyl acetate (31a) 
 
1H NMR (600 MHz, CDCl3): δ 1.75 (m, 1H; H5eq), 1.83 (m, 1H; H6ax), 1.94 (m, 1H; 
H3eq), 2.02 (m, 1H; H6eq), 2.06 (m, 1H, H5ax), 2.11 (s, 3H; CH3), 2.91 (m, 1H; H4), 3.89 (m, 
195 
1H; H2), 5.01 (q, J = 3.4 Hz, 1H; H1), 7.21 (m, 1H; Ph), 7.31 (m, 2H; Ph), 7.38 (m, 2H; Ph).  13C 
NMR (150 MHz, CDCl3): δ 20.96 (CH3), 23.84 (C6), 25.69 (C5), 29.73 (C3), 34.90 (C4), 63.47 
(C2), 77.43 (C1), 124.35, 124.47 (CH; Ph), 125.46, 125.49 (CH; Ph), 128.08 (CH; Ph), 147.01 
(C; Ph), 170.14 (C=O).  HRMS: C14H18N3O2
+ [M+H]cal m/z 260.1394; [M+H]exp m/z 260.1388. 
(1R,2R,5S)-2-azido-5-phenylcyclohexyl acetate (31b) 
 
1H NMR (600 MHz, CDCl3): δ 1.75 (m, 1H; H4eq), 1.79 (m, 1H; H3ax), 1.82 (m, 1H; 
H6ax), 1.92 (m, 2H; H3eq, H4ax), 2.04 (m, 1H, H6eq), 2.12 (s, 3H; CH3), 2.91 (m, 1H; H5), 
3.81 (m, 1H; H2), 4.92 (q, J = 3.6 Hz, 1H; H1), 7.23 (m, 1H; Ph), 7.34 (m, 2H; Ph), 7.39 (m, 2H; 
Ph).  13C NMR (150 MHz, CDCl3): δ 21.04 (CH3), 22.34 (C3), 26.04 (C4), 29.84 (C6), 37.87 
(C5), 65.00 (C2), 78.94 (C1), 124.35, 124.47 (CH; Ph), 125.47, 125.48 (CH; Ph), 128.14 (CH; 
Ph), 147.47 (C; Ph), 171.47 (C=O).  HRMS: C14H18N3O2
+ [M+H]cal m/z 260.1394; [M+H]exp m/z 
260.1388. 
Compounds 32a and 32b were prepared in the same reaction. Reaction occurred in a 
reflux of azides 23a and 23b with acetyl chloride. Products remained a mixture and were NOT 
separated by column chromatography to give a yellow oil of both 31a and 31b with a yield of 






(1R,2R,4S)-2-azido-4-(tert-butyl)-cyclohexyl acetate (32a) 
 
1H NMR (600 MHz, CDCl3): δ 0.86 (m, 9H; CH3), 1.24 (m, 1H; H5ax), 1.32 (m, 1H; 
H3ax), 1.46 (m, 1H; H5eq), 1.49 (m, 1H; H3eq), 1.56 (m, 1H, H4), 1.76 (m, 2H; H6ax, H6eq), 
2.06 (s, 3H; CH3), 3.72 (q, J = 3.0 Hz, 1H; H2), 4.93 (m, 1H; H1).  13C NMR (150 MHz, 
CDCl3): δ 19.47 (CH3), 22.92 (C5), 24.70 ((CH3)3), 26.48 (C6), 29.55 (C3), 33.82 (C(CH3)3), 
45.09 (C4), 62.17 (C2), 77.83 (C1), 178.14 (C=O).  HRMS: C12H22N3O2
+ [M+H]cal m/z 
240.1707; [M+H]exp m/z 240.1733. 
(1R,2R,5S)-2-azido-5-(tert-butyl)-cyclohexyl acetate (32b) 
 
1H NMR (600 MHz, CDCl3): δ 0.83 (m, 9H; CH3), 1.30 (m, 2H; H4ax, H4eq), 1.34 (m, 
1H; H6ax), 1.46 (m, 1H; H3ax), 1.50 (m, 1H, H6eq), 1.52 (m, 1H; H3eq), 1.56 (m, 1H; H5), 1.73 
(m, 1H; H6eq), 1.82 (m, 1H; H6ax), 2.06 (s, 3H; CH3), 3.85 (m, 1H; H2), 4.80 (q, J = 2.9 Hz, 
1H; H1).  13C NMR (150 MHz, CDCl3): δ 19.32 (CH3), 22.18 (C4), 23.94 (C3), 24.70 ((CH3)3), 
26.98 (C6), 33.82 (C(CH3)3), 43.82 (C5), 64.57 (C2), 78.39 (C1), 176.10 (C=O).  HRMS: 
C12H22N3O2




General procedure for azido-tosylate/alkyl halide substitution (Sn2) 
Tosylate (2 mmol) or a1kyl halide (2 mmol) was dissolved in 20 mL mixture of DMSO.  
NaN3 (3 mmol) was dissolved in the reaction mixture and reaction mixture was heat to reflux for 
48 h while monitoring the consumption of tosylate by TLC.  All solvent was removed on rotary 
evaporator.  The crude product was dissolved in 25 mL of EtOAc and washed with x3 10 mL of 
DI H2O.  The organic solution was separated and dried for 12 h over anhyd Na2SO4.  Organic 
solution was filtered and removed by rotary evaporator to give the crude product. 
Azidocyclohexane (39)  
 
Compound 39 yielded yellow oil of 0.182 g (72%) without purification.  Rf: 0.29 
(Hex:EtOAc, 10:1).    1H NMR (600 MHz, CDCl3): δ 1.34 (m, 6H; H3eq, H3ax, H4eq, H4ax, 
H5eq, H5ax), 1.77 (m, 2H; H2ax, H6ax), 1.90 (m, 2H; H2eq, H6eq), 3.31 (m, 1H; H1).   13C 
NMR (150 MHz, CDCl3): δ 24.32 (C3, C5), 25.35 (C4), 31.69 (C2, C6), 60.00 (C1).  HRMS: 
C16H12N3
+ [M+H]cal m/z 126.1015; [M+H]exp m/z 126.1031. 
1-azido-4-methylcyclohexane(42a) 
 
Compound 42a yielded yellow oil without purification.  Rf: 0.31 (Hex:EtOAc, 19:1).  
trans-42a: 1H NMR (600 MHz, CDCl3): δ 0.71 (s, 3H; CH3), 0.93 (m,1H, H4), 1.32 (m, 4H; H3, 
H3, H5, H5), 1.56 (m, 2H; H2ax, H6ax), 1.91 (m, 2H; H2eq, H6eq), 3.84 (m, 1H; H1). 13C NMR 
(150 MHz, CDCl3): δ 26.38 (C3), 26.42 (C5), 26.49 (CH3), 30.18 (C2, C6), 42.17 (C4), 57.02 
(C1). cis-42a: 1H NMR (600 MHz, CDCl3): δ 0.77 (s, 3H; CH3), 0.96 (m,1H, H4), 1.14 (m, 2H; 
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H3, H5), 1.32 (m, 2H; H3, H5), 1.53 (m, 2H; H2ax, H6ax), 1.91 (m, 2H; H2eq, H6eq), 3.99 (m, 
1H; H1). 13C NMR (150 MHz, CDCl3): δ 26.33 (C3), 26.42 (C5), 26.49 (CH3), 30.24 (C2), 30.54 
(C6), 42.05 (C4), 57.57 (C1).   HRMS: C7H14N3 




Compound 42b yielded yellow oil without purification.  Rf: 0.52 (Hex:EtOAc, 3:2).  
trans-42b 1H NMR (600 MHz, CDCl3): δ 1.70 (m, 4H; H3eq, H3ax, H5eq, H5ax), 1.80 (m, 2H; 
H2ax, H6ax), 1.99 (m, 2H; H2eq, H6eq), 2.51 (m, 1H; H4), 3.82 (m, 1H; H1).  13C NMR (150 
MHz, CDCl3): δ 28.40 (C3, C5), 30.11 (C2, C6), 43.45 (C4), 57.33 (C1), 100.31, 126.23, 126.91, 
128.51, 128.53 (5CH; phenyl), 148.47 (C; phenyl).  cis-42b 1H NMR (600 MHz, CDCl3): δ 1.70 
(m, 4H; H3eq, H3ax, H5eq, H5ax), 1.80 (m, 2H; H2ax, H6ax), 1.99 (m, 2H; H2eq, H6eq), 2.54 
(tt, J = 11.7, 3.6 Hz, 1H; H4), 3.97 (quintet, J = 3.1 Hz, 1H; H1).  13C NMR (150 MHz, CDCl3): 
δ 28.40 (C3, C5), 30.11 (C2, C6), 43.45 (C4), 57.33 (C1), 100.31, 126.23, 126.91, 128.51, 
128.53 (5CH; phenyl), 148.47 (C; phenyl).  HRMS: C12H14N3 










Compound 42c yielded yellow oil of 0.477 mg (79%) with no purification needed.  Rf: 
0.42 (Hex:EtOAc, 5:2).  trans-42c 1H NMR (600 MHz, CDCl3): δ 0.851 (s, 9H, C(CH3)3), 1.10 
(m, 1H; H4), 1.29 (m, 4H; H3ax, H3eq, H5ax, H5eq), 1.62 (m, 2H; H2, H6), 1.92 (m, 1H; H2).  
2.03 (m, 1H; H6), 3.87 (m,1H, H1).  13C NMR (150 MHz, CDCl3): δ 21.73 (C3), 26.03 (C5), 
27.55 (3C(CH3)3), 30.45 (C(CH3)3), 32.31 (C6), 32.40 (C2), 47.76 (C4), 60.55 (C1).  cis-42c 
1H 
NMR (600 MHz, CDCl3): δ 0.851 (s, 9H, C(CH3)3), 1.24 (m, 1H; H4), 1.29 (m, 4H; H3ax, H3eq, 
H5ax, H5eq), 1.62 (m, 2H; H2, H6), 1.92 (m, 1H; H2).  2.07 (m, 1H; H6), 3.87 (m,1H, H1).  13C 
NMR (150 MHz, CDCl3): δ 21.73 (C3), 26.03 (C5), 27.55 (3C(CH3)3), 30.45 (C(CH3)3), 32.31 
(C6), 32.40 (C2), 47.76 (C4), 60.55 (C1). 
General procedure for synthesis of triazoles through copper catalyzed click reactions. 
CuSO4.5H2O (10 mmol) was dissolved in 7 mL of H2O.  Azide (2 mmol), alkyne (2 
mmol) and ascorbic acid (3 mmol) were dissolved in a mixture of 3 mL of H2O and 2 mL of 1,4-
dioxane.  CuSO4 solution was added to mixture and stirred for 8 hours while checking for 
completion with TLC.  After completion mixture was washed with 2 x 20 ml CHCl3, dried with 
anhydrous Na2SO4 crystals for 12 hours.  Na2SO4 crystals were filtered off and rotary evaporator 







Compound 18a was isolated as colorless oil with a yield of 587 mg (81%).  Rf: 0.36 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.87 (t, J = 7.1 Hz, 3H; CH3), 1.26 (m, 2H; 
CH2), 1.44 (m, 5H; CH2, H6ax, H5ax, H5eq), 1.54 (m, 1H; H4ax), 1.69 (m, 2H; CH2), 1.94 (m, 
4H; H4eq, H3ax, CH2), 2.19 (m, 2H; H3eq, H6eq), 2.79 (dd, J = 8.8, 6.8 Hz, 2H; CH2), 3.88 (dt, 
J = 14.9, 5.4 Hz, 1H; H1), 4.32 (m, 1H; H2), 7.71 (s, 1H; triazolyl).  13C NMR (150MHz, 
CDCl3): δ 14.17 (CH3), 22.65 (CH2), 24.09 (C5), 24.81, 25.79, 29.48 (CH2), 31.66 (C3), 31.71 
(C4), 33.57 (CH2), 62.27 (C6), 70.14 (C2), 72.71 (C1), 120.19(CH; triazolyl), 148.16 (C; 
triazolyl).  HRMS: C14H26N3O
+ [M+H]Cal m/z 252.2070; [M+H]exp m/z 252.2079. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)cyclohexyl acetate (19a) 
 
Compound 19a was isolated as colorless oil with a yield of 168 mg (73%).  Rf: 0.71 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 7.1 Hz, 3H; CH3), 1.31 (m, 6H; 
2CH2, H6ax, H5ax), 1.63 (m, 3H; CH2, H5eq), 1.84 (s, 1H; CH3), 1.85 (m, 2H; CH2), 1.93 (m, 
2H; H4eq, H4ax), 2.21 (m, 2H; H3ax, H6eq), 2.68 (t, J = 7.7 Hz, 2H; CH2), 3.70 (m, 1H; H3eq), 
4.48 (m, 1H; H2), 5.05 (td, J = 10.4, 4.8 Hz, 1H; H1), 7.27 (s, 1H; triazolyl).  13C NMR 
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(150MHz, CDCl3): δ 14.15 (CH3), 20.84 (COCH3), 22.64 (CH2), 23.87 (C5), 24.81, 25.79, 29.48 
(CH2), 31.66 (C4), 31.63 (C6), 32.24 (C3), 63.12 (CH2), 67.16 (C2), 74.02 (C1), 119.08 (CH; 
triazolyl), 143.20 (C; triazolyl), 170.04 (C=O).  HRMS: C16H28N3O2
+ [M+H]Cal m/z 294.2176; 
[M+H]exp m/z 294.2182. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclohexanol (18b) 
 
Compound 18b was isolated as white crystals with a yield of 524 mg (76%).  Rf: 0.34 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.45 (m, 3H; H4ax, H5ax, H6eq), 1.89 (m, 
2H; H4eq, H5eq), 1.95 (m, 1H; H3ax), 2.22 (m, 2H; H3eq, H6ax), 3.48 (br.s, 1H; OH), 4.06 (dt, 
J = 10.5, 4.4 Hz, 1H; H1), 4.15 (ddd, J = 12.5, 9.3, 4.1 Hz, 1H; H2), 7.29 (m, 1H; Ph), 7.35 (m, 
2H; Ph), 7.67 (m, 2H; Ph),  7.75 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 23.94 (C5), 
24.76 (C4), 31.56 (C3), 33.66 (C6), 67.05 (C2), 72.64 (C1), 119.62 (CH; triazolyl), 125.46 (2C; 
Ph), 128.09 (C; Ph), 129.01 (2C; Ph), 131.32 (C; Ph), 148.21 (C; triazolyl).  HRMS: C14H18N3O
+ 
[M+H]Cal m/z 244.1444; [M+H]exp m/z 244.1452. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclohexyl acetate (19b) 
 
Compound 19b was isolated as white crystals with a yield of 139 mg (85%).  Rf: 0.37 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 1.47 (m, 3H; H4ax, H5ax, H6eq), 1.86 (s, 
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3H; CH3), 1.97 (m, 3H; H3eq, H4eq, H5eq), 2.21 (m, 1H; H6ax), 2.28 (m, 1H; H3ax), 4.58 (ddd, 
J = 13.4, 9.3, 3.1 Hz, 1H; H2), 5.15 (dt, J = 10.5, 4.7 Hz, 1H; H1), 7.33 (m, 1H; Ph), 7.42 (m, 
2H; Ph), 7.77 (s, 1H; triazolyl), 7.83 (m, 2H; Ph).  13C NMR (150MHz, CDCl3): δ 20.80 
(COCH3), 23.76 (C5), 24.58 (C4), 32.36 (C3), 33.66 (C6), 63.26 (C2), 73.86 (C1), 118.00 (CH; 
triazolyl), 125.34 (2CH; Ph), 128.12 (CH; Ph), 128.99 (2CH; Ph), 130.21 (C; Ph), 149.94 (C; 
triazolyl), 171.37 (C=O).  HRMS: C16H20N3O2
+ [M+H]Cal m/z 286.1550; [M+H]exp m/z 286.1557. 
2-(4,5-diphenyl-1H-1,2,3-triazol-1-yl)cyclohexanol (18c) 
 
Compound 18c was isolated as white crystals with a yield of 124 mg (83%).  Rf: 0.31 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 1.15 (m, 1H; H5ax), 1.43 (m, 2H; H4ax, 
H5eq), 1.77 (m, 3H; H3eq, H3ax, H4eq), 2.09 (m, 1H; H6ax), 2.26 (m, 1H; H6eq), 3.85 (m, 1H; 
H2), 4.48 (ddd, J = 12.4, 8.1, 2.8 Hz, 1H; H1), 7.16 (m, 7H; Ph), 7.33 (m, 2H; Ph), 7.40 (m, 1H; 
Ph).  13C NMR (150MHz, CDCl3): δ 24.30 (C5), 24.99 (C4), 32.42 (C3), 34.09 (C6), 64.92 (C2), 
72.32 (C1), 127.19 (2CH; Ph), 127.83 (CH; Ph), 128.39 (2CH; Ph), 129.02 (2CH; Ph), 129.52, 
129.83 (C; triazolyl), 130.71 (2C; Ph).  HRMS: C20H22N3O
+ [M+H]Cal m/z 320.1752; [M+H]exp 
m/z 320.1760. 
Compounds 24a and 25a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 21a and 21b with 1-octyne. Products remained a mixture and were NOT 
separated by column chromatography to give a colorless oil of both 24a and 25a with a yield of 
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1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 6.8 Hz, 3H; CH3), 1.08 (t, J = 6.9 Hz, 3H; 
CH3), 1.27 (m, 6H; CH2), 1.31 (m, 1H; H4), 1.64 (m, 6H; H5ax, H5eq, CH2), 1.97 (m, 2H; H3ax, 
H3eq), 2.19 (m, 2H; H6ax, H6eq), 2.63 (q, J = 7.8 Hz, 2H; CH2), 3.59 (br.s, 1H; OH), 3.98 (m, 
1H; H1), 4.07 (m, 1H; H2),  7.28 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 13.62, 20.44 
(CH3), 21.98, 26.37, 28.09 (CH2), 28.92 (C6), 29.12 (C3), 30.11 (C5), 30.59 (CH2), 30.68 (C4), 
31.72 (CH2), 63.81 (C2), 69.48 (C1), 127.02 (CH; triazolyl), 138.72 (C; triazolyl).  HRMS: 
C15H27N3O
+ [M+H]Cal m/z 265.2154; [M+H]exp m/z 265.2160. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-methylcyclohexanol (25a) 
 
1H NMR (600 MHz, CD3OD): δ 0.86 (t, J = 6.8 Hz, 3H; CH3), 1.08 (t, J = 6.9 Hz, 3H; 
CH3), 1.27 (m, 4H; CH2), 1.31 (m, 2H; H4ax, H4eq), 1.44 (m, 3H; H5, CH2), 1.97 (m, 2H; H6ax, 
H6eq), 2.09 (m, 2H; H3ax, H3eq), 2.19 (m, 2H; CH2), 2.63 (q, J = 7.8 Hz, 2H; CH2), 3.48 (br.s, 
1H; OH), 4.03 (ddd, J = 12.7, 8.4, 3.5 Hz, 1H; H1), 4.42 (m, 1H; H2),  7.31 (s, 1H; triazolyl).  
13C NMR (150MHz, CD3OD): δ 13.03, 21.42 (CH3), 22.73 (C4), 22.91, 25.27, 26.91 (CH2), 
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30.11 (C3), 31.13 (C5), 31.81, 31.98 (CH2), 42.31 (C6), 65.71 (C2), 70.47 (C1), 124.08 (CH; 
triazolyl), 142.07 (C; triazolyl).  HRMS: C15H27N3O
+ [M+H]Cal m/z 265.2154; [M+H]exp m/z 
265.2160. 
Compounds 33a and 34a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 30a and 30b with 1-octyne. Products remained a mixture and were NOT 
separated by column chromatography to give a yellow oil of both 33a and 34a with a yield of 
184 mg (84%).  Rf: 0.49 (Hex:EtOAc, 3:2).  Products 33a and 34a exist in a 1:1 ratio in the 
reaction mixture. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-4-methylcyclohexyl acetate (33a) 
 
1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 6.9 Hz, 3H; CH3), 1.10 (t, J = 6.9 Hz, 3H; 
CH3), 1.29 (m, 5H; CH2, H5eq), 1.71 (m, 6H; H5ax, H6eq, CH2), 1.89 (s, 3H; CH3), 1.97 (m, 
1H; H4), 2.11 (m, 3H; H3ax, H3eq, H6ax), 2.68 (m, 2H; CH2), 3.71 (br.s, 1H; OH), 4.70 (m, 1H; 
H2), 5.07 (td, J = 9.3, 4.5 Hz, 1H; H1),  7.31 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 
12.13, 19.87 (CH3), 20.83 (COCH3), 22.70 (CH2), 25.93 (C6), 26.44, 28.71 (CH2), 29.03 (C3), 
29.57 (C3), 30.85 (C5), 32.47 (CH2), 62.59 (C2), 73.41 (C1), 119.92 (CH; triazolyl), 137.33 (C; 
triazolyl), 172.12 (C=O).  HRMS: C17H30N3O2





2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-methylcyclohexyl acetate (34a) 
 
1H NMR (600 MHz, CDCl3): δ 0.87 (t, J = 6.9 Hz, 3H; CH3), 1.09 (t, J = 6.9 Hz, 3H; 
CH3), 1.34 (m, 6H; CH2, H4ax, H4eq), 1.71 (m, 6H; H6ax, H6eq, CH2), 1.89 (s, 3H; CH3), 2.02 
(m, 1H; H5),  2.11 (m, 2H; H3ax, H3eq), 2.68 (m, 2H; CH2), 3.76 (br.s, 1H; OH), 4.45 (td, J = 
9.7, 4.1 Hz, 1H: H2), 5.32 (td, J = 9.4, 4.3 Hz, 1H; H1),  7.31 (s, 1H; triazolyl).  13C NMR 
(150MHz, CDCl3): δ 12.15, 19.87 (CH3), 20.88 (COCH3), 22.70 (CH2), 24.40 (C3), 27.44, 
27.79, 28.05 (CH2), 28.89 (C4), 31.11 (C5), 32.47 (CH2), 36.00 (C6), 63.92 (C2), 70.34 (C1), 
121.45 (CH; triazolyl), 134.68 (C; triazolyl), 171.96 (C=O).  HRMS: C17H30N3O2
+ [M+H]Cal m/z 
308.2333; [M+H]exp m/z 308.2342. 
Compounds 24b and 25b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 21a and 21b with phenylacetylene. Products remained a mixture and were 
NOT separated by column chromatography to give white crystals of both 24b and 25b with a 
yield of 209 mg (84.3%).  Rf: 0.41 (Hex:EtOAc, 3:2).  Products 24b and 25b exist in a 1:1 ratio 









1H NMR (600 MHz, CDCl3): δ 1.12 (d, J = 7.2 Hz, 3H; CH3), 1.65 (m, 1H; H4), 1.74 (m, 
2H; H5ax, H5eq), 2.02 (m, 2H; H3eq, H6eq), 2.23 (m, 2H; H3ax, H6ax), 3.25 (br.s, 1H; OH), 
4.08 (m, 1H; H1), 4.44 (ddd, J = 12.6, 8.5, 3.6 Hz, 1H; H2), 7.32 (m,1H; Ph), 7.38 (m, 2H; Ph), 
7.73 (m, 2H; Ph), 7.28 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 20.68 (CH3), 25.53 
(C3), 25.96 (C6), 28.06 (C5), 30.01 (C4), 64.23 (C2), 70.92 (C1), 126.02, 126.34, 126.92 (CH; 
Ph), 127.02 (CH; triazolyl), 131.28, 131.88 (CH; Ph), 133.69 (C; Ph), 149.31 (C; triazolyl).  
HRMS: C15H20N3O
+ [M+H]Cal m/z 258.1601; [M+H]exp m/z 258.1609. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-methylcyclohexanol (25b) 
 
1H NMR (600 MHz, CDCl3): δ 1.24 (s, 3H; CH3), 1.65 (m, 1H; H5), 1.72 (m, 2H; H4ax, 
H4eq), 2.02 (m, 2H; H6ax, H6eq), 2.23 (m, 2H; H3ax, H3eq), 3.25 (br.s, 1H; OH), 4.12 (m, 1H; 
H1), 4.39 (ddd, J = 12.7, 8.4, 3.3 Hz, 1H; H2), 7.33 (m,1H; Ph), 7.38 (m, 2H; Ph), 7.73 (m, 2H; 
Ph), 7.28 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 21.44 (CH3), 24.61 (C3), 27.02 (C5), 
28.47 (C4), 41.28 (C6), 65.01 (C2), 69.52 (C1), 126.02, 126.34, 126.92 (CH; Ph), 126.98 (CH; 
triazolyl), 131.28, 131.88 (CH; Ph), 133.69 (C; Ph), 149.24 (C; triazolyl).  HRMS: C15H20N3O
+ 
[M+H]Cal m/z 258.1601; [M+H]exp m/z 258.1609. 
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Compounds 33b and 34b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 30a and 30b with phenylacetylene. Products remained a mixture and were 
NOT separated by column chromatography to give yellow crystals of both 33b and 34b with a 
yield of 193 mg (91%).  Rf: 0.46 (Hex:EtOAc, 3:2).  Products 33b and 34b exist in a 1:1 ratio in 
the reaction mixture. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)-4-methylcyclohexyl acetate (33b) 
 
1H NMR (600 MHz, CDCl3): δ 1.12 (t, J = 3.6 Hz, 3H; CH3), 1.70 (m, 4H; H5ax, H5eq, 
H6ax, H6eq), 1.91 (s, 3H; CH3), 2.01 (m, 1H; H4), 2.19 (m, 2H; H3ax, H3eq), 4.78 (m. 1H; H2), 
5.15 (td, J = 9.3, 4.6 Hz, 1H; H1), 7.32 (s, 1H; triazolyl) 7.40 (m, 2H; Ph), 7.81 (m, 3H; Ph).  13C 
NMR (150MHz, CDCl3): δ 21.36 (CH3), 22.67 (COCH3), 23.96 (C3), 27.88 (C6), 29.04 (C5), 
32.83 (C4), 61.27 (C2), 71.07 (C1), 122.66 (CH; triazolyl), 125.23, 125.87, 128.93, 129.11, 
129.94 (CH; Ph), 131.55 (C; Ph), 136.94 (C; triazolyl), 170.27 (C=O).  HRMS: C17H30N3O2
+ 








2-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-methylcyclohexyl acetate (34b) 
 
1H NMR (600 MHz, CDCl3): δ 1.14 (t, J = 3.6 Hz, 3H; CH3), 1.70 (m, 4H; H4ax, H4eq, 
H6ax, H6eq), 1.93 (s, 3H; CH3), 2.01 (m, 1H; H5), 2.21 (m, 2H; H3ax, H3eq), 4.53 (m. 1H; H2), 
5.40 (td, J = 9.4, 4.4 Hz, 1H; H1), 7.30 (s, 1H; triazolyl), 7.40 (m, 2H; Ph), 7.81 (m, 3H; Ph).  
13C NMR (150MHz, CDCl3): δ 21.31 (CH3), 22.94 (COCH3), 24.14 (C3), 29.92 (C5), 30.21 
(C4), 37.36 (C6), 61.27 (C2), 71.12 (C1), 123.01 (CH; triazolyl), 125.23, 125.87, 128.93, 129.11, 
129.94 (CH; Ph), 130.79 (C; Ph), 137.36 (C; triazolyl), 170.10 (C=O).  HRMS: C17H30N3O2
+ 
[M+H]Cal m/z 300.1707; [M+H]exp m/z 300.1732. 
Compounds 26a and 27a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 22a and 22b with 1-octyne. Products remained a mixture and were NOT 
separated by column chromatography to give a colorless oil of both 26a and 27a with a yield of 
141 mg (83%).  Products 26a and 27a exist in a 1:1 ratio in the reaction mixture.’ 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-4-phenylcyclohexanol (26a) 
 
1H NMR (600 MHz, CD3OD): δ 0.87 (t, J = 5.7 Hz, 3H; CH3), 1.32 (m, 6H; CH2), 1.65 
(m, 2H; CH2), 1.87 (m, 2H; H5ax, H5eq), 1.98 (m, 1H; H6eq), 2.05 (s, 3H; CH3), 2.14 (m, 2H; 
H5ax, H6ax)), 2.51 (m, 1H; H3ax), 2.55 (m, 1H; H3eq), 2.72 (t, J = 7.8 Hz, 2H; CH2), 3.25 
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(sept, J = 3.6 Hz, 1H; H4), 4.15 (dt, J = 7.4, 3.7 Hz, 1H; H1), 4.46 (m, 1H; H2), 7.21 (m, 1H; 
Ph), 7.36 (m, 2H; Ph), 7.41 (m, 2H; Ph), 7.52 (s, 1H; triazolyl).  13C NMR (150MHz, CD3OD): δ 
13.82 (CH3), 20.67, 21.24 (CH2), 23.32 (C5), 24.63 (CH2), 25.49 (C6), 26.89, 31.31 (CH2), 32.35 
(C3), 35.28 (C4), 63.38 (C2), 70.02 (C1), 123.02 (CH; triazolyl), 126.38 (CH; Ph), 128.23, 
129.02 (2CH; Ph), 146.09 (C; triazolyl), 148.33 (C; Ph).  HRMS: C20H30N3O
+ [M+H]Cal m/z 
328.2383; [M+H]exp m/z 328.2376. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-phenylcyclohexanol (27a) 
 
1H NMR (600 MHz, CD3OD): δ 0.88 (t, J = 5.7 Hz, 3H; CH3), 1.30 (m, 4H; CH2), 1.38 
(m, 2H; CH2), 1.74 (m, 2H; CH2), 1.85 (m, 1H; H6eq), 1.95 (m, 1H; H5eq), 2.01 (s, 3H; CH3), 
2.09 (m, 1H; H6ax), 2.21 (m, 1H; H5ax), 2.46 (m, 1H; H3ax), 2.57 (m, 1H; H3eq), 2.89 (t, J = 
7.8 Hz, 2H; CH2), 3.33 (sept, J = 3.8 Hz, 1H; H4), 4.27 (dt, J = 7.5, 3.6 Hz, 1H; H1), 4.43 (m, 
1H; H2), 7.26 (m, 1H; phenyl), 7.32 (m, 2H; Ph), 7.37 (m, 2H; Ph), 7.58 (s, 1H; triazolyl).  13C 
NMR (150MHz, CD3OD): δ 13.21 (CH3), 21.89, 22.27, 23.47 (CH2), 26.52 (C5), 26.88 (C6), 
27.99, 32.36 (CH2), 33.86 (C3), 34.97 (C4), 62.35 (C2), 71.84 (C1), 125.01 (CH; triazolyl), 
128.31 (CH; Ph), 129.29, 129.66 (2CH; Ph), 147.20 (C; triazolyl), 149.84 (C; Ph).  HRMS: 
C20H30N3O
+ [M+H]Cal m/z 328.2383; [M+H]exp m/z 328.2376. 
Compounds 35a and 36a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 31a and 31b with 1-octyne. Products were separated by column 
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chromatography (silica gel; Hex:EtOAc, 7:3)  to give a colorless oil for both 35a and 36a.  
Products 35a and 36a exist in a 1:1 ratio in the reaction mixture. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-4-phenylcyclohexyl acetate (35a) 
 
Compound 35a was isolated a colorless oil with a yield of 93 mg (42%).  Rf: 0.74 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 0.89 (t, J = 5.7 Hz, 3H; CH3), 1.30 (m, 4H; 
CH2), 1.38 (m, 2H; CH2), 1.74 (m, 2H; CH2), 1.85 (m, 1H; H6eq), 1.95 (m, 1H; H5eq), 2.01 (s, 
3H; CH3), 2.09 (m, 1H; H6ax), 2.21 (m, 1H; H5ax), 2.46 (m, 1H; H3ax), 2.57 (m, 1H; H3eq), 
2.89 (t, J = 7.8 Hz, 2H; CH2), 3.33 (sept, J = 3.8 Hz, 1H; H4), 4.73 (dt, J = 11.0, 3.7 Hz, 1H; 
H2), 5.24 (dt, J = 10.7, 3.5 Hz, 1H; H1), 7.26 (m, 1H; Ph), 7.32 (m, 2H; Ph), 7.37 (m, 2H; Ph), 
7.58 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 14.10 (CH3), 21.00 (CH3), 22.58, 24.37 
(CH2), 26.37 (C6), 26.97 (C5), 28.81, 28.88, 31.45 (CH2), 34.27 (C3), 36.35 (C4), 60.52 (C2), 
71.84 (C1), 122.18 (CH; triazolyl), 126.77 (CH; Ph), 126.90, 128.95 (2CH; Ph), 142.45 (C; 
triazolyl), 146.38 (C; Ph), 169.98 (C=O).  HRMS: C22H32N3O2
+ [M+H]Cal m/z 370.2489; 







2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-phenylcyclohexyl acetate (36a) 
 
Compound 36a was isolated a colorless oil with a yield of 69 mg (31%).  Rf: 0.74 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 0.86 (t, J = 6.1 Hz, 3H; CH3), 1.30 (m, 6H; 
CH2), 1.64 (m, 2H; CH2), 1.95 (m, 1H; H4ax, H4eq), 2.05 (s, 3H; CH3), 2.20 (m, 3H; H3ax, H3eq, 
H6eq), 2.44 (m, 1H; H6ax), 2.72 (t, J = 7.6 Hz, 2H; CH2), 3.20 (sept, J = 3.8 Hz, 1H; H5), 4.63 
(m, 1H; H2), 5.39 (m, 1H; H1), 7.22 (m, 1H; Ph), 7.32 (m, 1H; triazolyl), 7.34 (m, 4H; Ph). 13C 
NMR (150MHz, CDCl3): δ 14.12 (CH3), 21.10 (COCH3), 22.61 (CH2), 25.21 (C3), 26.95, 28.70, 
28.93 (CH2), 29.20 (C4), 31.56 (CH2), 33.24 (C6), 36.83 (C5), 60.57 (C2), 70.92 (C1), 120.59 
(CH; triazolyl), 126.55 (CH; Ph), 127.03, 128.82 (2CH; Ph), 143.12 (C; triazolyl), 143.29 (C; Ph), 
170.16 (C=O).  HRMS: C22H32N3O2
+ [M+H]Cal m/z 370.2489; [M+H]exp m/z 370.2496. 
Compounds 26b and 27b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 22a and 22b with phenylacetylene. Products remained a mixture and were NOT 
separated by column chromatography to give white crystals of both 26b and 27b with a yield of 









1H NMR (600 MHz, CD3OD): δ 1.85 (m, 1H; H4ax), 1.96 (m, 1H; H4eq), 2.13 (m, 1H; 
H3eq), 2.35 (m, 1H; H3ax), 2.50 (m, 1H; H6eq), 2.60 (m, 1H; H6ax), 3.34 (m, 1H; H5), 4.31 (m, 
1H; H1), 4.41 (m, 1H; H2), 7.29 (m, 2H; Ph), 7.33 (m, 2H; Ph), 7.36 (s, 1H; triazolyl), 7.39 (m, 
2H; Ph), 7.75 (m, 4H; Ph).  13C NMR (150MHz, CD3OD): δ 26.3 (C4), 29.48 (C6), 30.82 (C3), 
43.25 (C5), 64.85 (C2), 70.38 (C1), 125.55, 125.61, 125.64, 125.68 (4CH; Ph), 126.83, 126.94 
(2CH; Ph), 128.41 (CH; triazolyl), 128.70 (C; Ph), 128.83, 128.91, 129.22, 129.52 (4CH; Ph), 
140.23 (C; Ph), 145.20 (C; triazolyl).  HRMS: C20H22N3O




1H NMR (600 MHz, CD3OD): δ 1.96 (m, 1H; H5ax), 2.13 (m, 1H; H5eq), 2.24 (m, 1H; 
H6ax), 2.35 (m, 1H; H6eq), 2.50 (m, 1H; H3eq), 2.68 (m, 1H; H3ax), 2.98 (m, 1H; H4), 4.40 (m, 
1H; H1), 4.41 (m, 1H; H2), 7.26 (m, 2H; Ph), 7.33 (m, 2H; Ph), 7.35 (s, 1H; triazolyl), 7.39 (m, 
2H; Ph), 7.75 (m, 4H; Ph).  13C NMR (150MHz, CD3OD): δ 21.84 (C3), 28.97 (C4), 33.36 (C6), 
42.21 (C5), 65.33 (C2), 69.94 (C1), 125.55, 125.62, 125.64, 125.68 (4CH; Ph), 126.83, 126.93 
(2CH; Ph), 128.39 (CH; triazolyl), 128.62 (C; Ph), 128.83, 128.91, 129.22, 129.53 (4CH; Ph), 
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140.28 (C; Ph), 145.37 (C; triazolyl).  HRMS: C20H22N3O
+ [M+H]Cal m/z 320.1757; [M+H]exp 
m/z 320.1752. 
Compounds 35b and 36b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 31a and 31b with phenylacetylene. Products were separated by column 
chromatography (silica gel; Hex:EtOAc, 7:3)  to give white crystals for both 35b and 36b.  
Products 35b and 36b exist in a 1:1 ratio in the reaction mixture. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)-4-phenylcyclohexyl acetate (35b) 
 
Compound 35b was isolated a colorless oil with a yield of 77 mg (71%).  Rf: 0.74 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.88 (m, 1H; H6ax), 1.95 (m, 1H; H5ax), 2.03 
(s, 3H; CH3), 2.18 (m, 2H; H5eq, H6eq), 2.55 (m, 2H; H3ax, H3eq), 3.38 (sept, J = 4.0 Hz, 1H; 
H4), 4.74 (m, 1H; H2), 5.37 (dt, J = 9.8, 3.3 Hz, 1H), 7.25 (m, 1H; triazolyl), 7.35 (m, 5H; Ph), 
7.43(m, 2H; Ph), 7.84 (m, 3H; Ph).  13C NMR (150MHz, CDCl3): δ 21.13 (C6), 26.42 (COCH3), 
27.20 (C5), 34.45 (C3), 36.67 (C4), 58.77 (C2), 72.00 (C1), 119.14, 125.80 (C; Ph), 126.56 (CH; 
triazolyl), 127.02 (C; Ph), 128.30 (2C, Ph), 128.82 (C; Ph), 128.95 (2C; Ph), 130.58 (C; triazolyl), 
143.46, 147.60 (C; Ph), 170.15 (C=O).  HRMS: C22H24N3O2






2-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-phenylcyclohexyl acetate (36b) 
 
Compound 36b was isolated a colorless oil with a yield of 96 mg (88%).  Rf: 0.66 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.98 (m, 2H; H4ax, H6ax), 2.07 (s, 3H; CH3), 
2.28 (m, 3H; H3ax, H3eq, H4eq), 2.50 (m, 1H; H6eq), 3.22 (sept, J = 4.1 Hz, 1H; H5), 4.71 (m, 
1H; H2), 5.48 (td, J = 6.5, 3.6 Hz, 1H), 7.23 (m, 1H; triazolyl), 7.33 (m, 1H; Ph), 7.35 (m, 4H; 
Ph), 7.42 (m, 2H; Ph), 7.78 (s, 1H; Ph), 7.82 (m, 2H; Ph).  13C NMR (150MHz, CDCl3): δ 21.17 
(C4), 27.12 (COCH3), 28.77 (C6), 33.26 (C3), 36.97 (C5), 52.28 (C2), 71.08 (C1), 117.95, 
121.99 123.02 (C; Ph), 125.94 (CH; triazolyl), 126.94, 127.05 (C; Ph), 129.34 (2C, Ph), 130.59 
(2C; Ph), 131.33 (C; triazolyl), 147.56 (C; Ph), 170.26 (C=O).  HRMS: C22H24N3O2
+ [M+H]Cal 
m/z 362.1863; [M+H]exp m/z 362.1889. 
Compounds 28a and 29a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 23a and 23b with 1-octyne. Products remained a mixture and were NOT 
separated by column chromatography to give a yellow oil of both 28a and 29a with a yield of 









1H NMR (600 MHz, CD3OD): δ 0.85 (s, 9H; C(CH3)3), 0.91 (m, 3H; CH3), 1.33 (m, 4H; 
CH2), 1.57 (m, 3H; H5ax, H5eq, H6ax), 1.68 (m, 3H; H4, CH2) 1.87 (m, 1H; H6eq), 2.25 (m, 
3H; H3ax, H3eq CH2), 2.69 (m, 2H; CH2), 4.43 (m, 1H; H1), 4.48 (m, 1H; H2), 7.79 (s, 1H; 
triazolyl).  13C NMR (150MHz, CD3OD): δ 13.02 (CH3), 20.18 (CH2), 22.14 (C3), 23.21 (C5), 
26.83 (3CH3), 29.38, 29.47 (CH2), 30.89 (C6), 31.43, 32.09 (CH2), 33.43 (C(CH3)3), 42.78 (C4), 
60.78 (C2), 68.65 (C1), 122.90 (CH; triazolyl), 147.39 (C; triazolyl).  HRMS: C18H34N3O
+ 
[M+H]Cal m/z 308.2696; [M+H]exp m/z 308.2702. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-(tert-butyl)-cyclohexanol (29a) 
 
1H NMR (600 MHz, CD3OD): δ 0.89 (s, 9H; C(CH3)3), 0.91 (m, 3H; CH3), 1.33 (m, 4H; 
CH2), 1.80 (m, 3H; H5, H6ax, H6eq), 2.03 (m, 1H; H4ax), 2.16 (m, 3H; H4eq, CH2), 2.31(m, 
4H; H3ax, H3eq, CH2), 2.69 (m, 2H; CH2), 4.37 (m, 1H; H1), 4.57 (q, J = 3.4 Hz, 1H; H2), 7.76 
(s, 1H; triazolyl).  13C NMR (150MHz, CD3OD): δ 13.02 (CH3), 21.38, 22.28 (CH2), 23.28 (C3), 
26.37 (C4), 28.75 (3CH3), 30.68 (CH2), 34.36 (C6), 33.43 (C(CH3)3), 35.25, 36.98(CH2), 47.23 
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(C5), 60.23(C2), 68.94 (C1), 122.32 (CH; triazolyl), 148.36 (C; triazolyl).  HRMS: C18H34N3O
+ 
[M+H]Cal m/z 308.2696; [M+H]exp m/z 308.2702. 
Compounds 37a and 38a were prepared in the same reaction. Reaction occurred in a 
mixture of azides 32a and 32b with 1-octyne. Products remained a mixture and were NOT 
separated by column chromatography to give a colorless oil of both 37a and 38a with a yield of 
188 mg (89%). Rf: 0.64 (Hex:EtOAc, 7:3).  Products 37a and 38a exist in a 1:1 ratio in the 
reaction mixture. 
2-(4-hexyl-1H-1,2,3-triazol-1-yl)-4-(tert-butyl)-cyclohexyl acetate (37a) 
 
1H NMR (600 MHz, CD3OD): δ 0.86 (s, 3H; CH3), 0.89 (s, 9H; C(CH3)3), 1.35 (m, 1H; 
H4), 1.45 (m, 2H; CH2), 1.65 (m, 6H; CH2), 1.92, (m, 2H; H6ax, H6eq), 2.10, (s, 3H; CH3), 2.11 
(m, 3H; H3eq, H5ax, H5eq), 2.30 (m, 1H; H3ax), 2.70 (t, J = 7.7 Hz, 2H; CH2), 4.58 (m, 1H; H2), 
5.52 (m, 1H; H1), 7.81 (m, 1H; triazolyl). 13C NMR (150MHz, CD3OD): δ 13.24 (CH3), 19.68 
(CH3), 21.07, 21.34 (CH2), 22.30 (C5), 26.18 (C3), 26.30 (3CH3), 26.74, 28.52, 31.35 (CH2), 31.70 
(C(CH3)3), 40.73 (C4), 57.25 (C2), 71.12 (C1), 121.37 (CH; triazolyl), 147.65 (C; triazolyl), 
170.36 (C=O).  HRMS: C20H36N3O2






2-(4-hexyl-1H-1,2,3-triazol-1-yl)-5-(tert-butyl)-cyclohexyl acetate (38a) 
 
1H NMR (600 MHz, CD3OD): δ 0.86 (s, 3H; CH3), 0.90 (s, 9H; C(CH3)3), 1.35 (m, 6H; 
CH2), 1.51 (m, 2H; CH2), 1.54 (m, 1H; H5), 1.90, (m, 2H; H3ax, H3eq), 2.12, (s, 3H; CH3), 2.11 
(m, 2H; H4ax, H4eq), 2.25 (m, 1H; H6eq), 2.32 (m, 1H; H6ax), 2.70 (t, J = 7.7 Hz, 2H; CH2), 
4.71 (m, 1H; H2), 5.44 (m, 1H; H1), 7.84 (m, 1H; triazolyl).  13C NMR (150MHz, CD3OD): δ 
13.04 (CH3), 20.65 (CH3), 21.07, 21.45 (CH2), 24.87 (C4), 26.18 (C3), 26.36 (3CH3), 27.45, 
29.18, 31.35 (CH2), 31.70 (C(CH3)3), 40.88 (C5), 58.57 (C2), 69.34 (C1), 121.54 (CH; triazolyl), 
147.55 (C; triazolyl), 170.36 (C=O).  HRMS: C20H36N3O2
+ [M+H]Cal m/z 350.2802; [M+H]exp 
m/z 350.2814. 
Compounds 28b and 29b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 23a and 23b with phenylacetylene. Products remained a mixture and were 
NOT separated by column chromatography to give colorless crystals of both 28b and 29b with a 
yield of 148 mg (71%). Rf: 0.25 (Hex:EtOAc, 7:3).  Products 28b and 29b exist in a 1:1 ratio in 









1H NMR (600 MHz, CD3OD): δ 0.88 (s, 9H; C(CH3)3), 1.48 (m, 1H; H5eq), 1.61 (m, 3H; 
H4, H5ax, H6eq), 1.86 (m, 2H; H3eq, H6ax), 2.08, (m, 1H; H3ax), 4.52 (q, J = 3.5 Hz, 1H; H1), 
4.55 (q, J = 3.3 Hz, 1H; H2), 7.35 (m, 1H; Ph), 7.44 (m, 2H; Ph), 7.84 (m, 2H; Ph), 8.40 (m, 1H; 
triazolyl).  13C NMR (150MHz, CD3OD): δ 20.08 (C3), 25.56 (C5), 26.47 (3CH3), 28.49 (C6), 
31.73 (C(CH3)3), 39.80 (C4), 62.05 (C2), 68.19 (C1), 120.63 (CH; triazolyl), 125.35 (2C; Ph), 
127.99 (C; Ph), 128.64 (2C; Ph), 130.42 (C; Ph), 147.03 (C; triazolyl).  HRMS: C18H26N3O
+ 
[M+H]Cal m/z 300.2070; [M+H]exp m/z 300.2068. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-(tert-butyl)-cyclohexanol (29b) 
 
1H NMR (600 MHz, CD3OD): δ 0.92 (s, 9H; C(CH3)3), 1.68 (m, 3H; H5, H4ax, H6eq), 
1.86 (m, 2H; H4eq, H6ax), 2.35, (m, 2H; H3ax, H3eq), 4.42 (q, J = 3.2 Hz, 1H; H1), 4.66 (q, J = 
3.6 Hz, 1H; H2), 7.35 (m, 1H; Ph), 7.44 (m, 2H; Ph), 7.84 (m, 2H; Ph), 8.37 (m, 1H; triazolyl). 
13C NMR (150MHz, CD3OD): δ 21.44 (C3), 26.47 (3CH3), 26.73 (C4), 29.24 (C6), 31.96 
(C(CH3)3), 41.22 (C5), 62.91 (C2), 66.70 (C1), 120.45 (CH; triazolyl), 125.35 (2C; Ph), 127.99 
(C; Ph), 128.64 (2C; Ph), 130.42 (C; Ph), 147.03 (C; triazolyl).  HRMS: C18H26N3O
+ [M+H]Cal 
m/z 300.2070; [M+H]exp m/z 300.2068. 
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Compounds 37b and 38b were prepared in the same reaction. Reaction occurred in a 
mixture of azides 32a and 32b with phenylacetylene.. Products remained a mixture and were 
NOT separated by column chromatography to give white crystals of both 37b and 38b with a 
yield of 167 mg (78%). Rf: 0.72 (Hex:EtOAc, 7:3).  Products 37b and 38b exist in a 1:1 ratio in 
the reaction mixture. 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)-4-(tert-butyl)-cyclohexyl acetate (37b) 
 
1H NMR (600 MHz, CD3OD): δ 0.85 (s, 9H; C(CH3)3), 1.52 (m, 2H; H5ax, H5eq), 1.62 (m, 1H; 
H4), 1.71 (m, 2H; H3ax, H6ax), 2.10 (s, 3H; CH3), 2.18 (m, 1H; H3eq), 2.36, (m, 2H; H6eq), 
4.58 (m, 1H; H2), 5.52 (m, 1H; H1), 7.33 (m, 1H; Ph), 7.42 (m, 2H; Ph), 7.78 (m, 2H; Ph), 8.36 
(m, 1H; triazolyl). 13C NMR (150MHz, CD3OD): δ 21.54 (CH3), 22.94 (C3), 23.79 (C5), 26.08 
(C6), 27.02 (3CH3), 32.21 (C(CH3)3), 43.67 (C4), 61.99 (C2), 72.14 (C1), 121.97 (CH; triazolyl), 
122.48 (2C; Ph), 126.85 (C; Ph), 128.86 (2C; Ph), 130.05 (C; Ph), 147.62 (C; triazolyl), 172.34 
(C=O).  HRMS: C20H28N3O2








2-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-(tert-butyl)-cyclohexyl acetate (38b) 
 
1H NMR (600 MHz, CD3OD): δ 0.88 (s, 9H; C(CH3)3), 1.55 (m, 2H; H4ax, H6ax), 1.71 
(m, 1H; H5), 1.93 (m, 3H; H4eq, H6eq, H3ax), 2.10 (s, 3H; CH3), 2.18 (m, 1H; H3eq), 4.67 (m, 
1H; H2), 5.58 (m, 1H; H1), 7.33 (m, 1H; Ph), 7.42 (m, 2H; Ph), 7.78 (m, 2H; Ph), 8.38 (m, 1H; 
triazolyl).  13C NMR (150MHz, CD3OD): δ 21.05 (CH3), 23.64 (C4), 24.07 (C3), 27.02 (3CH3), 
28.24 (C6), 32.21 (C(CH3)3), 42.03 (C5), 63.21 (C2), 70.24 (C1), 121.36 (CH; triazolyl), 122.48 
(2C; Ph), 126.85 (C; Ph), 128.86 (2C; Ph), 129.34(C; Ph), 146.38 (C; triazolyl), 171.58(C=O).  
HRMS: C20H28N3O2
+ [M+H]Cal m/z 342.4547; [M+H]exp m/z 342.4552. 
Diethyl-5-(4-hexyl-1,2,3-triazolyl)-4-hydroxy-1,2-cyclohexanedicarboxylate (11a) 
 
Product was purified by column chromatography (silica gel; Hex:EtOAc, 4:1) to give 
1.61 g (84%) of colorless oil of pure triazole.   1H NMR (600 MHz, CD3OD): δ 0.90 (t, J =7.0 
Hz, 3H; CH3, hexyl), 1.28 (t, J =7.0 Hz, 3H; CH3), 1.29 (t, J =7.0 Hz, 3H; CH3), 1.36 (m, 6H; 
CH2, hexyl), 1.68 (quintet, J =7.0 Hz, 2H; CH2, hexyl), 1.80 (ddd, J=13.7, 9.2, 4.7 Hz, H3ax), 
2.33 (m, 2H, H3eq, H6ax), 2.42 (m, 1H, H6eq), 2.70 (t, J =7.6 Hz, 2H; CH2, hexyl), 3.32 (m, 2H, 
H1, H2), 4.09 (m, 1H; H4), 4.14 (m, 4H; OCH2), 4.48 (ddd, J =9.2, 8.5, 4.5 Hz, 1H; H5), 7.81 (s, 
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1H; triazolyl).13C NMR (600 MHz, CD3OD): δ 13.04 (CH3, hexyl), 13.12 (CH3, Et), 22.28, 
25.06, 29.14, 28.62 (CH2, hexyl), 28.72 (C6), 31.36 (CH2, hexyl) 31.64 (C3), 40.27 (C2), 40.36 
(C1), 60.92, 60.99 (OCH2), 62.07 (C5), 67.97 (C4), 122.61 (CH; triazolyl), 126.67(C; triazolyl), 
173.24, 173.43(C=O).  HRMS: C20H34N3O5 [M+H]Cal m/z 396.2493; [M+H]exp m/z 396.2511. 
Diethyl-5-(4-hexyl-1,2,3-triazolyl)-4-acetoxy-1,2-cyclohexanedicarboxylate (11b) 
 
Product was purified by column chromatography (silica gel; Hex:EtOAc, 4:1) to give 
2.19 g (77%) of colorless oil of pure triazole.  1H NMR (600 MHz, CDCl3): δ 0.87 (t, J = 7.1 Hz, 
CH3), 1.28 (t, J =7.1 Hz, 3H; CH3), 1.29 (t, J =7.1 Hz, 3H; CH3), 1.32 (m, 2H;,CH2,hexyl), 1.70 
(m, 2H; CH2, hexyl), 1.82 (m, 1H, H3ax), 2.29 (m, 2H, H3eq, H6ax), 2.48 (m, 1H, H6eq), 2.68 
(t, J =7.6 Hz, 2H; CH2, hexyl), 3.26 (q, J =5.1 Hz, 1H, H2), 3.38 (q, J =5.1 Hz, 1H, H1),  4.20 
(m, 4H; OCH2), 4.63 (td, J = 8.3, 4.0 Hz, 1H; H5), 5.25 (td, J = 8.2, 4.0 Hz, 1H; H4),  7.34(s, 
1H; triazolyl).  13C NMR (600 MHz, CDCl3): δ 12.25 (CH3, hexyl), 13.95 (CH3, Et), 20.17 (CH3-
Acetyl), 22.54, 25.85, 29.64, 28.64 (CH2, hexyl), 29.01 (C6), 31.54 (CH2, hexyl) 31.78 (C3), 
40.67 (C2), 40.92 (C1), 61.28, 61.39 (OCH2), 65.28 (C5), 71.36 (C4), 123.68 (CH; triazolyl), 
129.58(C; triazolyl), 168.34, 172.54, 173.95 (C=O).  HRMS: C22H36N3O6
+ [M+H]Cal m/z 





Diethyl- 5-(4-phenyl-1,2,3-triazolyl)-4-hydroxy-1,2-cyclohexanedicarboxylate (12a) 
 
Product was purified by column chromatography (silica gel; Hex:EtOAc, 2:1) to give 
1.84 g (81%) of white crystals of pure triazole.  1H NMR (600 MHz, CD3OD): δ 1.25 (t, J =7.0 
Hz, 3H; CH3), 1.29 (t, J =7.1 Hz, 3H; CH3), 1.85 (ddd, J =13.6, 11.7, 5.3 Hz, 1H; H3ax), 2.47 
(dtd, J =13.5, 4.3, 1.4 Hz 1H; H6ax), 2.57 (m, 2H; H3eq, H6eq), 2.93 (dt, J=12.8, 4.2 Hz, 1H, 
H1), 3.43 (m, 1H, H2), 4.03 (ddd, J =11.6, 10.1, 4.4 Hz, 1H; H4), 4.18 (m, 4H; OCH2), 4.42 
(ddd, J =12.6, 10.0, 4.4 Hz, 1H; H5), 7.34 (m, 1H; Ph), 7.43 (m, 2H; Ph), 7.83 (m, 2H; Ph), 8.32 
(s, 1H; triazolyl).  13C NMR (600 MHz, CD3OD): δ 13.06 (CH3), 13.14 (CH3), 29.75 (C6), 34.93 
(C3), 41.36 (C2), 41.89 (C1), 60.66, 60.77 (OCH2), 65.50 (C5), 68.55 (C4), 120.82 (CH; 
triazolyl), 125.34 (2C; Ph), 127.92 (1C; Ph), 128.62 (2C; Ph), 130.54 (1C; Ph), 146.95 (C; 
triazolyl), 172.46, 172.82 (C=O).  HRMS: C20H26N3O5
+ [M+H]Cal m/z 388.1867; [M+H]exp m/z 
388.1895. 
Diethyl- 5-(4-phenyl-1,2,3-triazolyl)-4-acetoxy-1,2-cyclohexanedicarboxylate (12b)  
 
Product was purified by column chromatography (silica gel; Hex:EtOAc, 4:1) to give 
1.67 g (75%) of colorless oil of pure triazole.  1H NMR (600 MHz, CD3OD): δ 1.29 (t, J =7.1 
Hz, 3H; CH3), 1.30 (t, J =7.1 Hz, 3H; CH3), 1.94 (m, 1H; H3ax), 1.95(s, 3H, CH3), (dtd, J =13.5, 
223 
4.3, 1.4 Hz 1H; H6ax), 2.57 (m, 2H; H3eq, H6eq), 3.31 (dt, J=12.8, 4.2 Hz, 1H, H1), 3.43 (m, 
1H, H2), 4.03 (ddd, J =11.6, 10.1, 4.4 Hz, 1H; H4), 4.18 (m, 4H; OCH2), 4.48 (m, 1H; H5), 5.38 
(ddd, J =12.6, 10.0, 4.4 Hz, 1H; H4), 7.34 (m, 1H; Ph), 7.43 (m, 2H; Ph), 7.83 (m, 2H; Ph), 8.32 
(s, 1H; triazolyl).  13C NMR (600 MHz, CD3OD): δ 14.14 (CH3), 14.18 (CH3), 20.82 (CH3; 
Acetyl), 28.85 (C3), 29.15 (C6), 40.07 (C1), 40.020 (C2), 58.64 (C5), 61.43, 61.46 (OCH2), 
70.25 (C4), 118.76 (CH; triazolyl), 125.71 (2C; Ph), 128.23 (1C; Ph), 128.83 (2C; Ph), 130.40 
(1C; Ph), 147.59 (C; triazolyl), 169.47, 172.60, 172.85 (C=O).  HRMS: C22H27N3O6
+ [M+H]Cal 
m/z 430.1978; [M+H]exp m/z 430.1945. 
Dimethyl-5-(4-hexyl-1,2,3-triazolyl)-4-hydroxy-1,2-cyclohexanedicarboxylate (53a) 
 
A crude product initially of 0.41 g was obtained.  Product was purified by column 
chromatography (Hex:EtOAc/ 4:2) to give 282 mg (72%) of colorless oil of pure triazole.  1H 
NMR (600 MHz, CDCl3): δ 0.88 (t, J =7.0 Hz, 3H; CH3, hexyl), 1.31 (m, 6H; CH2, hexyl), 1.62 
(quintet, J =7.6 Hz, 2H; CH2, hexyl), 2.04 (dt, J =13.2, 11.5 Hz, 1H; H3ax), 2.29 (ddd, J =13.7, 
12.7, 5.0 Hz, 1H; H6ax), 2.49 (dt, J =13.7, 4.7 Hz, 1H; H3eq), 2.57 (dt, J =13.7, 3.5 Hz, 1H; H6eq), 
2.63 (dd, J =9.2, 7.2 Hz, 2H; CH2, hexyl), 2.77 (dt, J =13.0, 4.0 Hz, 1H; H2), 3.42 (q, J =4.0 Hz, 
1H; H1), 3.69 (m, OH), 3.72 (S, 3H; OCH3), 3.73 (S, 3H; OCH3), 4.15 (ddd, J =11.2, 9.7, 4.7 Hz, 
1H; H4), 4.30 (ddd, J =12.1, 9.7, 4.2 Hz, 1H; H5), 7.33 (s, 1H; triazolyl).  13C NMR (600 MHz, 
CDCl3): δ 14.13 (CH3, hexyl), 22.62, 25.65, 29.05, 29.36 (CH2, hexyl), 31.50 (C3), 31.64 (CH2, 
hexyl) 32.04 (C6), 41.02 (C1), 42.01 (C2), 52.27, 52.38 (OCH3), 62.64 (C5), 71.43 (C4), 121.52 
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(CH; triazolyl), 147.87(C; triazolyl), 172.55, 172.69(C=O).  HRMS: C18H30N3O5
+ [M+H]Cal m/z 




A crude product initially of 351 mg was obtained.  Product was purified by column 
chromatography (Hex:EtOAc/ 4:2) to give 0.30 g (75%) of colorless oil of pure triazole.  1H 
NMR (600 MHz, CDCl3): δ 2.07 (q, J =12.8 Hz, 1H; H3ax), 2.41 (td, J =13.1, 4.9, 1H; Hz, 
H6ax), 2.54 (dt, J =13.6, 3.9 Hz, 1H; H3eq), 2.60 (dt, J =13.6, 3.3 Hz, 1H; H6eq), 2.81 (dt, J 
=12.9, 4.0 Hz, 1H; H2), 3.45 (q, J =4.1 Hz, 1H; H1), 3.73 (S, 3H; OCH2), 3.75 (S, 3H; OCH3), 
4.20 (m, 1H; H4), 4.21 (m, 1H; OH), 4.37 (ddd, J =12.6, 9.2, 4.1 Hz, 1H; H5), 7.29 (m,1H; Ph), 
7.34 (m, 2H; Ph), 7.59 (m, 2H; Ph), 7.73 (s, 1H; triazolyl).  13C NMR (600 MHz, CDCl3): δ 
31.59 (C3), 31.87 (C6), 41.06 (C1), 42.11 (C2), 52.30, 52.41 (OCH3), 63.32 (C5), 71.54 (C4), 
120.90 (CH; triazolyl), 125.50 (2C; Phenyl), 128.22 (2C; Ph), 128.86 (C; Ph), 130.06 (C; Ph), 
146.85(C; triazolyl), 172.53, 172.66(C=O).  HRMS: C18H22N3O5 [M+H]Cal m/z 360.1554; 










Product was isolated as colorless oil with a yield of 180 mg (81%).  Rf: 0.64 
(Hex:EtOAc, 9:1).  1H NMR (600 MHz, CDCl3): δ 0.90 (t, J = 6.9 Hz, 3H; CH3), 1.33 (m, 4H; 
CH2), 1.55 (m, 2H; H4ax, H4eq), 1.51 (m, 4H; H3ax, H5ax), 1.78 (m, 4H; CH2), 1.92 (m, 2H; 
H3eq, H5eq), 2.13 (m, 2H; H2ax, H6ax), 2.67 (m, 2H; H2eq, H6eq), 2.75 (t, J = 7.1Hz, 2H; 
CH2), 4.44 (tt, J = 11.8, 3.9 Hz, 1H; H1), 7.78 (s, 1H; triazolyl).  
13C NMR (150 MHz, CDCl3): 
14.13 (CH3), 22.83 (CH2), 25.14 (C4), 25.93 (C3), 26.01(C5), 27.03, 28.93, 29.11, 30.34 31.95 
(CH2), 31.02 (C6), 31.98 (C2), 60.81 (C1) 128.14 (CH; triazolyl), 145.21 (C; triazolyl).  HRMS: 
C14H26N3 [M+H]cal m/z 236.2121; [M+H]exp m/z 236.2209. 
Cyclohexyl-4-phenyl-1H-1,2,3-triazole (40b) 
 
Product was isolated as white crystals with a yield of 175 mg (85%).  Rf: 0.62 
(Hex:EtOAc, 9:1).  1H NMR (600 MHz, CD3OD): δ 1.35 (m, 1H; H4ax), 1.55 (m, 2H; H3ax, 
H5ax), 1.80 (m, 1H; H4eq), 1.92 (m, 4H; H2ax, H6ax, H3eq, H5eq), 2.22 (m, 2H; H2eq, H6eq), 
4.53 (tt, J = 11.7, 3.9 Hz, 1H; H1), 7.33 (m, 1H; Ph), 7.43 (m, 2H; Ph), 7.82 (m, 2H; Ph), 8.36 (s, 
1H; triazolyl).  13C NMR (150 MHz, CD3OD): 25.31 (C3), 25.86 (C5), 26.01 (C4), 31.13(C2), 
31.95 (C6), 59.34 (C1), 125.34, 126.91 (2CH; Ph), 127.91 (CH; Ph), 129.00 (C; Ph), 129.18 




Compounds exist as a mixture of cis and trans configurational isomers of 43a.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded a colorless oil 134 mg (62%) 
of both isomers.  Rf: 0.42 (Hex:EtOAc, 5:2). 
 
43a-cis 1H NMR (600 MHz, CDCl3): δ 0.89 (t, J = 7.1 Hz, 3H; CH3), 1.00 (d, J = 6.5 Hz, 
1H, H4), 1.32 (m, 6H; CH2), 1.41 (m, 2H; H3eq, H5eq), 1.64 (m, 4H; H3ax, H5ax, CH2), 1.64 
(m, 2H, CH2), 1.82(m, 1H; H4), 1.93 (m, 2H; H2eq, H6eq), 2.24(m, 2H; H2ax, H6ax), 2.67 (t,  J 
= 7.5 Hz, 1H; CH2), 4.49 (septet, J = 4 Hz, 1H; H1), 7.78 (s, 1H; triazolyl).  
13C NMR (150 
MHz, CDCl3): δ 14.12 (CH3), 22.21 (CH3), 23.10, 25.09, 29.84, 31.24, 32.86 (CH2), 32.15 (C4), 
33.99 (C2, C6), 34.28 (C3, C5), 61.38 (C1), 121.28 (CH; triazolyl), 148.36 (C; triazolyl).  
HRMS: C15H28N3 [M+H]cal m/z 250.2278; [M+H]exp m/z 250.2271. 
 
43a-trans 1H NMR (600 MHz, CDCl3): δ 0.89 (t, J = 7.1 Hz, 3H; CH3), 0.97 (d, J = 6.5 
Hz, 1H,H4) 1.21 (m, 2H; H3ax, H5ax), 1.32 (m, 6H; CH2), 1.53 (m, 1H; H4), 1.64 (m, 2H, CH2), 
1.86 (m, 4H; H3eq, H5eq, H2ax, H6ax), 2.14 (m, 2H; H2eq, H6eq), 2.66 (m, 2H; CH2), 2.72 (t,  
J = 7.7 Hz, 1H; CH2), 4.41 (tt, J = 12.0, 4.1 Hz, 1H; H1), 7.74 (s, 1H; triazolyl).  
13C NMR (600 
MHz, CDCl3): δ 14.38 (CH3), 22.37 (CH3), 23.62, 26.34, 29.96, 30.59, 32.70 (CH2), 32.92 (C4), 
34.32 (C2, C6), 34.88 (C3, C5), 61.46 (C1), 121.06 (CH; triazolyl), 148.87 (C; triazolyl).  
HRMS: C15H28N3 [M+H]cal m/z 250.2278; [M+H]exp m/z 250.2271. 
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(4-methylcyclohexyl)-4-phenyl-1H-1,2,3-triazole (43b) 
Compounds exist as a mixture of cis and trans configurational isomers of 43b.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded a colorless oil 174 mg (66%) 
of both isomers.  Rf: 0.51 (Hex:EtOAc, 3:2). 
 
43b-cis 1H NMR (600 MHz, CDCl3): δ 0.82 (t, J = 7.1 Hz, 3H; CH3), 1.75 (m, 2H; H3ax, 
H5ax), 1.80 (m, 1H; H4), 1.93(m, 2H; H3eq, H5eq), 2.11 (m, 2H; H2ax, H6ax), 2.59(m, 2H; 
H2eq, H6eq),4.61 (m, 1H; H1), 7.15 (m, 3H; Ph), 7.23 (m, 2H; Ph), 7.78 (s, 1H; triazolyl).  13C 
NMR (150 MHz, CDCl3): δ 14.12 (CH3), 32.22 (C4), 34.69 (C2, C6), 35.26 (C3, C5), 61.21 
(C1), 121.28 (CH; triazolyl), 119.53, 126.23, 126.99, 127.01 (CH; Ph), 127.31 (CH,triazolyl), 
128.52 (C; Ph), 145.36 (C; triazolyl).  HRMS: C15H20N3 [M+H]cal m/z 242.1652; [M+H]exp m/z 
242.1684. 
 
43b-trans 1H NMR (600 MHz, CDCl3): δ 0.89 (t, J = 7.1 Hz, 3H; CH3), 1.62(m, 2H; 
H3ax, H5ax), 1.80 (m, 1H; H4), 1.95 (m, 2H; H3eq, H5eq), 2.07 (m, 2H; H2ax, H6ax), 2.34 (m, 
2H; H2eq, H6eq), 4.62 (m, 1H; H1), 7.29 (m, 3H; Ph), 7.33(m, 2H; Ph), 7.92 (s, 1H; triazolyl).  
13C NMR (150 MHz, CDCl3): δ 14.12 (CH3), 32.22 (C4), 34.69 (C2, C6), 35.26 (C3, C5), 61.21 
(C1), 119.53, 126.23, 126.99, 127.01 (CH; Ph), 127.31 (CH,triazolyl), 128.52 (C; Ph), 145.36 




Compounds exist as a mixture of cis and trans configurational isomers of 44a.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded a colorless oil 219 mg (68%) 
of both isomers.  Rf: 0.37 (Hex:EtOAc, 3:2). 
 
44a-cis 1H NMR (600 MHz, CDCl3): δ 0.88 (t, J = 7.1 Hz, 3H; CH3), 1.32 (m, 4H; CH2), 
1.67 (m, 2H; H3ax, H5ax), 1.89 (m, 4H; H3eq, H5eq, CH2), 2.05 (m, 2H; H2ax, H6ax), 2.46 (m, 
2H; H2eq, H6eq), 2.72 (t, J = 7.7 Hz, 2H; CH2), 2.77 (m,1H; H4), 4.64 (quintet, J = 4.3 Hz, 1H; 
H1), 7.20 (m, 3H; Ph), 7.29 (m, 2H; Ph), 7.35 (s, 1H; triazolyl).  13C NMR (600 MHz, CDCl3): δ 
14.18 (CH3), 22.67, 25.84, 28.64, 28.74 (CH2), 29.08 (C3), 29.94 (CH2), 29.57 (C5), 30.14 (C2), 
31.80 (C6), 41.81 (C4), 55.90 (C1), 119.53, 126.23, 126.99, 127.01 (CH; Ph), 128.52 (C; Ph), 
145.82, 148.12 (C; triazolyl).  HRMS: C20H30N3 [M+H]cal m/z 312.2434; [M+H]exp m/z 
312.2429. 
        
44a-trans 1H NMR (600 MHz, CDCl3): δ 0.86(t, J = 7.1 Hz, 3H; CH3), 1.31 (m, 4H; 
CH2), 1.65 (m, 2H; H3ax, H5ax), 1.90 (m, 4H; H3eq, H5eq, CH2), 2.04 (m, 2H; H2ax, H6ax), 
2.44(m, 2H; H2eq, H6eq), 2.72 (t, J = 7.7 Hz, 1H; CH2), 2.75 (m,1H; H4), 4.52 (tt, J = 12.1, 3.9 
Hz, 1H; H1), 7.24 (m, 3H; Ph), 7.31(m, 2H; Ph), 7.39 (s, 1H; triazolyl).  13C NMR (600 MHz, 
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CDCl3): δ 14.18 (CH3), 22.67, 25.84, 28.64, 28.94 (CH2), 29.08 (C3), 29.814 (CH2), 29.57 (C5), 
30.14 (C2), 31.80 (C6), 41.81 (C4), 55.90 (C1), 119.53, 126.23, 126.99, 127.01 (CH; Ph), 128.52 
(C; Ph), 145.82, 148.12 (C; triazolyl).  HRMS: C20H30N3 [M+H]cal m/z 312.2434; [M+H]exp m/z 
312.2429. 
(4-methylcyclohexyl)-4-phenyl-1H-1,2,3-triazole (44b) 
Compound exists as a mixture of cis and trans configurational isomers of 44b.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded a white solid 0.134mg (68%) 
of both isomers.  Rf: 0.42 (Hex:EtOAc, 3:2). 
 
44a-cis 1H NMR (600 MHz, CDCl3): δ 1.27 (m, 2H; H3ax, H5ax), 1.90 (m, 4H; H3eq, 
H5eq, H2ax, H6ax), 2.59 (m, 2H; H2eq, H6eq), 2.83 (m, 1H; H4), 4.51 (quintet, J = 2.84 Hz, 
1H; H1), 7.12-7.33 (m, 8H; Ph), 7.50 (m, 2H; Ph), 7.85 (s, 1H; triazolyl).  13C NMR (150MHz, 
CDCl3): δ 20.05 (C4), 27.86 (C3), 29.73 (C5), 32.29 (C2), 32.95 (C6), 41.81 (C4), 56.34 (C1), 
125.59-127.47 (8CH, Ph), 128.48, 129.22 (C; Ph), 146.06, 147.40 (C; triazolyl).  HRMS: 
C20H22N3 [M+H]cal m/z 304.1808 [M+H]exp m/z 304.1822. 
      
44a-trans 1H NMR (600 MHz, CDCl3): δ 1.23 (m, 2H; H3ax, H5ax), 1.82(m, 4H; H3eq, 
H5eq, H2ax, H6ax), 2.62 (m, 2H; H2eq, H6eq), 2.74 (ttt, J = 12.3, 3.3 Hz, 1H; H4), 4.46 (tt, J = 
230 
12.0, 4.0 Hz, 1H; H1), 7.18-7.31 (m, 8H; Ph), 7.42 (m, 2H; Ph), 7.82 (s, 1H; triazolyl).  13C 
NMR (150MHz, CDCl3): δ 19.94 (C4), 25.17 (C3), 29.73 (C5), 32.29 (C2), 32.95 (C6), 41.81 
(C4), 56.34 (C1), 125.12-127.10 (8CH, Ph), 128.48, 129.22 (C; Ph), 147.01, 147.62 (C; 
triazolyl).  HRMS: C20H22N3 [M+H]cal m/z 304.1808 [M+H]exp m/z 304.1822. 
(4-methylcyclohexyl)-4-hexyl-1H-1,2,3-triazole (45a) 
Compound exists as a mixture of cis and trans configurational isomers of 45a.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded a colorless oil 141mg (77%) 
of both isomers.  Rf: 0.65 (Hex:EtOAc, 3:2). 
      
45a-cis 1H NMR (600 MHz, CDCl3): δ 0.81 (s, 9H; C(CH3)3), 0.93 (m, 3H; CH3), 1.13 (m, 
4H; H3ax, H5ax, CH2), 1.36 (m, 6H; H3eq, H5eq, H2ax, H6ax, CH2), 1.67 (m, 3H; H4, CH2), 2.52 
(m, 2H; H2eq, H6eq), 2.71 (t, J = 7.5 Hz, 2H; CH2), 4.57 (m,1H; H1), 7.34 (s, 1H; triazolyl).  
13C 
NMR (150MHz, CDCl3): δ 18.24 (3CH3), 19.36 (CH3), 21.02, 21.42, 21.69 (CH2), 23.10 (C5), 
24.01 (C3), 24.52 (C4), 25.41 (CH2), 30.01 (C6), 31.61 (C2), 33.72 (C(CH3)3), 59.82 (C1), 120.36, 
139.24 (C; triazolyl).  HRMS: C18H34N3 [M+H]cal m/z 292.2747 [M+H]exp m/z 292.2747. 
 
45b-trans 1H NMR (600 MHz, CDCl3): δ0.89(s, 9H; C(CH3)3), 0.93 (m, 3H; CH3), 1.13 
(m, 4H; H3ax, H5ax, CH2), 1.36 (m, 6H; H3eq, H5eq, H2ax, H6ax, CH2), 1.84 (m, 3H; H4, 
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CH2), 1.94 (m, 2H; H2eq, H6eq), 2.26 (m, 2H; CH2), 2.69 (m, 2H; CH2), 4.36 (ttt, J = 12.1, 3.4 
1H; H1), 7.25 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 18.31 (3CH3), 19.24 (CH3), 
21.02, 21.42, 21.69 (CH2), 23.51 (C5), 24.57 (C3), 24.52 (C4), 25.81 (CH2), 30.01 (C6), 31.61 
(C2), 33.72 (C(CH3)3), 60.57 (C1), 120.01, 139.28 (C; triazolyl).  HRMS: C18H34N3 [M+H]cal 
m/z 292.2747 [M+H]exp m/z 292.2747. 
(4-methylcyclohexyl)-4-phenyl-1H-1,2,3-triazole (45b) 
Compound exists as a mixture of cis and trans configurational isomers of 45b.  Column 
chromatography (silica gel; Hex:EtOAc, 3:2) was done and yielded brown crystals 182mg (81%) 
of both isomers.  Rf: 0.56 (Hex:EtOAc, 3:2). 
 
45b-cis 1H NMR (600 MHz, CDCl3): δ 0.91 (s, 9H; C(CH3)3), 1.21 (m, 2H; H3ax, H5ax), 
1.43 (m, 4H; H3eq, H5eq, H2ax, H6ax), 1.57 (m, 1H; H4), 2.57 (m, 2H; H2eq, H6eq), 4.67 
(m,1H; H1), 7.12-7.21 (m, 3H; phenyl), 7.59 (m, 2H; phenyl), 7.99 (s, 1H; triazolyl).  13C NMR 
(150MHz, CDCl3): δ 18.24 (3CH3), 23.64 (C5), 24.36 (C3), 26.17 (C4), 30.24 (C6), 32.29 (C2), 
34.25 (C(CH3)3), 58.30 (C1), 119.36, 121.62, 121.97, 122.08, 122.67 (CH, phenyl), 129.34 (C; 





45b-trans 1H NMR (600 MHz, CDCl3): δ 0.94 (s, 9H; C(CH3)3), 1.23 (m, 2H; H3ax, 
H5ax), 1.41 (m, 4H; H3eq, H5eq, H2ax, H6ax), 1.58 (ttt, J = 12.4, 3.2 Hz, 1H; H4), 2.35 (m, 2H; 
H2eq, H6eq), 4.67 (ttt, J = 12.1, 3.4 Hz, 1H; H1), 7.22 (m, 3H; phenyl), 7.62 (m, 2H; phenyl), 
8.18 (s, 1H; triazolyl).  13C NMR (150MHz, CDCl3): δ 18.36 (3CH3), 23.64 (C5), 24.36 (C3), 
26.17 (C4), 30.24 (C6), 33.08 (C2), 34.25 (C(CH3)3), 58.30 (C1), 119.36, 121.62, 121.37, 
122.08, 122.85 (CH, phenyl), 129.21 (C; Ph), 134.08, 143.21 (C; triazolyl).  HRMS: C18H26N3 
[M+H]cal m/z 284.21.21 [M+H]exp m/z 284.2108. 
General procedure for synthesis of triazoles through toluene reflux 
Azide (2 mmol) was dissolved in 20 mL of toluene.  Alkyne (3 mmol) was dissolved in 
the mixture and stirred for 72 hours while checking for completion with TLC.  After completion, 
all solvent was removed by rotary evaporator and the crude product was dissolved in EtOAc.  
Solution was dried with anhydrous Na2SO4 crystals for 12 hours.  Na2SO4 crystals were filtered 








Azide 10a reacted with ethyl-2-butynoate to give a crude mixture of 15a and 16a that 




Compound 15a was isolated as colorless oil with a yield of 271 mg (50%).  Rf: 0.52 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.28 (t, J =7.1 Hz, 3H; CH3), 1.32 (t, J =7.1 
Hz, 3H; CH3), 2.11 (m, 2H; H3ax, H6ax), 2.21 (m, 1H; H3eq), 2.59 (s, 3H; CH3), 2.73 (m, 1H; 
H6eq), 3.52 (m, 1H; H2), 4.19 (m, 4H, OCH2), 4.41 (td, J =10.9, 4.2 Hz, 1H; H5), 4.47 (td, J 
=11.0, 4.5 Hz, 1H; H4).  13C NMR (150MHz, CDCl3): δ 11.28 (CH3), 14.25, 14.31 (CH3), 25.20 
(C3), 27.63 (C6), 39.74 (C2), 40.57 (C1), 56.24 (C5), 61.03 (OCH2), 61.03, 62.04 (OCH2), 77.11 
(C4), 121.99, 149.72 (C; triazolyl).  156.70, 172.01, 172.07 (C=O).  HRMS: C16H22N3O6
+ 




Compound 16a was isolated as yellow oil with a yield of 322 mg (63%).  Rf: 0.24 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 1.28 (t, J =7.1 Hz, 3H; CH3), 1.30 (t, J =7.1 
Hz, 3H; CH3),  1.38 (t, J =7.1 Hz, 3H; CH3), 1.84 (m, 1H; H3ax), 2.32 (m, 1H; H6ax), 2.46 (s, 
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3H; CH3), 2.50 (m, 1H; H3eq), 2.55 (m, 1H, H6e), 2.90 (d, J =5.6 Hz, 1H; OH), 3.36 (m, 1H; 
H1), 3.42 (m, 1H; H2), 4.22 (m, 4H, OCH2), 4.28 (spt, J =5.1 Hz, 1H; H4), 4.38 (m, 2H; OCH2), 
5.24 (m, 1H; H5).  13C NMR (150MHz, CDCl3): δ 12.58 (CH3), 14.23, 14.29 (CH3), 21.15 
(CH3), 29.78 (C3), 32.16 (C6), 40.70 (C2), 40.87 (C1), 60.47 (OCH2), 61.41, 61.70 (OCH2), 
62.10 (C5), 69.50 (C4), 125.78, 147.77 (C; triazolyl), 171.29, 172.85, 172.92 (C=O).  HRMS: 
C18H28N3O7
+ [M+H]Cal m/z 398.1922; [M+H]exp m/z 398.1902. 
Azide 10a reacted with methyl-2-hexynoate to give a crude mixture of 15b and 16b that 




Compound 15b was isolated as colorless oil with a yield of 296 mg (56%).  Rf: 0.64 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.97 (t, J =7.0 Hz, 3H; CH3), 1.29 (t, J =7.1 
Hz, 3H; CH3), 1.31 (t, J =7.1 Hz, 3H; CH3), 1.76 (m, 2H; CH2), 2.03 (m, 1H; H6eq), 2.07 (m, 
1H; H3eq), 2.71 (m, 1H; H6ax), 2.94 (t, J = 8.2 Hz 2H; CH2), 3.44 (m, 1H; H3ax), 3.50 (m, 2H; 
H1, H2), 4.18 (m, 4H, OCH2), 4.43 (td, J =10.8, 4.2 Hz, 1H; H5), 4.45 (td, J =11.1, 4.3 Hz, 1H; 
H4).  13C NMR (150MHz, CDCl3): δ 13.88 (CH3), 14.25, 14.30 (CH3), 22.21 (CH2), 25.20 (C6), 
27.50 (C6), 39.75 (C2), 40.55 (C1), 56.42 (C5), 61.96, 62.03 (OCH2), 77.74 (C4), 121.65, 
153.98 (C; triazolyl).  156.59, 172.01, 172.11 (C=O).  HRMS: C20H26N3O5
+ [M+H]Cal m/z 







Compound 16b was isolated as yellow oil with a yield of 342 mg (60%).  Rf: 0.41 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.96 (t, J =7.0 Hz, 3H; CH3), 1.30 (t, J =7.1 
Hz, 3H; CH3),  1.31 (t, J =7.1 Hz, 3H; CH3), 1.72 (m, 2H; CH2), 1.86 (ddd, J = 13.7, 11.0, 5.2 
Hz, 1H; H3ax), 2.31 (ddd, J = 14.1, 11.2, 5.0 Hz, 1H; H3ax), 2.55 (m, 2H; H3ex, H6ex), 2.86 
(m, 2H; CH2), 3.93 (s, 3H; CH3), 3.37 (m, 1H; H1), 3.41 (m, 1H; H2), 4.24 (m, 4H, OCH2), 4.35 
(m, 1H; H4), 5.22 (ddd, J = 11.3, 9.2, 4.2 Hz, 1H; H5).  13C NMR (150MHz, CDCl3): δ 13.01 
(CH3), 14.05, 14.27 (CH3), 22.48, 28.45 (CH2), 29.88 (C6), 32.10 (C3), 40.69 (C2), 40.85 (C1), 
52.44 (OCH2), 61.48, 62.24 (OCH2), 62.30 (C4), 69.39 (C5), 125.25, 152.12 (C; triazolyl), 
160.19, 172.88, 172.90 (C=O).  HRMS: C19H30N3O7









Azide 10a reacted with methyl-2-octynoate to give a crude mixture of 15c and 16c that 




Compound 15c was isolated as colorless oil with a yield of 354 mg (61%).  Rf: 0.68 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.93 (t, J =7.0 Hz, 3H; CH3), 1.28 (t, J =7.1 
Hz, 3H; CH3), 1.30 (t, J =7.1 Hz, 3H; CH3), 1.74 (m, 4H; CH2), 2.00 (m, 1H; H6eq), 2.05 (m, 
3H; H3eq, CH2), 2.79 (m, 1H; H6ax), 2.91 (t, J = 7.9 Hz 2H; CH2), 3.38 (m, 1H; H3ax), 3.47 (m, 
2H; H1, H2), 4.19 (m, 4H, OCH2), 4.41 (td, J =11.2, 4.0 Hz, 1H; H5), 4.48 (td, J =11.0, 4.2 Hz, 
1H; H4).  13C NMR (150MHz, CDCl3): δ 12.10 (CH3), 14.22, 14.28 (CH3), 21.24, 21.86, 22.91, 
23.14 (CH2), 25.16 (C6), 26.83 (C6), 38.27 (C2), 40.02 (C1), 58.36 (C5), 61.09, 61.18 (OCH2), 
77.64 (C4), 121.34, 149.79 (C; triazolyl), 156.59, 171.84, 172.18 (C=O).  HRMS: C20H30N3O6
+ 












Compound 16c was isolated as colorless oil with a yield of 451 mg (63%).  Rf: 0.49 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.95 (t, J =7.0 Hz, 3H; CH3), 1.29 (t, J =7.1 
Hz, 3H; CH3),  1.30 (t, J =7.1 Hz, 3H; CH3), 1.52 (m, 2H; CH2), 1.56 (m, 2H; CH2), 1.71 (m, 
2H; CH2), 1.92 (ddd, J = 13.5, 11.3, 4.9 Hz, 1H; H3ax), 2.30 (ddd, J = 14.0, 11.4, 5.1Hz, 1H; 
H3ax), 2.51 (m, 1H; H3ex,), 2.55 (m, 1H; H6ex), 2.74 (m, 2H; CH2), 3.35 (m, 1H; H1), 3.42 (m, 
1H; H2), 3.96 (s, 3H; CH3), 4.23 (m, 4H, OCH2), 4.36 (m, 1H; H4), 5.22 (ddd, J = 11.4, 9.2, 4.0 
Hz, 1H; H5).  13C NMR (150MHz, CDCl3): δ 11.62 (CH3), 14.09, 14.38 (CH3), 22.31, 22.91, 
23.37, 28.45 (CH2), 29.15 (C6), 32.91 (C3), 40.44 (C2), 41.02 (C1), 57.34 (OCH2), 60.91, 61.38 
(OCH2), 62.28 (C4), 69.31 (C5), 125.38, 148.39 (C; triazolyl), 162.33, 172.36, 172.60 (C=O).  
HRMS: C21H34N3O7








Azide 10a reacted with methyl-2-nonynoate to give a crude mixture of 15d and 16d that 




Compound 15d was isolated as colorless oil with a yield of 162 mg (70%).  Rf: 0.67 
(Hex:EtOAc, 7:3).  1H NMR (600 MHz, CDCl3): δ 0.90 (t, J =7.1 Hz, 3H; CH3), 1.29 (t, J =7.1 
Hz, 3H; CH3), 1.30 (t, J =7.0 Hz, 3H; CH3), 1.71 (m, 4H; CH2), 1.98 (m, 3H; H6eq, CH2), 2.09 
(m, 3H; H3eq, CH2), 2.68 (m, 1H; H6ax), 2.90 (t, J = 8.0 Hz 2H; CH2), 331 (m, 1H; H3ax), 3.42 
(m, 2H; H1, H2), 4.18 (m, 4H, OCH2), 4.35 (td, J =11.2, 4.2 Hz, 1H; H5), 4.51 (td, J =10.7, 4.4 
Hz, 1H; H4).  13C NMR (150MHz, CDCl3): δ 12.05 (CH3), 14.23, 14.26 (CH3), 21.34, 21.79, 
22.53, 23.14 (CH2), 25.16 (C6), 26.31 (C6), 38.27 (C2), 41.24 (C1), 58.56 (C5), 61.08, 61.0 
(OCH2), 78.24(C4), 121.24, 148.24 (C; triazolyl), 157.32, 171.84, 172.38 (C=O).  HRMS: 
C21H32N3O6












Compound 16d was isolated as colorless oil with a yield of 186 mg (60%).  Rf: 0.21 
(Hex:EtOAc,7:3).  1H NMR (600 MHz, CDCl3): δ 0.99 (t, J =7.0 Hz, 3H; CH3), 1.28(t, J =7.1 
Hz, 3H; CH3),  1.29 (t, J =7.0 Hz, 3H; CH3), 1.51 (m, 4H; CH2), 1.58 (m, 2H; CH2), 1.69 (m, 
2H; CH2), 1.93 (ddd, J = 13.4, 11.3, 5.0 Hz, 1H; H3ax), 2.28 (m,1H; H3ax), 2.52 (m, 1H; 
H3ex,), 2.60 (m, 1H; H6ex), 2.82 (m, 2H; CH2), 3.34 (m, 1H; H1), 3.43 (m, 1H; H2), 4.01 (s, 
3H; CH3), 4.25 (m, 4H, OCH2), 4.36 (m, 1H; H4), 5.25 (ddd, J = 11.6, 9.0, 4.1 Hz, 1H; H5).  
13C 
NMR (150MHz, CDCl3): δ 11.63 (CH3), 14.12, 14.23 (CH3), 22.30, 22.82, 23.01, 23.49, 28.75 
(CH2), 29.28 (C6), 23.54 (C3), 40.28 (C2), 41.12 (C1), 58.39 (OCH2), 60.81, 61.59 (OCH2), 
62.34 (C4), 70.21 (C5), 124.69, 143.54 (C; triazolyl), 162.34, 171.35, 172.86 (C=O).  HRMS: 
C22H36N3O7











11c was synthesized with 11a and could not be separated. Product was cleaned by 
column chromatography (silica gel; hexane:EtOAc, 4:1) to give 0.82 g (42%) of colorless oil of 
11c.  1H NMR (600 MHz, CD3OD): δ 0.92 (t, J =7.0 Hz, 3H; CH3, hexyl), 1.26 (t, J =7.0 Hz, 
3H; CH3), 1.28 (t, J =7.0 Hz, 3H; CH3), 1.32 (m, 6H; CH2, hexyl), 1.68 (quintet, J =7.0 Hz, 2H; 
CH2, hexyl), 1.80 (m, 2H; H3ax, H3eq), 2.34 (m, 1H, H6ax), 2.42 (m, 1H, H6eq), 2.71 (t, J =7.5 
Hz, 2H; CH2, hexyl), 3.44 (m, 1H, H1), 3.46 (m, H1; H2), 4.14 (m, 4H; OCH2), 4.33 (m, 1H; 
H4), 4.43 (m,1H; H5), 7.79 (s, 1H; triazolyl).  13C NMR (600 MHz, CD3OD): δ 13.03 (CH3, 
hexyl), 13.12 (CH3, Et), 22.28, 25.06, 29.14, 28.62 (CH2, hexyl), 28.72 (C6), 31.36 (CH2, hexyl) 
31.64 (C3), 40.27 (C2), 40.36 (C1), 60.92, 60.99 (OCH2), 62.07 (C5), 67.97 (C4), 122.61 (CH; 
triazolyl), 126.67(C; triazolyl), 173.24, 173.43(C=O).  HRMS: C20H34N3O5 [M+H]Cal m/z 









Diethyl- 5-(5-phenyl-1,2,3-triazolyl)-4-hydroxy-1,2-cyclohexanedicarboxylate (12c) 
 
12c was synthesized with 12a and could not be separated. Product was cleaned by 
column chromatography (silica gel; hexane:EtOAc, 4:1) to give 0.92 g (46%) of colorless oil of 
12c.  1H NMR (600 MHz, CD3OD): δ 1.25 (t, J =7.0 Hz, 3H; CH3), 1.29 (t, J =7.1 Hz, 3H; CH3), 
1.85 (ddd, J =13.6, 11.7, 5.3 Hz, 1H; H3ax), 2.45 (dtd, J =13.5, 4.3, 1.4 Hz 1H; H6ax), 2.57 (m, 
2H; H3eq, H6eq), 2.93 (dt, J=12.8, 4.2 Hz, 1H, H1), 3.44 (m, 1H, H1), 3.46 (m, 1H; H2) 4.18 
(m, 4H; OCH2), 4.33 (ddd, J =11.6, 10.1, 4.4 Hz, 1H; H4), 4.44 (ddd, J =12.6, 10.0, 4.4 Hz, 1H; 
H5), 7.34 (m, 1H; Ph), 7.43 (m, 2H; Ph), 7.83 (m, 2H; Ph), 8.32 (s, 1H; triazolyl).  13C NMR 
(600 MHz, CD3OD): δ 13.06 (CH3), 13.14 (CH3), 29.75 (C6), 34.93 (C3), 41.36 (C2), 41.89 
(C1), 60.66, 60.77 (OCH2), 65.50 (C5), 68.55 (C4), 120.82 (CH; triazolyl), 125.34 (2C; Ph), 
127.92 (1C; Ph), 128.63 (2C; Ph), 130.54 (1C; Ph), 146.95 (C; triazolyl), 172.46, 172.82 (C=O).  
HRMS: C20H26N3O5










Diethyl 4-(4,5-diphenyl-1H-1,2,3-triazol-1-yl)-5-hydroxycyclohexane-1,2-dicarboxylate (13) 
 
Compound 13 was isolated as white crystals with a yield of 186 mg (69.9%).  Rf: 0.27 
(Hex:EtOAc,7:3).  1H NMR (600 MHz, CDCl3): δ 1.24 (t, J =7.1 Hz, 3H; CH3), 1.26 (t, J =7.1 
Hz, 3H; CH3), 1.85 (ddd, J = 13.2, 11.1, 5.0 Hz, 1H; H3ax), 2.01 (m,1H; H3eq), 2.52 (m, 1H; 
H6ex), 3.35 (m, 2H; H1, H2), 4.12 (m, 1H; H5), 4.22 (m, 4H, OCH2), 4.56 (ddd, J = 11.4, 9.0, 
4.1 Hz, 1H; H5). 7.28 (m, 4H; Ph), 7.34 (m, 2H; Ph), 7.39 (m, 4H; Ph).  13C NMR (150MHz, 
CDCl3): δ 14.04, 14.09 (CH3), 23.24 (C6), 26.97 (C3), 41.39 (C2), 41.44 (C1), 60.04, 60.97 
(OCH2), 62.13 (C4), 70.55 (C5), 124.30 (C;triazolyl), 125.64, 125.67, 125.94, 126.02, 126.34, 
126.41, 126.57, 126.75, 126.82, 127.36 (CH; Ph), 135.26, 136.27 (C; Ph),  145.36 (C;triazolyl), 
171.24, 171.89 (C=O).  HRMS: C22H36N3O7
+ [M+H]Cal m/z 464.2180; [M+H]exp m/z 464.1280. 
Diethyl-5-(5-hexyl-1,2,3-triazolyl)-4-acetoxy-1,2-cyclohexanedicarboxylate (11d) 
 
11d was synthesized with 11b and could not be separated. Product was cleaned by 
column chromatography (silica gel; Hex:EtOAc, 4:1) to give 0.78 g (41%) of colorless oil of 
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11d.  1H NMR (600 MHz, CDCl3): δ 0.89 (t, J = 7.1 Hz, CH3), 1.29 (t, J =7.1 Hz, 3H; CH3), 1.31 
(t, J =7.1 Hz, 3H; CH3), 1.33 (m, 2H;,CH2,hexyl), 1.71 (m, 2H; CH2, hexyl), 1.82 (m, 1H, H3ax), 
2.29 (m, 2H, H3eq, H6ax), 2.48 (m, 3H, H6eq, CH2, hexyl), 3.41 (m, 1H, H2), 3.48 (m, 1H, H1),  
4.20 (m, 4H; OCH2), 4.68 (m, 1H; H5), 5.52 (td, J = 8.1, 4.0 Hz, 1H; H4),  7.32 (s, 1H; 
triazolyl).  13C NMR (600 MHz, CDCl3): δ 12.25 (CH3, hexyl), 13.95 (CH3, Et), 20.17 (CH3-
Acetyl), 22.54, 25.85, 29.64, 28.64 (CH2, hexyl), 29.01 (C6), 31.54 (CH2, hexyl) 31.78 (C3), 
40.67 (C2), 40.92 (C1), 61.28, 61.39 (OCH2), 65.28 (C5), 71.36 (C4), 123.68 (CH; triazolyl), 
129.58(C; triazolyl), 168.34, 172.59, 173.95 (C=O).  HRMS: C22H36N3O6
+ [M+H]Cal m/z 
438.2599; [M+H]exp m/z 438.2595. 
Diethyl- 5-(5-phenyl-1,2,3-triazolyl)-4-acetoxy-1,2-cyclohexanedicarboxylate (12d)  
 
12d was synthesized with 12b and could not be separated. Product was cleaned by 
column chromatography (silica gel; Hex:EtOAc, 4:1) to give 0.72g (40%) of colorless oil of 12d.  
1H NMR (600 MHz, CDCl3): δ 0.96 (t, J =7.0 Hz, 3H; CH3), 1.29 (t, J =7.1 Hz, 3H; CH3), 1.30 
(t, J =7.1 Hz, 3H; CH3), 1.94 (m, 1H; H3ax), 1.95 (s, 3H, CH3), (m, 1H; H6ax), 2.57 (m, 2H; 
H3eq, H6eq), 3.44 (m, 1H, H2), 3.53 (m, 1H, H1), 4.18 (m, 4H; OCH2), 4.77 (ddd, J =12.6, 10.0, 
4.4 Hz, 1H; H5), 5.59 (m, 1H; H4), 7.34 (m, 1H; phenyl), 7.43 (m, 2H; phenyl), 7.83 (m, 2H; 
phenyl), 8.32 (s, 1H; triazolyl).  13C NMR (600 MHz, CD3OD): δ 14.14 (CH3), 14.18 (CH3), 
20.82 (CH3; Acetyl), 28.85 (C3), 29.15 (C6), 40.07 (C1), 40.020 (C2), 58.64 (C5), 61.43, 61.46 
(OCH2), 70.25 (C4), 118.76 (CH; triazolyl), 125.71 (2CH; Ph), 128.23 (1CH; Ph), 128.83 (2CH; 
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Phenyl), 130.40 (1C; Ph), 147.59 (C; triazolyl), 160.24, 172.60, 172.85 (C=O).  HRMS: 
C22H27N3O6
+ [M+H]Cal m/z 430.1978; [M+H]exp m/z 430.1945. 
Diethyl 4-acetoxy-5-(4,5-diphenyl-1H-1,2,3-triazol-1-yl)cyclohexane-1,2-dicarboxylate (14) 
 
Compound 14 was isolated as colorle with a yield of 0.94 g (82%).  Rf: 0.28 
(Hex:EtOAc,5:4). 1H NMR (600 MHz, CDCl3): δ 0.92 (t, J =6.9 Hz, 3H; CH3), 1.28 (t, J =7.1 
Hz, 3H; CH3), 1.30 (t, J =7.1 Hz, 3H; CH3), 1.84 (s, 3H, CH3), 1.96 (m, 2H; H3ax, H6ax), 2.41 
(m, 2H; H3eq, H6eq), 3.22 (m, 1H, H2), 3.39 (m, 1H, H1), 4.14 (m, 4H; OCH2), 4.44 (ddd, J 
=12.6, 10.0, 4.4 Hz, 1H; H5), 5.59 (m, 1H; H4), 7.31 (m, 2H; phenyl), 7.34 (m, 4H; phenyl), 
7.62 (m, 4H; phenyl), 8.07 (s, 1H; triazolyl).  13C NMR (600 MHz, CD3OD): δ 14.14 (CH3), 
14.18 (CH3), 20.82 (CH3; Acetyl), 28.85 (C3), 29.15 (C6), 40.07 (C1), 40.020 (C2), 58.64 (C5), 
61.43, 61.46 (OCH2), 70.25 (C4), 118.76 (CH; triazolyl), 125.01, 125.34. 125.69, 125.87, 
126.24, 126.59, 128.08, 128.83 (CH; Phenyl), 130.40, 132.04 (1C; Phenyl), 147.36 (C; triazolyl), 
159.64, 170.36, 173.67 (C=O).  HRMS: C28H32N3O6






Azide 10a reacted with ethyl-2-butynoate to give a crude mixture of 57a and 58a that were 
separated by column chromatography (silica gel; Hex:EtOAc, 1:1). 
3-methyl-5,6,7,8,9,9-hexahydro-4H-benzo(1,2,3)triazolo(1,5-d)(1,4)oxazin-4-one  (57a) 
 
Compound 57a was isolated as a white crystal with a yield of 0.263 g (52%).  Rf: 0.49 
(Hex:EtOAc, 3:17).  1H NMR (600 MHz, CDCl3): δ 1.50 (m, 2H; H4eq, H5eq), 1.71 (m, 1H; 
H5ax), 1.79 (m, 1H; H4ax), 2.01 (m, 2H; H3eq, H6eq), 2.35 (m, 1H; H3ax), 2.61 (s, 3H; CH3), 
3.06 (m, 1H; H6ax), 4.19 (td, J = 11.0, 4.3 Hz, 1H; H2), 4.31 (td, J = 11.0, 4.4 Hz, 1H, H1).  13C 
NMR (150 MHz, CDCl3): δ 11.24 (CH3), 23.20 (C5), 23.54 (C4), 26.88 (C6), 29.50 (C3), 59.74 
(C2), 81.41 (C1), 121.97, 149.36 (2C; triazolyl), 156.96 (C=O).  HMRS: C10H14N3O2
+ [M+H]cal 
m/z 208.1081; [M+H]exp m/z 208.1096. 
Ethyl 1-(2-hydroxycyclohexyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate (58a) 
 
Compound 58a was isolated as colorless oil with a yield of 0.52 g (62%).  Rf: 0.36 
(Hex:EtOAc, 3:7).  1H NMR (600 MHz, CDCl3): δ 1.40 (t, J = 7.2 Hz, 3H; CH3), 1.41 (m, 1H; 
H5ax), 1.49 (m, 2H; H3ax, H4ax), 1.88 (m, 2H; H4eq, H5eq), 1.99 (m, 1H; H6eq), 2.12 (qd, J = 
13.0, 3.6 Hz, 1H; H6ax), 2.21 (m, 1H; H3eq), 2.57 (s, 1H; OH), 2.60 (s, 3H; CH3), 3.97 (ddd, J = 
12.9, 8.8, 3.6 Hz, 1H; H2), 4.27 (td, J = 10.1, 4.7 Hz, 1H; H1), 4.45-4.36 (m, 2H; OCH2).  
13C 
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NMR (150 MHz, CD3OD): δ 9.20, 14.38 (CH3), 24.18 (C4), 24.90 (C5), 31.28 (C6), 34.09 (C3), 
61.00 (OCH2), 64.74 (C1), 72.52 (C2), 135.67, 139.31 (C; triazolyl), 161.57 (C=O).  HMRS: 
C12H20N3O3
+ [M+H]cal m/z 254.1499; [M+H]exp m/z 254.1512. 
Azide 10a reacted with methyl-2-hexynoate to give a crude mixture of 57b and 58b that 
were separated by column chromatography (silica gel; Hex:EtOAc, 1:1). 
3-propyl-5,6,7,8,9,9-hexahydro-4H-benzo(1,2,3)triazolo(1,5-d)](1,4)oxazin-4-one (57b) 
 
Compound 57b was isolated as a white crystal with a yield of 0.1 g (22%).  Rf: 0.47 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.97 (t, J = 7.4 Hz, 3H; CH3), 1.50 (m, 2H; 
H4ax, H5ax), 1.75 (m, 4H; H3eq, H6eq, CH2), 2.01 (m, 2H; H4eq, H5eq), 2.33 (m, 1H; H3ax), 
2.94 (t, J = 7.7 Hz, 2H; CH3), 3.06 (m, 1H; H6ax), 4.18 (td, J = 11.0, 4.3 Hz, 1H; H1), 4.30 (td, J 
= 11.0, 4.4 Hz, 1H; H2).  13C NMR (150 MHz, CDCl3): δ 13.87 (CH3), 22.20 (CH2), 23.22 (C4), 
23.55 (C5), 26.88 (C6), 27.52 (CH2), 29.49 (C3), 59.62 (C1), 81.15 (C2), 121.54, 153.71 (C; 
triazolyl), 157.24 (C=O).  HMRS: C12H18N3O2










Methyl 1-(2-hydroxycyclohexyl)-5-propyl-1H-1,2,3-triazole-4-carboxylate (58b) 
 
1H NMR (600 MHz, CDCl3): δ 0.95 (t, J = 7.3 Hz, 3H; CH3), 1.39 (m, 1H; H5ax), 1.62-
1.45 (m, 4H; H3ax, H4ax, CH2), 1.90 (m, 3H; H4eq, H5eq, H6ax), 2.18 (m, 2H; H3eq, H6eq), 
2.93 (m, 1H; CH2), 3.04 (m, 1H; CH2), 3.82 (s, 1H; OH), 3.86 (s, 3H; CH3), 3.92 (m, 1H; H1), 
4.22 (m, 1H; H2).  13C NMR (150 MHz, CDCl3): δ 13.90 (CH3), 22.39 (CH2), 24.06 (C4), 24.71 
(C5), 25.21 (CH2), 31.67 (C6), 34.12 (C3), 51.89 (CH3), 64.83 (C1), 72.47 (C2), 134.92, 143.50 
(C; triazolyl), 161.88 (C=O).  HRMS: C13H22N3O3
+ [M+H]Cal m/z 268.1656; [M+H]exp m/z 
268.1645. 
Azide 10a reacted with methyl-2-octynoate to give a crude mixture of 57b and 58b that 
were separated by column chromatography (silica gel; Hex:EtOAc, 1:1). 
3-pentyl-5,6,7,8,9,9-hexahydro-4H-benzo(1,2,3)triazolo(1,5-d)](1,4)oxazin-4-one (57c) 
 
Compound 57c was isolated as a white crystal with a yield of 0.30 g (42%).  Rf: 0.51 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.98 (t, J = 7.3 Hz, 3H; CH3), 1.38 (m, 2H; 
H4ax, H5ax), 1.71 (m, 8H; H3eq, H6eq, 2CH2), 1.97 (m, 1H; H4eq), 2.03 (m, 3H; H5eq, CH2), 
2.12 (m, 1H; H3ax), 2.18 (t, J = 7.5 Hz, 2H; CH2), 3.01 (m, 1H; H6ax), 4.17 (td, J = 11.0, 4.1 
Hz, 1H; H1), 4.28 (td, J = 11.0, 4.2 Hz, 1H; H2).  13C NMR (150 MHz, CDCl3): δ 13.87 (CH3), 
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22.04, 22.18 (CH2), 23.07 (C4), 23.25 (C5), 24.67 (CH2), 25.37 (C6), 26.47 (CH2), 28.26 (C3), 
60.48 (C1), 79.98 (C2), 120.47, 150.37 (C; triazolyl), 161.04 (C=O).  HMRS: C14H22N3O2
+ 
[M+H]cal m/z 264.1707; [M+H]exp m/z 264.1714. 
Methyl 1-(2-hydroxycyclohexyl)-5-pentyl-1H-1,2,3-triazole-4-carboxylate (58c) 
 
Compound 58c was isolated as colorless oil with a yield of 0.52 g (64%).  Rf: 0.38 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.89 (t, J =7.0 Hz, 3H; CH3, pentyl), 1.47 (m, 
9H; H4ax, H5ax, H6ax, 3CH2, pentyl), 1.88 (m, 2H; H4eq, H5eq), 1.97 (m, 1H; H3eq), 2.14 (qd, 
J =13.1, 3.7 Hz, 1H; H3ax), 2.23 (m, 1H; H6eq), 2.96 (ddd, J =14.0, 9.9, 6.0 Hz, 1H; CH2 
pentyl), 3.04 (ddd, J =14.1, 9.9, 6.0 Hz, 1H; CH2 pentyl), 3.91 (S, 3H; COOCH3), 3.95 (m, 1H; 
H1), 4.30 (m, 1H; H2).  13C NMR (600 MHz, CDCl3): δ 13.95 (CH3, pentyl), 22.30, 22.84 (CH2, 
pentyl), 24.19 (C3), 25.09 (CH2, pentyl) 28.66 (C5), 31.48 (CH2, pentyl), 32.00 (C3), 34.13 (C6), 
51.90 (OCH3), 62.72 (C1), 72.40 (C2), 130.85, 143.64 (C; triazolyl), 162.05 (C=O).  HRMS: 
C15H26N3O3







Azide 10a reacted with methyl-2-nonynoate to give a crude mixture of 57d and 58d that 
were separated by column chromatography (silica gel; Hex:EtOAc, 1:1). 
3-hexyl-5,6,7,8,9,9-hexahydro-4H-benzo(1,2,3)triazolo(1,5-d)](1,4)oxazin-4-one (57d) 
 
Compound 57d was isolated as a white crystal with a yield of 0.38 g (44%).  Rf: 0.53 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.97 (t, J = 7.3 Hz, 3H; CH3), 1.21 (m, 4H; 
CH2), 1.27 (m, 1H; H4ax), 131 (m, 1H: H5ax), 1.54 (m, 2H; H3eq, H6eq) , 1.59 (m, 2H; CH2), 
1.82 (m, 1H; H4eq), 1.94 (m, 3H; H5eq, CH2), 2.07 (m, 1H; H3ax), 2.18 (m, 2H; CH2), 3.05 (m, 
1H; H6ax), 4.19 (td, J = 11.0, 4.0 Hz, 1H; H1), 4.26 (td, J = 10.8, 4.2 Hz, 1H; H2).  13C NMR (150 
MHz, CDCl3): δ 10.34 (CH3), 20.24, 20.55, 20.74 (CH2), 20.87 (C4), 22.47 (C5), 22.52 (CH2), 
25.00 (C6), 26.64 (CH2), 27.94 (C3), 61.51 (C1), 80.26 (C2), 124.66, 148.34 (C; triazolyl), 164.67 
(C=O).  HMRS: C15H24N3O2
+ [M+H]cal m/z 278.1863; [M+H]exp m/z 278.1892. 
Methyl 1-(2-hydroxycyclohexyl)-5-hexyl-1H-1,2,3-triazole-4-carboxylate (58d) 
 
Compound 58d was isolated as colorless oil with a yield of 0.57 g (62%).  Rf: 0.39 
(Hex:EtOAc, 1:1).  1H NMR (600 MHz, CDCl3): δ 0.84 (t, J =7.0 Hz, 3H; CH3, hexyl), 1.24 (m, 
4H; CH2), 1.31 (m, 5H; H4ax, H5ax, H6ax, CH2, pentyl), 1.67 (m, 1H; H4eq) 1.72 (m, 1H; 
H5eq), 1.92 (m, 1H; H3eq), 2.14 (m, 2H; H3ax, H6eq), 2.84 (m, 2H; CH2 hexyl), 3.13 (ddd, J 
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=14.1, 9.9, 6.0 Hz, 1H; CH2 hexyl), 3.85 (S, 3H; COOCH3), 3.97 (m, 1H; H1), 4.24 (m, 1H; H2).  
13C NMR (600 MHz, CDCl3): δ 13.04 (CH3, hexyl), 19.24, 19.98, 20.04 (CH2, hexyl), 22.64 
(C3), 24.67 (CH2, hexyl) 27.68 (C5), 30.24 (CH2, hexyl), 31.47 (C6), 33.33 (C3), 54.37 (OCH3), 
63.24 (C1), 74.27 (C2), 131.36, 141.67 (C; triazolyl), 163.47 (C=O).  HRMS: C16H28N3O3
+ 





Compound 57e was synthesized from azide 10a and dimethyl acetylenedicarboxylate.  
Product was isolated as a white crystal with a yield of 310 mg (88%).  Rf: 0.35 (Hex:EtOAc, 
2:3).  1H NMR (600 MHz, CDCl3): δ 1.53 (m, 2H; H4ax, H5ax), 1.77 (m, 2H; H3ax, H6ax), 2.02 
(m, 2H; H4eq, H5eq), 2.36 (m, 1H; H6eq), 3.10 (m, 1H; H3eq), 3.99 (s, 3H; CH3), 4.29 (td, J = 
11.0, 4.3 Hz, 1H; H2), 4.36 (td, J = 11.0, 4.3 Hz, 1H; H1).  13C NMR (150 MHz, CDCl3): δ 
22.86 (C5), 23.34 (C4), 27.17 (C3), 29.18 (C6), 53.28 (CH3), 60.27 (C2), 81.11 (C1), 125.95, 
141.46 (C=O), 153.46, 160.21 (C; triazolyl).  HMRS: C11H14N3O4
+ [M+H]cal m/z 252.0979; 












Compound 57f was synthesized from azide 10a and diethyl acetylenedicarboxylate.  
Product was isolated as a white crystal with a yield of 283 mg (76%).  Rf: 0.25 (Hex:EtOAc, 
3:2).  1H NMR (600 MHz, (CD3)2CO): δ 1.35 (t, J = 7.1 Hz, 3H; CH3), 1.56 (qt, J = 13.2, 3.5 Hz, 
1H; H5ax), 1.66 (qt, J = 13.4, 3.6 Hz, 1H; H4ax), 1.84 (m, 2H; H3ax, H6ax), 2.00 (m, 2H; H4eq, 
H5eq), 2.29 (m, 1H; H6eq), 3.01 (m, 1H; H3eq), 4.39 (m, 2H; OCH2), 4.62 (td, J = 11.0, 4.4 Hz, 
1H; H2), 4.71 (td, J = 11.0, 4.4 Hz, 1H; H1).  13C NMR (150 MHz, (CD3)2CO): δ 13.61 (CH3), 
23.00 (C6), 23.19 (C5), 26.48 (C4), 26.72 (C3), 59.63 (C2), 61.36 (OCH2), 80.67 (C1), 126.06, 
141.11 (C=O), 153.74, 159.77 (C; triazolyl).  HMRS: C12H16N3O4
+ [M+H]cal m/z 266.1135; 
[M+H]exp m/z 266.1153. 
General procedure for synthesis of 5-triazolyl-4-hydroxy-1,2-cyclohexanedicarboxylic acids 
(hydrolysis of esters). 
 
5-triazolyl-4-hydroxy-1,2-cyclohexanedicarboxylates (3 mmol) was dissolved in 3 mL of 
MeOH, and 1M KOH (10 mL) was added.  The mixture was stirred at room temperature till 
consumption of the starting material (6 h).  Aqueous layer was washed 2 x 10 mL of DCM.  
Reaction mixture was concentrated to 1/3 of the volume by rotary evaporator, and acidified with 
6 M HCl to pH ~ 1.  The aqueous layer was separated and extracted 4 x 8 mL EtOAc.  Combined 
organic extracts were dried over anyhydrous Na2SO4 for 12 hours and the product was 
concentrated with rotary evaporator.  Carboxylic acids were purified by chromatography 





Product was purified by column chromatography (silica gel; Hex:EtOAc, 1:1(with 2% 
acetic acid)) to give 128 mg (34%) of colorless oil of pure acid.   1H NMR (600 MHz, CD3OD): 
δ 0.95 (t, J =7.0 Hz, 3H; CH3, hexyl), 1.42 (m, 6H; CH2, hexyl), 1.68 (m, 2H; CH2), 1.88 (m, 
H3ax), 2.34 (m, 2H, H3eq, H6ax), 2.53 (m, 1H, H6eq), 2.70 (t, J =7.6 Hz, 2H; CH2), 3.35 
(m,1H; H1, H2), 3.38 (m, 1H; H1), 4.12 (m, 1H; H4), 4.75 (ddd, J = 9.4, 8.4, 4.3Hz, 1H; H5), 
7.81 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): δ 13.04 (CH3, hexyl), 22.28, 25.06, 29.14, 
28.67 (CH2, hexyl), 28.72 (C6), 30.37 (CH2, hexyl) 31.22 (C3), 40.17 (C2), 40.36 (C1), 62.07 
(C5), 67.97 (C4), 121.73 (CH; triazolyl), 126.34 (CH; triazolyl).  HRMS: C16H26N3O5 [M+H]Cal 




Product was purified by column chromatography (silica gel; Hex:EtOAc,1:1 (with 
2%acetic acid) to give 102 mg (23%) of white crystals of pure acid.  1H NMR (600 MHz, 
CD3OD): δ 1.85 (m, 1H; H3ax), 2.36 (m, 3H; H3eq, H6ax, H6eq), 3.24 (m, 1H, H1), 3.34 (m, 
1H, H2), 3.56 (ddd, J =11.8, 10.0, 4.1 Hz, 1H; H4), 4.62 (m, 1H; H5), 7.21 (m, 1H; phenyl), 7.33 
(m, 2H; phenyl), 7.83 (m, 2H; phenyl), 8.36 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): 
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27.03 (C6), 29.34 (C3), 42.36 (C2), 42.39 (C1), 65.31 (C5), 69.27 (C4), 118.32 (CH; triazolyl), 
124.39 (2C; Phenyl), 127.34 (1C; Phenyl), 128.02 (2C; Phenyl), 129.94 (1C; Phenyl), 146.99 (C; 
triazolyl).  HRMS: C16H18N3O5




Product was purified by column chromatography (silica gel; hexane:EtOAc, 1:1 (with 2% 
acetic acid)) to give 191 mg (46%) of colorless oil of pure acid.  1H NMR (600 MHz, CD3OD): δ 
0.93 (t, J =7.0 Hz, 3H; CH3, hexyl), 1.44 (m, 4H; CH2, hexyl), 1.47 (m, 2H; CH2, hexyl) 1.60 (m, 
2H; CH2, hexyl)), 1.86 (m, H3ax), 2.28 (m, 2H, H3eq, H6ax), 2.59 (m, 1H, H6eq), 2.70 (t, J =7.5 
Hz, 2H; CH2), 3.30 (m,1H; H1, H1), 3.48 (m, 1H; H2), 4.11 (m, 1H; H4), 4.62 (ddd, J = 9.7, 8.0, 
4.3Hz, 1H; H5), 7.79 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): δ 16.47 (CH3, hexyl), 
24.34, 25.06, 28.61, 28.88 (CH2, hexyl), 28.97 (C6), 30.92 (CH2, hexyl) 33.24 (C3), 43.45 (C2), 
46.24 (C1), 63.57 (C5), 72.94 (C4), 122.34 (CH; triazolyl), 139.24 (CH; triazolyl).  HRMS: 












Product was purified by column chromatography (silica gel; Hex:EtOAc,1:1 (with 
2%acetic acid) to give 102 mg (23%) of white crystals of pure acid.  1H NMR (600 MHz, CD3OD): 
δ 1.85 (m, 1H; H3ax), 2.36 (m, 3H; H3eq, H6ax, H6eq), 3.24 (m, 1H, H1), 3.34 (m, 1H, H2), 4.07 
(ddd, J =11.8, 10.0, 4.1 Hz, 1H; H4), 4.62 (m, 1H; H5), 7.21 (m, 1H; phenyl), 7.33 (m, 2H; phenyl), 
7.83 (m, 2H; phenyl), 8.36 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): 27.03 (C6), 29.34 
(C3), 42.36 (C2), 42.39 (C1), 65.31 (C5), 69.27 (C4), 118.32 (CH; triazolyl), 124.39 (2C; Phenyl), 
127.34 (1C; Ph), 128.02 (2C; Ph), 129.94 (1C; Ph), 146.99 (C; triazolyl).  HRMS: C16H18N3O5
+ 




Product was purified by column chromatography (silica gel; Hex:EtOAc, 1:1 (with 2% 
acetic acid)) to give 214 mg (53%) of colorless oil of pure acid.  1H NMR (600 MHz, CD3OD): δ 
0.91 (t, J =6.8 Hz, 3H; CH3, hexyl), 1.31 (m, 4H; CH2, hexyl), 1.39 (m, 2H; CH2, hexyl), 1.51 
(m, 2H; CH2, hexyl), 1.91 (m, 2H; H3ax, H6ax), 2.14 (m, 1H, H3eq,), 2.62 (m, 1H, H6eq), 2.78 
(t, J =7.5 Hz, 2H; CH2), 3.34 (m,1H; H1, H2), 3.48 (m, 1H; H1), 4.03 (m, 1H; H4), 4.62 (m, 1H; 
H5), 7.96 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): δ 14.37 (CH3, hexyl), 23.47, 24.06, 
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26.30, 27.94 (CH2, hexyl), 28.34 (C6), 31.24 (CH2, hexyl) 33.47 (C3), 44.34 (C2), 46.64 (C1), 
63.44 (C5), 73.64 (C4), 123.47 (CH; triazolyl), 140.20 (CH; triazolyl).  HRMS: C16H26N3O5 




Product was purified by column chromatography (silica gel; Hex:EtOAc,1:1 (with 2% 
acetic acid) to give 204 mg (50%) of white crystals of pure acid.  1H NMR (600 MHz, CD3OD): 
δ 1.80 (m, 1H; H3ax), 2.14 (m,1H; H3eq), 2.34 (m, 1H; H6ax), 2.82 (m,1H; H6eq), 3.28 (m, 1H, 
H2), 3.41 (m, 1H, H1), 4.15 (m,1H; H4), 4.62 (ddd, J =11.6, 9.8, 4.1 Hz, 1H; H5), 7.28 (m, 1H; 
Ph), 7.31 (m, 2H; Ph), 7.45 (m, 2H; Ph), 8.14 (s, 1H; triazolyl).  13C NMR (150 MHz, CD3OD): 
30.21 (C6), 30.63 (C3), 41.54 (C2), 43.12 (C1), 69.36 (C5), 74.27 (C4), 122.67 (CH; triazolyl), 
123.24, 124.25 (CH; Ph), 127.34 (CH; Ph), 129.94, 131.67 (CH; Ph), 130.69 (C; Ph), 147.36 (C; 
triazolyl).  HRMS: C16H18N3O5








NMR Analysis of pH-dependent Conformational Equilibrium 
Azaaryl compound was dissolved in CD3OD (0.02-0.03 M), and the change in chemical 
width and the chemical shifts of the protons geminal to the azaaryl groups, hydroxyl group and the 
ethyl ester-lipid tails were monitored by 1H NMR spectra (600 MHz) during titration of the 
solution with d-trifluoroacetic acid (d-TFA).  Acid was dissolved in CD3OD (1 M) and added to 
the solution of azaaryl -lipid in an NMR tube (0.6 mL) in small portions (1-5 μL).   After every 
addition the solution was mixed thoroughly by gentle shaking, and its pH (pD) was measured using 
a micro combination pH electrode for NMR cells (9826BN, Thermo Scientific).  Shaking and 
measuring was repeated 3-4 times until a constant value of pD reading was constant.   After 
recording the 1H NMR spectrum, pD was measured again: the original and final values matched 
within 0.05 units.   The spin-spin coupling constants between several pairs of vicinal protons 
attached to the cyclohexane moiety are strongly conformation-dependent, which allowed an 
assignment of a predominant conformation and an estimation of a position of the conformational 
equilibrium as described previously18,25–29,37,99. 
Calculations for Conformational Preference of Triazolylcyclohexanes 
As a model compound, methyl, phenyl and triazole substituted cyclohexanes were used for 
the computational studies.   All the calculations are performed using Gaussian 09 program 
package.  The MP2 method84 was utilized for geometry optimization in which the structure or 
geometry with the lowest potential energy was obtained.  This optimization accounted for all 
rotamers, isomers of a molecule that can be obtained by rotation of a substituent at a particular 
bond, of each structure.  The geometry optimizations were performed at MP2 level with 6-
311+G(d,p) basis set.  For each optimized structure, vibrational frequency calculations were 
carried out to confirm if it was a minimum with no imaginary frequency and to obtain 
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thermodynamic correction terms including zero-point vibration energy, thermal correction (Cp) to 
enthalpy (∆H298), and entropy (∆S).  For more accurate description of thermodynamics of the axial 
and equatorial conformers, coupled cluster CCSD(T) method was used for single point energy 
calculation based on the MP2 optimized geometries of each structure.  This was done to find the 
lowest potential energy for the already optimized structures while accounting for all excitations, 
i.e.  up to triple excitations (T).  The single point energy calculations were carried out at MP2/6-
311++G(3df,3pd) and CCSD(T)/6-311+G(d,p) levels.  In order to mimic the experimental 
environment, the single-point energy calculations were carried out using the conductor polarizable 
continuum model (CPCM)5 at the B3LYP/6-311+G(3df,2p) level with methanol as a solvent.  
Finally, to estimate more accurate energetics, the CCSD(T)/6-311+G(d,p) level energies were 
extrapolated to CCSD(T)/6-311++G(3df,3pd) level using basis set effect obtained at MP2 level 
via following equation: CCSD(T)/6-311++G(3df,3pd) = CCSD(T)/6-311+G(d,p) +MP2/6-
311++G(3df,3pd)– MP2/6-311+G(d,p) 
Procedure for Glycosidase Inhibition 
The enzyme activities (β-D-galactosidases and β-D-glucosidases) were assayed using 
multi-enzyme complexes isolated from fungi P.  canescens and A.  oryzae as described  before.85  
All assays were performed in a standard way by monitoring spectrophotometrically (with 
Beckman Du-65 spectrometer) the release of p-nitrophenol from the corresponding p-nitrophenyl 
glycosides at 30oC.   One unit of enzyme activity was defined as the amount of enzyme that releases 
1 µmol of p-nitrophenol per minute.Enzyme and substrate concentrations were selected so that the 
degree of hydrolysis was never more than 20%, and in most cases was less than 10%, over the 
course of the assay.  The method used to measure the rate of the reaction assumes that the amount 
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of the substrate is high enough, such that the disappearance over a given period is insignificant, 
that is the rate of the reaction is close to linear for the first stage of the reaction.    
For the preliminary estimation, the enzyme solutions (100 µL with activities 750±150 µU) 
were mixed with a set of inhibitor/activator solutions (100 µL, 10 mM), then diluted with 700 µL 
of 0.2 M acetic buffer (pH 4.2), and the mixture was incubated for 1 h at 30°C.  The reaction was 
initiated with addition of a proper substrate (100 µL of 20 mM p-nitrophenyl glycopyranoside), 
and aliquots were taken after 5 and 10 min.  The reaction was terminated by addition of 1 mL of 1 
M Na2CO3 to 0.5 mL of aliquot solution.  The concentration of the released p-nitrophenol was 
determined at 400 nm using molar extinction coefficient 18.3 mM-1 cm-1.  The 
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Titration 1H NMR Data and Conformational Parameters for 3c.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD solution; 
c) Partially or completely overlapped with other signals; d) Unresolved signal (a width at 1/3 of its height is shown); e) 







pD H4 (O) 
           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 
       % 
GB-A, 
kJ/mol 
7.89b) 4.03 9.91 4.19 10.70 2.89 26.81 3.07 26.98 7 6.2 
7.89 b) 4.03 9.91 4.19 10.70 2.89 26.83 3.07 26.95 7 6.2 
5.30 b) 4.03 9.94 4.18 10.75 2.89 26.80 3.07 26.94 7 6.2 
5.12 b) 4.03 9.95 4.18 10.76 2.89 26.77 3.07 26.92 8 6.1 
4.78 b) 4.03 9.99 4.18 10.78 2.89 26.75 3.07 26.90 8 6.1 
4.17 b) 4.03 10.03 4.17 10.81 2.89 26.73 3.07 26.88 8 6.0 
3.85 b) 4.02 10.12 4.16 10.88 2.90 26.69 3.08 26.85 8 5.9 
3.70 b) 4.02 10.25 4.15 10.97 2.90 26.67 3.08 26.84 8 5.8 
3.49 b) 4.01 10.47 4.13 11.40 2.90 26.41 3.08 26.58 10 5.3 
3.29 b) 4.00 10.99 4.10 12.29 2.91 25.89 3.08 26.08 14 4.5 
3.27 b) 3.99 11.11 4.10 12.41 2.93 25.84 3.09 26.06 14 4.4 
3.07 b) 3.99 11.90 4.06 13.41 2.94 25.32 3.09 25.49 18 3.7 
2.94 b) 3.98 12.77 4.05 14.27 2.95 24.43 3.10 24.93 23 3.0 
2.79 b) 3.97 13.68 4.03 14.98 2.99 23.75 3.12 24.28 27 2.4 
2.66 b) 3.97 14.52 4.01 15.82 3.01 22.81 3.14 23.14 32 1.8 
2.47 b) 3.95 15.44 3.98 16.74 3.03 21.42 3.17 21.74 39 1.1 
2.35 b) 3.94 15.97c) 3.96 17.27c) 3.06 20.97 3.19 21.29 42 0.8 
2.06 b) 3.92 c) 3.92 c) 3.08 19.61 3.21 19.98 45 0.5 
1.69 b) 3.92 c) 3.92 c) 3.09 18.99 3.23 19.28 49 0.1 
1.24 b) 3.92 c) 3.92 c) 3.09 18.59 3.24 18.85 51 -0.1 
1.07 b) 3.92 c) 3.92 c) 3.09 18.40 3.24 18.80 52 -0.2 
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Titration 1H NMR Data and Conformational Parameters for 3d.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD solution; 
c) Partially or completely overlapped with other signals; d) Unresolved signal (a width at 1/3 of its height is shown); e) 





pD H4 (O) 
           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 
       % 
GB-A, 
kJ/mol 
7.29 3.97 11.01 3.76 12.30 2.94 25.10 3.10 25.22 16 4.1 
7.29 3.97 11.01 3.76 12.30 2.94 25.10 3.10 25.22 16 4.1 
6.97 3.97 11.01 3.76 12.30 2.94 25.10 3.10 25.22 16 4.1 
6.17 3.97 11.01 3.76 12.30 2.94 25.10 3.10 25.22 16 4.1 
5.96 3.97 11.01 3.76 12.30 2.94 25.10 3.10 25.22 16 4.1 
5.55 3.97 11.01 3.76 12.34 2.94 25.10 3.10 25.22 16 4.0 
5.42 3.97 11.06 3.76 12.36 2.94 25.05 3.10 25.21 16 4.0 
5.20 3.97 11.11 3.76 12.37 2.94 25.01 3.10 25.18 16 4.0 
4.98 3.97 11.18 3.77 12.40 2.94 24.87 3.11 25.08 17 3.9 
4.74 3.97 11.23 3.77 12.54 2.95 24.67 3.11 24.98 18 3.8 
4.46 3.97 11.41 3.79 12.70 2.95 24.56 3.12 24.81 19 3.6 
4.15 3.96 11.93 3.81 13.31 2.96 23.99 3.13 24.13 22 3.1 
3.97 3.96 12.34 3.82 13.63 2.97 23.54 3.14 23.76 24 2.8 
3.76 3.96 12.96 3.85 14.10 2.98 23.02 3.16 23.24 27 2.4 
3.47 3.96 13.56 3.87 14.77 3.00 22.33 3.18 22.62 31 2.0 
3.17 3.96 14.06 3.89 15.29 3.01 21.69 3.19 22.02 34 1.6 
2.84 3.96 14.43 3.91 15.72 3.02 21.39 3.20 21.67 36 1.4 
2.67 3.96 14.54 3.91 15.81 3.02 21.20 3.21 21.53 37 1.3 
2.36 3.95 14.85 3.91 16.02 3.02 20.95 3.21 21.18 39 1.1 
2.02 3.95 15.10 3.91 16.19 3.02 20.68 3.21 20.94 40 1.0 
1.89 3.94 15.24 3.91 16.33 3.02 20.53 3.21 20.79 41 0.9 
1.53 3.94 15.50 3.91 16.51 3.02 20.30 3.21 20.59 42 0.8 
1.27 3.93 15.70 3.91 16.60 3.02 20.10 3.21 20.50 43 0.7 
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Titration 1H NMR Data and Conformational Parameters for 3f.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD solution; 
c) Partially or completely overlapped with other signals; d) Unresolved signal (a width at 1/3 of its height is shown); e) 
Poorly resolved signal; f) Used as WA 
 
  
pD H4 (O) 
           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 
       % 
GB-A, 
kJ/mol 
7.41 3.88 10.70 3.46 11.30 2.95 25.40 3.04 25.53 13 4.6 
7.23 3.88 10.70 3.46 11.30 2.95 25.40 3.04 25.53 13 4.6 
6.63 3.88 10.70 3.46 11.30 2.95 25.40 3.04 25.53 13 4.6 
6.52 3.88 10.70 3.46 11.30 2.95 25.40 3.04 25.53 13 4.6 
6.34 3.85 10.72 3.46 11.31 2.95 25.38 3.04 25.51 13 4.6 
6.18 3.85 10.76 3.46 11.33 2.96 25.36 3.04 25.50 13 4.5 
5.89 3.85 10.81 3.46 11.35 2.97 25.26 3.04 25.42 14 4.5 
5.72 3.85 10.84 3.46 11.39 2.97 25.20 3.04 25.36 14 4.4 
5.37 3.85 10.92 3.47 11.53 2.97 25.07 3.04 25.21 15 4.3 
5.24 3.84 11.04 3.47 11.67 2.97 24.94 3.05 25.16 15 4.2 
5.05 3.84 11.27 3.48 11.95 2.98 24.70 3.05 24.89 17 3.9 
4.90 3.84 11.66 3.48 12.22 2.98 24.47 3.06 24.59 19 3.6 
4.60 3.83 12.33 3.5 13.12 2.99 23.85 3.07 24.00 23 3.0 
4.29 3.83 13.26 3.53 14.21 3.01 22.86 3.1 23.02 28 2.3 
3.95 3.82 14.29 3.57 15.32 3.03 21.80 3.12 21.94 34 1.6 
3.62 3.81 15.02 3.59 16.10 3.04 21.06 3.14 21.22 39 1.1 
3.37 3.81 15.45 3.6 16.49 3.05 20.60 3.15 20.81 41 0.9 
2.92 3.80 15.93 3.61 17.04 3.05 19.87 3.16 20.00 45 0.5 
2.44 3.80 16.44 3.62 17.51 3.06 19.45 3.16 19.60 47 0.3 
2.13 3.80 16.68 3.62 17.74 3.06 19.26 3.16 19.39 49 0.1 
1.71 3.80 16.94 3.62 17.90 3.06 19.06 3.16 19.21 50 0.0 
1.51 3.80 17.02 3.62 18.11 3.07 19.04 3.17 19.17 50 0.0 
1.37 3.80 17.04 3.62 18.11 3.08 18.96 3.18 19.09 50 0.0 
270 
Titration 1H NMR Data and Conformational Parameters for 3k.a) 
 
 
a) 600 MHz; 0.02-0.03 M solutions at 294K; b) d-trifluoroacetic acid was added in large excess (x10-15) to CD3OD solution; 
c) Partially or completely overlapped with other signals; d) Unresolved signal (a width at 1/3 of its height is shown); e) 
Poorly resolved signal; f) Used as WA 
pD H4 (O) 
           W, Hz 
H5 (S) 
           W, Hz 
H1  
           W, Hz 
H2 
           W, Hz 
nB (nBD+), 
       % 
GB-A, 
kJ/mol 
7.61 4.03 10.09 4.01 10.89 2.94 26.25 3.08 26.34 7 6.5 
7.54 4.03 10.09 4.01 10.89 2.94 26.25 3.08 26.34 7 6.5 
6.27 4.03 10.11 4.01 10.92 2.94 26.25 3.08 26.34 7 6.4 
5.65 4.03 10.15 4.01 10.96 2.94 26.25 3.08 26.34 7 6.4 
5.34 4.03 10.22 4.01 11.00 2.94 26.25 3.08 26.34 7 6.3 
5.23 4.03 10.23 4.01 11.03 2.94 26.25 3.08 26.34 7 6.3 
4.85 4.03 10.27 4.01 11.07 2.95 26.22 3.08 26.34 7 6.2 
4.63 4.03 10.33 4.01 11.09 2.95 26.09 3.08 26.28 8 6.1 
4.43 4.03 10.37 4.01 11.10 2.95 26.00 3.08 26.21 8 6.0 
4.17 4.02 10.42 4.02 11.17 2.95 25.94 3.08 26.05 8 5.8 
4.01 4.02 10.53 4.02 11.48 2.96 25.70 3.08 25.95 10 5.5 
3.72 4.01 10.82 4.01 12.01 2.96 25.56 3.09 25.72 11 5.0 
3.41 4.00 11.65 4.00 13.14 2.98 24.79 3.11 24.88 17 3.9 
2.98 3.97 14.05 3.99 15.21 3.02 23.10 3.14 23.32 28 2.3 
2.67 3.95 15.28 3.99 16.27 3.06 21.56 3.17 21.99 36 1.4 
2.36 3.93 16.21 3.99 17.29 3.09 20.21 3.20 20.38 43 0.7 
1.90 3.92 17.34 3.98 18.20 3.12 18.83 3.22 19.01 50 0.0 
1.63 3.91 17.68 3.98 18.75 3.12 18.05 3.23 18.34 53 -0.3 
1.43 3.80 17.97 3.61 19.05 3.05 17.64 3.16 17.92 55 -0.5 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX D: SELECTED MASS SPECTRA 
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